Draft 2014 Reengineered Hospital-Wide All-Cause Unplanned Readmission Measure: Claims and EHR Data Hybrid

(Version 1.0)

Submitted By

Yale New Haven Health Services Corporation/Center for Outcomes Research & Evaluation (YNHHSC/CORE)

Prepared For:

Centers for Medicare & Medicaid Services (CMS)

July 2014

TABLE OF CONTENTS

| LI | IST OF TABLES | 3 |
|----|---|----|
| LI | IST OF FIGURES | 4 |
| 1 | . INTRODUCTION | 6 |
| | 1.10verview | 6 |
| | 1.2Rationale for Reengineering | ε |
| 2 | . METHODOLOGY | 8 |
| | 2.1Data Source | 8 |
| | 2.2Cohort | 8 |
| | 2.3Outcome Assessment | 11 |
| | 2.4Risk Factors | |
| | 2.5Model Specification and Validation | |
| | 2.6Measure Testing | 18 |
| | 2.7Comparison of HWR eMeasure and Original HWR Measure Results | |
| 3 | | |
| | 3.1Cohort | |
| | 3.2Outcome | 19 |
| | 3.3Risk-Adjustment Variables | 20 |
| | 3.4Model development and validation | |
| | 3.5Measure Testing | 27 |
| | 3.6Comparison of HWR and HWR eMeasure Results | |
| 4 | . SUMMARY | 29 |
| 5 | . GLOSSARY OF TERMS | 31 |
| 6 | . REFERENCES | 33 |
| 7 | . APPENDICES | 34 |
| | Appendix A: Original HWR Measure Specifications and Planned Readmission Algorithm | 34 |
| | Appendix B: Additional Model Testing Results | 64 |

LIST OF TABLES

| Table 2.1: Core Clinical Data Elements (CCDE) | 14 |
|---|-----|
| Table 3.1: Index Admissions by Specialty Cohort | 19 |
| Table 3.2: Unplanned Readmission Rates by Specialty Cohort and Data Sample | 20 |
| Table 3.3: Rates of Capture of CCDE in Specified Timeframes by Specialty Cohort and Data Sample \dots | 20 |
| Table 3.4: CCDE Data Values by Specialty Cohort and Data Sample | 22 |
| Table 3.5: Logistic Regression C-Statistic Comparisons across Four Risk Model Approaches | |
| (Development Sample) | |
| Table 3.6: SRR & RSRR Distribution by Specialty Cohort for the HWR eMeasure | 25 |
| Table 3.7: Logistic Regression Model Statistics by Specialty Cohort and Data Sample | 26 |
| Table 3.8: Distribution of Model Residuals by Specialty Cohort and Data Sample | 26 |
| Table 3.9: Correlation of Original HWR and HWR eMeasure RSRRs (Development Sample) | 28 |
| Table 3.10: Hospital Rankings by Risk Model Approach (Development Sample) | 28 |
| Table A.1: Psychiatric Discharge Diagnosis Categories Excluded from the Measure | 36 |
| Table A.2: Procedure Categories Defining the Surgery/Gynecology Cohort* | 36 |
| Table A.3: Cancer Discharge Diagnosis Categories Excluded from the Measure | 38 |
| Table A.4: Diagnosis Categories Defining the Cardiorespiratory Cohort | 39 |
| Table A.5: Diagnosis Categories Defining the Cardiovascular Cohort | 39 |
| Table A.6: Diagnosis Categories Defining the Neurology Cohort | 40 |
| Table A.7: Diagnosis Categories Defining the Medicine Cohort | 40 |
| Table A.8: Principal Discharge Diagnosis Risk Variables Common to All HWR Specialty Cohorts | 44 |
| Table A.9: Comorbidity Indicators for Medicine Specialty Cohort | 44 |
| Table A.10: Comorbidity Indicators for Surgery/Gynecology Specialty Cohort | 48 |
| Table A.11: Comorbidity Indicators for Cardiovascular Specialty Cohort | 52 |
| Table A.12: Comorbidity Indicators for Cardiorespiratory Specialty Cohort | 53 |
| Table A.13: Comorbidity Indicators for Neurology Specialty Cohort | 53 |
| Table A.14: Complications of Care Variables Not Used in Risk Adjustment If Occurring Only During th | ıe |
| Index Admission | 53 |
| Table PR.1: Procedure Categories that are Always Planned (Version 3.0) | 57 |
| Table PR.2: Diagnosis Categories that are Always Planned (Version 3.0) | 57 |
| Table PR.3: Potentially Planned Procedure Categories (Version 3.0) | 57 |
| Table PR.4: Acute Diagnosis Categories (Version 3.0) | 59 |
| Table B.1: Surgery/Gynecology Specialty Cohort Hierarchical Logistic Regression Model Risk Factor | |
| Frequencies, Estimates, and Odds Ratios by Sample | 64 |
| Table B.2: Cardiorespiratory Specialty Cohort Hierarchical Logistic Regression Model Risk Factor | |
| Frequencies, Estimates, and Odds Ratios by Sample | 67 |
| Table B.3: Cardiovascular Specialty Cohort Hierarchical Logistic Regression Model Risk Factor | |
| Frequencies, Estimates, and Odds Ratios by Sample | |
| Table B.4: Neurology Specialty Cohort Hierarchical Logistic Regression Model Risk Factor Frequencie | ٤s, |
| Estimates, and Odds Ratios by Sample | |
| Table B.5: Medicine Specialty Cohort Hierarchical Logistic Regression Model Risk Factor Frequencies | i, |
| Estimates, and Odds Ratios by Sample | 76 |

LIST OF FIGURES

| Figure 3.1: Index HWR Cohort in 2010-2012 KPNC Dataset | 19 |
|--|-----|
| Figure 3.2: Correlation of RSRRs in Development and Validation Samples | 27 |
| Figure A.1: HWR Flow Diagram of Inclusion and Exclusion Criteria and Specialty Cohort Assignment | for |
| the Index Admission | 35 |
| Figure PR.1 – Planned Readmission Algorithm Version 3.0 Flowchart | 56 |



YNHHSC/CORE PROJECT TEAM

Karen B Dorsey, MD, PhD* - Lead
Yongfei Wang, MS – Lead Analyst
Zhenqui Lin PhD – Lead Analyst
Megan Keenan, MPH – Project Coordinator
Amena Keshawarz, MPH – Research Assistant
Nicole Cormier, MPH - Research Associate
Leora Horwitz, MD, MHS* - Consulting Lead
Jeph Herrin, PhD* – Statistical Consultant
Weiwei Zhang, MPH – Supporting Analyst
Susannah Bernheim, MD, MHS – Project Director
Harlan M. Krumholz, M.D., S.M.* - Principal Investigator

*Yale School of Medicine

ACKNOWLEDGEMENTS

This work is a collaborative effort and the authors gratefully acknowledge and thank our many colleagues and collaborators for their thoughtful and instructive input.

Specifically, we would like to acknowledge the contribution of data from our colleagues affiliated with Kaiser Permanente of Northern California. We are also grateful for the ongoing support from the team:

Gabriel Escobar, M.D. Marla Gardner, B.A.

John Greene, M.A.

We appreciate the ongoing contributions to this work from our clinical consultants and colleagues at YNHHSC/CORE. These individuals include:

Kanchana Bhat, M.P.H. Elizabeth Drye, M.D., M.S. Jacqueline Grady, M.S. Julia Montague, M.P.H. Lisa Suter, M.D. Jessica Brewer, M.P.H. Elizabeth Eddy, B.A. Robert McNamara, M.D., M.H.S. Lori Schroeder, LL.M., J.D.

Finally, we would like to thank our Government Task Leader at the Centers for Medicare & Medicaid Services, Dr. Lein Han, for her continued support of our work.

1. INTRODUCTION

1.1 OVERVIEW

In 2013, the Centers for Medicare & Medicaid Services (CMS) contracted with Yale New Haven Services Corporation, Center for Outcomes Research and Evaluation (CORE) to demonstrate whether clinical data derived from electronic health records (EHRs) could be used to reengineer and enhance the Hospital-Wide All-Cause Unplanned Readmission (HWR) measure¹. Under contract with CMS, CORE had previously identified a set of core clinical data elements (CCDE) that are feasibly extracted from hospital EHRs and are related to patients' clinical status at the start of an inpatient encounter. This report builds on this prior work by investigating whether the CCDE can be used to enhance the HWR measure risk-adjustment methodology.

Version 1.0 of the CCDE consists of patients' gender, age, weight, the first set of vital signs captured within 2 hours of the start of the episode of care, and the results of the first complete blood count and basic chemistry panel drawn within 24 hours of the start of the episode of care². Preliminary work had established that the CCDE could be used to risk adjust measures of 30-day mortality across a variety of common and costly medical conditions². Application of these same data elements to the original HWR measure allows us to examine the use of the CCDE in a broader cohort of hospitalized medical and surgical patients as well as to examine its utility in predicting hospital readmission. Therefore, CORE specifically sought to determine whether the use of clinical data for risk adjustment in place of, or in combination with, comorbidity data from Medicare claims would improve the discrimination of the HWR models or the reliability of the measure.

To reengineer the original HWR measure, we considered a hybrid approach that links the patient-level EHR data to claims data for risk adjustment and utilizes the original HWR measure methodology for cohort and outcome determination. We compared four risk-adjustment strategies, the original HWR approach and three new approaches that used the CCDE in various combinations with claims data. One model applied the CCDE to the full HWR risk-adjustment model. We assumed that this model would out-perform models that used only clinical or only claims data because it is the most comprehensive model. A second model used only the CCDE for risk adjustment. A third model used the CCDE in addition to the principal discharge diagnoses from the original HWR risk-adjustment model. We tested these two models with the understanding that these simpler and more parsimonious models might be advantageous if they performed as well or better than the original HWR measure. We compared the statistical models for all the three approaches to the original HWR measure using claims and EHR datasets provided by a large hospital system in California. We then selected and tested the best-performing model to create the Hospital-Wide All-Cause Unplanned Readmission Hybrid eMeasure (HWR eMeasure).

1.2 RATIONALE FOR REENGINEERING

The increased use of EHRs by hospitals provides an opportunity to incorporate clinical data into outcome measures without the laborious process of abstracting them from paper medical records. Although claims-based risk adjustment has been shown to be comparable to risk adjustment using clinical data when observing hospital-level performance, clinical providers continue to express preference for using patient-level clinical data^{3,4}. Use of the CCDE for risk adjustment of outcome measures would be responsive to these stakeholder concerns about a claims-only approach.

There are several other potential benefits to incorporating clinical data from EHRs into hospital

outcome measures. For example, it provides an opportunity to align the measure with clinical decision support systems that many providers utilize to alert care teams about patients at increased risk of poor outcomes, such as readmission, in real time during the inpatient stay⁵. Utilizing the same variables that are used to support clinical decision-making to calculate hospital performance would be clinically sensible and cost effective, as it reduces the burden of EHR data mapping and extraction required for quality reporting. In addition, many clinical data elements that are captured in real-time to support patient care are less susceptible to gaming, coding drift, and variations in billing practices compared with administrative data used for billing purposes. This allows for more stable measurements over time.

In our previous work, CORE demonstrated that models of 30-day mortality that include the CCDE as predictor variables perform better than models that include only comorbidity information from claims data². This was true across a variety of common and costly medical conditions such as acute myocardial infarction, heart failure, pneumonia, and stroke. By reengineering the HWR measure into a hybrid measure that uses claims and EHR data, we have an opportunity to demonstrate the utility of the CCDE for risk adjustment of readmission measures.

Finally, a hospital-wide cohort includes a broad set of inpatient admissions for a variety of medical conditions and surgical procedures. If the CCDE can be shown to enhance prediction models across many conditions, it can potentially be adopted as the foundation of risk adjustment for many condition- or procedure-specific outcome measures. This would greatly reduce the cost and effort required for measure development and would improve harmonization in risk-adjustment across measures.

2. METHODOLOGY

2.1 DATA SOURCE

All data used to develop the HWR eMeasure were provided by Kaiser Permanente of Northern California (KPNC) from their administrative and EHR data warehouses. KPNC is an integrated health care delivery system that serves over 3.3 million members at its 21 acute-care hospitals. All KPNC hospitals use an integrated EHR system that runs Epic software to capture and store <u>patient management</u>, administrative, and clinical data in their outpatient and inpatient healthcare settings. The Systems Research Initiative within the Kaiser Permanente Division of Research has worked to develop an extensive clinical risk-adjustment methodology for internal benchmarking and quality assurance and is in the process of developing the capability to use these clinical data in real time for clinical decision support and quality measurement. Their work has required <u>mapping</u> specific clinical data elements within their databases, extracting data, and validating their source and accuracy.

Additionally, members enrolled in the KPNC health system receive nearly all of their care from the KPNC network of outpatient and inpatient providers. In the rare instance that a member is admitted to an acute-care facility outside of the network, KPNC will receive a claim for those services unless the patient decides to pay out-of-pocket. Thus, almost all hospital admissions in this patient population are captured in the KPNC administrative database, which facilitates observation of readmission outcomes.

We partnered with KPNC to provide datasets that include all admissions for adult patients to any of their member hospitals between January 1, 2009 and January 31, 2013. These datasets contained both the claims data as well as the clinical data that were used to derive the cohort, outcome, comorbidities, and CCDE. The clinical data included values for the 21 data elements in the CCDE from which we derived first-captured vital signs and laboratory test results from all hospital entry locations including the Emergency Department, operating rooms, inpatient floors, and units. Specifically they provided:

- Hospital identifier and hospital entry location;
- Time and date stamps for patients' arrival at the hospital for care;
- Principal discharge diagnosis (ICD-9 codes);
- Secondary diagnoses (ICD-9 codes);
- The patients' vital signs and laboratory test results from each admission (including data values, time and date stamps) from which we can derive the CCDE; and,
- Variables related to cohort exclusion criteria (discharged against medical advice, transferred to another acute care facility, and in-hospital death).

In addition, they provided the following information from claims submitted by their members for admissions to out-of-network hospitals: admission dates, discharge dates, and principal discharge diagnoses. In this dataset, all of these data elements were linked to a single hospital admission using a unique encounter identification number. Individual patients may have had one or more admissions in the database and were linked using unique patient identifiers assigned by KPNC.

2.2 COHORT

We adhered to the methodology of the original HWR measure to define the cohort. The inclusion and exclusion criteria applied are identical to the original HWR measure methodology except where the criteria did not apply to the Kaiser Healthcare system. The original HWR measure is specified for patients enrolled in Medicare Fee-For-Service (FFS). Kaiser's members do not participate in the FFS

program.

Inclusion and Exclusion Criteria

The inclusion and exclusion criteria for <u>index admissions</u>, the hospitalizations to which the readmission outcomes are attributed, were applied to this dataset for specification of the HWR eMeasure. We included admissions for patients:

Aged 65 or over

Rationale: Medicare patients younger than 65 usually qualify for the program due to severe disability. They are not included in the measure because Medicare patients younger than 65 are considered to be too clinically distinct from Medicare patients 65 and over. For measure development and testing, we used patients' age to approximate a population of Medicare beneficiaries within the KPNC dataset.

Without an in-hospital death

Rationale: Patients who die during the index admission are not eligible for readmission.

Not transferred to another acute care facility

Rationale: Readmission is attributed to the hospital that discharged the patient to the non-acute care setting. For measure development and testing, there were no transfers out of the KPNC network. Within network transfers were considered a single contiguous admission.

The following inclusion criteria would be applied in a <u>Medicare fee-for-service (FFS)</u> population according to the original HWR measure methodology, but did not apply to the KPNC patient population: 1) Enrolled in Medicare fee-for-service (FFS); 2) Enrolled in Part A for the 12 months prior to and including the date of the index admission; and, 3) Discharged from non-federal acute care hospitals because federal status does not apply to any KPNC hospitals.

The following measure exclusions were applied:

Discharged against medical advice (AMA)

Rationale: Providers did not have the opportunity to deliver full care and prepare the patient for discharge.

Admitted for primary psychiatric diagnoses

Rationale: Patients admitted for psychiatric treatment are typically cared for in separate psychiatric or rehabilitation centers that are not comparable to acute care hospitals (<u>Table</u> A.1).

Admitted for rehabilitation

Rationale: These admissions are not typically to an acute care hospital and are not for acute care.

Admitted for medical treatment of cancer

Rationale: These admissions have a different mortality and readmission profile than the rest of the Medicare population, and outcomes for these admissions do not correlate well with outcomes for other admissions (<u>Table A.3</u>). Patients with cancer admitted for other diagnoses or for surgical treatment of their cancer remain in the measure.

The following exclusion criteria from the original HWR measure methodology would be applied in a Medicare FFS population but did not apply to the KPNC patient population: 1) Admitted to Prospective

Payment System (PPS)-exempt cancer hospitals because admissions to such hospitals were not included in the KPNC dataset; and, 2) Without at least 30 days of post-discharge enrollment in Medicare FFS.

Transfers Between Hospitals

The HWR eMeasure uses the original HWR measure methodology to define transfers and attribute readmission outcomes. The measure considers multiple contiguous admissions to two different hospitals as a single acute episode of care. Admissions to a hospital within one day of discharge from another hospital are considered transfers, whether or not the first institution indicates intent to transfer the patient in the discharge disposition code.

Readmissions for transferred patients are attributed to the hospital that ultimately discharges the patient to a non-acute care setting (e.g., to home or a skilled nursing facility). Thus, if a patient is admitted to Hospital A, transferred to Hospital B, and ultimately discharged from Hospital B to a non-acute care setting, a readmission within 30 days of discharge to any acute care hospital is attributed to Hospital B.

If a patient is readmitted to the same hospital on the same day of discharge for the same diagnosis as the index admission, the measure considers the patient to have had one single continuous admission. However, if the second admission has a diagnosis that differs from the index admission it is considered a readmission.

Development and Testing Samples

Once the inclusion and exclusion criteria were applied, we defined three separate samples of index admissions to the 21 KPNC hospitals between January 1, 2010 and December 31, 2012. These samples were used for measure development and testing. The index admissions occurring between January 1, 2010 and December 31 2011 were randomly split into a *development sample* which we used to develop a risk-adjusted model and a *validation sample* which we used to re-test the model; the random split was stratified by hospital and specialty cohort. The third sample included index admissions between January 1, 2012 and December 31, 2012 and was used to assess the stability of risk-adjustment variables across calendar years.

Specialty Cohort Assignment

In each of these three samples, we replicated the methodology used in the original HWR measure to define cohorts of index admissions by specialty. Admissions were grouped into specialty cohorts based on the overlap in clinical presentations, treatment strategies, and in the teams of clinicians that typically provide care for patients in each condition category. For example, in large hospitals patients admitted for treatment of neurological conditions such as stroke or epilepsy are commonly cared for by teams of neurology specialists. Patients admitted for acute myocardial infarction or cardiac arrhythmia are commonly cared for by a separate team of cardiologists. These patients might also be located in separate units of the hospital.

To group patients into these cohorts, the principal discharge diagnosis codes associated with each admission were aggregated into the 285 mutually exclusive categories using the Agency for Healthcare Research & Quality (AHRQ) Clinical Classification Software (CCS). In addition, procedure codes associated with each admission were aggregated into 231 mutually exclusive AHRQ procedure

categories. The AHRQ CCS and procedure categories were further aggregated into <u>5 mutually exclusive specialty cohorts</u>. The original HWR measure development team created a list of AHRQ procedure categories which could typically result in surgical or gynecological teams caring for the patient. Any admission during which a procedure was performed with a CCS category code from this list (<u>Table A.2</u> in <u>Appendix A</u>) was assigned to the **Surgery/Gynecology** cohort regardless of the principal discharge diagnosis. After all surgical and gynecological admissions were aggregated the remaining admissions were sorted based on the principal discharge diagnosis into the following four non-surgical groups:

- The cardiorespiratory cohort, which includes admissions for heart failure as well as admissions
 for various chronic and acute respiratory diseases such as pneumonia, bronchitis, chronic
 obstructive pulmonary disease, asthma, and others (<u>Table A.4</u>);
- The cardiovascular cohort, which includes cardiovascular condition categories such as acute myocardial infarction, cardiac arrhythmias, and others (<u>Table A.5</u>);
- **The neurology cohort,** which includes admissions for neurologic diseases such as stroke and epilepsy (Table A.6); or,
- The medicine cohort, which includes all remaining CCS categories with the exception of excluded categories (e.g., admissions for primary psychiatric diagnoses, rehabilitation, and treatment of cancer) (Table A.7).

The updated 2013 AHRQ CCS categories were reviewed to ensure that no revisions to the specialty group assignment of CCS were required. For a diagram listing all of the inclusions, exclusions, and process for specialty cohort selection, refer to Figure A.1.

According to the original HWR measure methodology, hospitals must have at least 25 qualifying index admissions within each of the 5 specialty cohorts in order to calculate a measure result for each specialty cohort. However, the composite measure combining results from each of the 5 specialty cohorts is calculated if some but not all cohorts meet the 25 case criterion. All 21 hospitals in the KPNC dataset used for measure development and testing had sufficient numbers of admissions for inclusion in measure testing.

2.3 OUTCOME ASSESSMENT

The HWR eMeasure approach to assessment of the readmission outcome is identical to the original HWR measure methodology. The outcome is 30-day all-cause <u>unplanned readmissions</u>. The measure counts any unplanned readmissions because it is designed to capture readmissions that arise from acute clinical events requiring urgent re-hospitalization within 30 days of discharge. To assess the readmission outcome for the last month of the 2012 cohort, admissions through January 31, 2013 were included in the dataset. <u>Planned readmissions</u>, which are generally not a signal of quality of care, are not counted in the outcome of this or any other CMS readmission measure.

If the first readmission after discharge is planned, any subsequent unplanned readmission is not counted as an outcome for that index admission because the unplanned readmission could be related to care provided during the intervening planned readmission rather than during the index admission. In this measure a readmission is also included as an index admission if it meets all other eligibility criteria. However, because the measure only counts the first readmission for any given index admission, readmissions are never attributed to two different index admissions.

Planned readmissions are identified using an algorithm that uses a set of criteria and Medicare administrative claims data to classify readmissions among the general Medicare population. The

planned readmission algorithm identifies admissions that are typically planned and may occur within 30 days of discharge from the hospital.

The planned readmission algorithm has three fundamental principles:

- 1. A few specific, limited types of care are always considered planned (transplant surgery, maintenance chemotherapy/radiotherapy/ immunotherapy, rehabilitation);
- 2. Otherwise, a planned readmission is defined as a non-acute readmission for a scheduled procedure; and
- 3. Admissions for acute illness or for complications of care are never planned.

The algorithm was developed in 2011 as part of the original HWR measure, and in 2013, CMS applied the algorithm to its other readmission measures. The planned readmission algorithm uses a flowchart and four tables of specific procedure categories and discharge diagnosis categories to classify readmissions as planned (<u>Figure PR.1</u> in <u>Appendix A</u>). Readmissions are considered planned if any of the following occurs during the readmission:

- 1. A procedure is performed that is in one of the procedure categories that are always planned regardless of diagnosis (<u>Table PR1</u>);
- 2. The principal diagnosis is in one of the diagnosis categories that are always planned (<u>Table</u> PR2); or
- 3. A procedure is performed that is in one of the potentially planned procedure categories (<u>Table PR3</u>) and the principal diagnosis is not in the list of acute discharge diagnoses (<u>Table PR4</u>).

In the measure development and testing dataset, only index admissions to one of the 21 KPNC hospitals were eligible for inclusion as an index admission. Members who were admitted to and discharged from out-of-network hospitals were not included. However, readmissions to out-of-network hospitals were counted as readmissions if they met the definition for unplanned readmission. Data submitted to KPNC from out-of-network hospitals for purposes of payment included principal discharge diagnosis, procedures performed, admission dates, and discharge dates which were used to identify planned readmissions using the algorithm. In order to verify that qualified readmissions were captured in the KPNC administrative data we merged this dataset with data from the California Office of Statewide Health Planning and Development (OSHPD) for the same set of KPNC hospitals over the same period and calculated the proportion of readmissions captured in both systems.

2.4 RISK FACTORS

The approach to risk adjustment was the only component of the HWR eMeasure that differed from the original HWR measure methodology. The original HWR measure uses claims data to adjust for two aspects of risk: 1) <u>case mix</u> or how sick individual admitted patients are; and, 2) service mix or the proportion of admitted patients with various different principal discharge diagnoses. Different claims data are used to assess each of these.

- For case mix, patients' age and secondary conditions (or comorbidities) documented in inpatient claims from 12 months prior to, and including, the index admission are used.
 Comorbid conditions that could be a result of <u>complications</u> of care and that are present only during the index admission are not included (<u>Table A.14</u>).
- For service mix, the principal discharge diagnoses documented in the inpatient claims during the index admissions are used.

Refer to <u>Table A.8</u> for the list of service mix risk-adjustment variables, which are common to each specialty cohort, and <u>Table A.9</u>, <u>Table A.10</u>, <u>Table A.11</u>, <u>Table A.12</u>, and <u>Table A.13</u> for case mix risk-adjustment variables used in each specialty cohort. The original HWR measure does not adjust for the patients' admission source, their discharge disposition (e.g., skilled nursing facility), or for socioeconomic status (SES).

Risk-Adjustment Variables Tested in the Respecified HWR eMeasure

The risk-adjustment variables included in the development and testing of the HWR eMeasure are derived from both claims and clinical (EHR) data. The variables were:

- 1. The core clinical data elements (CCDE) derived from EHR data
- 2. The AHRQ CCS categories for the principal discharge diagnosis associated with each index admission derived from ICD-9 codes in administrative claims data from the index admission
- 3. Comorbid conditions of each patient identified from inpatient claims in the 12 months prior to and including the index admission derived from ICD-9 codes and grouped into the CMS condition categories (CC)

We sought to determine whether we could enhance the original HWR measure by including the CCDE for risk adjustment. When captured at the start of an index admission, the CCDE, like secondary diagnoses or comorbidities, can be used to adjust for case mix because the CCDE also provide information about how sick hospitalized patients are. In addition, the CCDE and comorbidities might convey slightly overlapping and complementary types of information. For example, a patient's claims data might tell us that they carry a diagnosis of hypertension. Their CCDE will tell us if they had an elevated blood pressure at the time they presented to the hospital. Both types of data might confer important information about the patient's risk of readmission. Therefore, we developed a model with the CCDE and comorbidities to adjust for case mix and claims data to adjust for service mix. We also developed a model with only CCDE for case mix and claims data to adjust for service mix.

We also developed a more parsimonious eMeasure which included only the CCDE with no service mix adjustment. A simpler model might be easier to calculate with very few variables and could align more closely with EHR-based clinical decision support tools designed to predict patients' risk of readmission in real time. We realized that the exclusion of service mix from the risk-adjustment approach might yield a less discriminating model of unplanned readmission. To determine the best approach for the HWR eMeasure risk-adjustment methodology, we compared each of these models in terms of discrimination (c-statistic):

1. Original HWR:

- <u>Service mix</u>: Agency for Healthcare Research and Quality (AHRQ) <u>Clinical Classification</u>
 <u>Software</u> (CCS) categories for patients' principal discharge diagnoses (<u>Appendix A</u>)
- <u>Case mix</u>: CMS <u>Condition Categories (CCs)</u> for patients' <u>comorbidities</u> captured during hospitalizations in the 12 months prior to and including the index admission (<u>Table</u> <u>A.8</u>);

2. CCDE with Original HWR:

- Service mix: Agency for Healthcare Research and Quality (AHRQ) Clinical Classification
 Software (CCS) categories for patients' principal discharge diagnoses
- <u>Case mix</u>: Both the CCDE and CMS Condition Categories (CCs) for patients' comorbidities captured during hospitalizations in the 12 months prior to and including the index admission;

- 3. CCDE with Principal Discharge Diagnosis CCS category:
 - Service mix: Agency for Healthcare Research and Quality (AHRQ) Clinical Classification
 Software (CCS) categories for patients' principal discharge diagnoses
 - <u>Case mix</u>: CCDE only; and,
- 4. CCDE Alone:

Service mix: NoneCase mix: CCDE only.

We included claims data in the KPNC dataset from January 2009 through December 2010 for development of our risk-adjusted models when historical information about patient comorbidities was required for the 2010-2011 split development and validation samples.

Feasibility of the CCDE

Unlike claims data, which is submitted for reimbursement of medical services, the CCDE is obtained from the clinical data in the EHR systems and is not currently collected through any national reporting program. The data elements in the CCDE were selected because they meet the following <u>feasibility</u> criteria: (1) obtained consistently under current clinical practice, (2) captured with a standard definition across providers and care settings, and (3) entered in a <u>structured</u> field to reduce the burden of extraction and ensure consistent reporting².

The CCDE is a set of 21 data elements that consists of patients' age, gender, weight, 6 vital signs captured in the EHR within the first 2 hours of arrival at the hospital, and 13 laboratory test results captured within the first 24 hours of arrival at the hospital (Table 2.1). The feasibility and stability of the CCDE were assessed in the HWR cohort by calculating the rate of capture and distribution of data values of each of the 21 data elements for all adult admissions occurring in each specialty cohort in the development, validation, and testing (2012) samples.

Table 2.1: Core Clinical Data Elements (CCDE)

| Clinical Data Elements | Units of Measurement | Timing of First Capture |
|--------------------------|-------------------------|-------------------------|
| | Patient Characteristics | |
| | Patient Characteristics | |
| Age | Years | |
| Gender | Male or female | |
| | Vital Signs | |
| Heart Rate | Beats per minute | 0-2 hours |
| Systolic Blood Pressure | mmHg | 0-2 hours |
| Diastolic Blood Pressure | mmHg | 0-2 hours |
| Respiratory Rate | Breath per minute | 0-2 hours |
| Temperature | Degrees Fahrenheit | 0-2 hours |
| Oxygen Saturation | Percent | 0-2 hours |
| Weight | Pounds | 0-24 hours |
| | Laboratory Results | |
| Hemoglobin | g/dL | 0-24 hours |
| Hematocrit | % red blood cells | 0-24 hours |
| Platelet | Count | 0-24 hours |
| WBC Count | Cells/mL | 0-24 hours |
| Potassium | mEq/L | 0-24 hours |

| Clinical Data Elements | Units of Measurement | Timing of First Capture |
|------------------------|----------------------|-------------------------|
| Sodium | mEq/L | 0-24 hours |
| Chloride | mEq/L | 0-24 hours |
| Bicarbonate | mmol/L | 0-24 hours |
| Anion Gap | mEq/L | 0-24 hours |
| BUN | mg/dL | 0-24 hours |
| Creatinine | mg/dL | 0-24 hours |
| Glucose | mg/dL | 0-24 hours |

Data Element Preparation

The values of several variables from the CCDE are highly correlated because they measure the same or very similar physiological processes. For example, hemoglobin measures the concentration of the iron-binding protein carried by red blood cells and hematocrit measures the percentage of blood made up of red blood cells respectively. Only one variable in a pair or set of highly correlated variables was included for testing in the risk-adjusted models. For consistency across models, we made the determination to use creatinine over BUN, sodium over chloride, bicarbonate over anion gap, hematocrit over hemoglobin, and systolic blood pressure over diastolic blood pressure. Patients' gender was not included for consideration in the models because we could not identify a physiological reason that would put patients of a certain gender at higher risk of readmission in a hospital-wide cohort; this was the same reasoning used to omit gender from the original HWR model. This left 15 candidate variables from the CCDE for inclusion in the risk-adjusted models

We also examined the distribution of the CCDE data values to determine what proportion were out of physiological range and might represent data errors. We found that most values fell within physiological range and that there were few apparent errors in the data entry. To reduce the effect of the spurious outliers, we transformed extreme values by replacing them with a value at the outer limit of a designated range by a process called Winsorization^{6,7}. All continuous variables with values less than 1st percentile or higher than the 99th percentile were Winsorized, percentiles (i.e., values less than the 1st percentile were assigned to the value of the 1st percentile, and values greater than the 99th percentile were assigned to the value of the 99th percentile). Missing data values were set to the median value for the cohort. In addition, dummy variables for missing data were included in the statistical models. Refer to the CCDE development report for additional information and results of this analysis².

Because each of the CCDE is a set of continuous variables with the exception of gender, we examined the plots for each of the remaining 15 Winsorized data elements against the <u>logit</u> of the unplanned readmission outcome within each specialty cohort to ensure that the relationships conformed to clinical expectations. For example, we anticipated that within the adult population increasing age in years would have a linear relationship with greater risk of unplanned readmission. However, some data elements, such as temperature, were expected to predict greater risk of readmission at very low and very high values and to have little predictive value within the physiologically normal range. Data elements that, upon visual inspection, appeared to have a linear relationship with the outcome were included in risk adjusted regression models without transformation. For data elements with more complex relationships with the outcome, such as temperature we tested two approaches to data transformation, quadratic functions and spline terms.

We sought to select the approach that improved predictive ability of readmission models without

adding unnecessary complexity to measure calculation. We determined that the use of splines might necessitate the need to recalculate new nodes or data values to properly split the data distribution, for each specialty cohort and potentially for each new data year. Because quadratic functions and spline transformations produced similar results in our models, we selected the simpler quadratic functions to adjust for non-linear relationship with the outcome. The variables that required this transformation were heart rate, systolic blood pressure, temperature, white blood cell count, potassium, and bicarbonate.

2.5 MODEL SPECIFICATION AND VALIDATION

To develop the HWR eMeasure, we tested and compared three different risk-adjustment approaches using the CCDE and the original HWR measure. All strategies were variations on the basic HWR structure which models the outcome for each of 5 specialty cohorts. For each strategy we made analogous modifications to each of the 5 models.

For model development we used logistic regression models, with outcome Y_i for the ith patient equal to 1 if the patient was readmitted within 30 days of discharge and 0 otherwise. In contrast with the final models described below for calculating the measure, logistic regression models are substantially less computationally intensive, and development using models with fully specified error structures would have taken prohibitively long. Also, by using logistic regression models that did not account for hospital effects, we were able to assess risk factors and model performance without reference to the variation in performance across hospitals. We developed separate logistic regression models of unplanned readmission using the three separate risk-adjustment strategies and the original HWR measure approach listed in Section 2.4. We compared the discrimination for each specialty cohort across the four different models. We selected the best-performing model based on discrimination in terms of the C-statistic. The two models with lower discrimination were discarded. We completed measure development and testing only for the best-performing model containing the CCDE.

After identifying the best approach using the ordinary logistic regression patient-level model, we used hierarchical logistic regression to model the log-odds of readmission for each of the five cohorts to account for patient clustering within hospitals⁸. This is also consistent with the original fully specified HWR models. We then compared the results of this best approach with the results from original HWR measure approach. Readmission within 30 days was modeled as a function of patient-level demographics, clinical characteristics, comorbidities, and a random hospital-level intercept. This model specification accounts for within-hospital correlation of the observed outcomes and models the assumption that underlying differences in quality among the health care facilities being evaluated lead to systematic differences in outcomes. We estimated a separate hierarchical logistic regression model for each specialty cohort.

Specifically, for a given specialty cohort, we estimated a hierarchical logistic regression model as follows. Let Y_{ij} denote the outcome (equal to 1 if patient i is readmitted within 30 days, zero otherwise) for a patient in cohort $C \subseteq \{1,...,5$ at hospital j; \mathbf{Z}_{ij} denotes a set of risk factors. Let M denote the total number of hospitals and m_j the number of index patient stays in hospital j. We assume the outcome is related linearly to the covariates via a logit function with dispersion:

$$logit(Prob(Y_i = 1)) = \alpha_j + \mathbf{6}^* \mathbf{Z}_{ij} + \varepsilon_i$$

$$\alpha_j = \mu + \omega_j ; \omega_j \sim N(0, \tau^2)$$
(1)

where $\mathbf{Z}_{ij} = (Z_1, Z_2, ... Z_k)$ is a set of k patient-level covariates. α_j represents the <u>hospital specific intercept</u>; μ is the adjusted average outcome over all hospitals; and τ^2 is the between hospital variance component and $\epsilon \sim N(0, \sigma^2)$ captures any over- or under-dispersion. The hierarchical logistic regression model for each cohort was estimated using the SAS software system (GLIMMIX procedure).

Hospital performance assessment

The previous section describes how the models for each specialty cohort are specified and estimated, using a separate hierarchical logistic regression model for that cohort. Each model is then used to calculate a standardized risk ratio (SRR) for each hospital which contributes index admissions to that model. These SRRs, weighted by volume, are then pooled for each hospital to create a composite hospital-wide SRR.

We used the results of each hierarchical logistic regression model to calculate the <u>predicted</u> number of readmissions and the <u>expected</u> number of readmissions at each hospital. The predicted number of readmissions in each cohort was calculated, using the corresponding hierarchical logistic regression model, as the sum of the predicted probability of readmission for each patient, including the hospital-specific (random) effect. The expected number of readmissions in each cohort for each hospital was similarly calculated as the sum of the predicted probability of readmission for each patient, ignoring the hospital specific (random) effect. Using the notation of the previous section, the model specific risk standardized readmission ratio is calculated as follows. To calculate the predicted number of admissions pred_{Ci} for index admissions in cohort C=1,...,5 at hospital *j*, we used

$$pred_{Ci} = \Sigma logit -1(\alpha_i + \boldsymbol{\delta^* Z_{ii}})$$
 (2)

where the sum is over all m_{cj} index admissions in cohort C with index admissions at hospital j. To calculate the expected number \exp_{cj} we used

$$\exp_{C_i} = \Sigma \log i t - 1(\mu + \mathbf{6}^* \mathbf{Z}_{ii})$$
 (3)

Then, as a measure of excess or reduced readmissions among index admissions in cohort C at hospital j, we calculated the standardized risk ratio SRR_{Cj} as

$$SRR_{Ci} = pred_{Ci}/exp_{Ci}$$
 (4)

Risk-standardized hospital-wide 30-day readmission rate

To report a single readmission score, the separate specialty cohort SRRs were combined into a single value. We created a single score as follows.

For a given hospital, j, which has patients in some subset of cohorts $C \subseteq \{1,...,5\}$, calculate the SRR as described above for each specialty cohort for which the hospital discharged patients. If the hospital does not have index admissions in a given cohort c, then $m_{cj} = 0$ and we take $SRR_{cj} = 1$. Then, calculate the volume-weighted logarithmic mean:

$$SRR_{i} = exp((\Sigma m_{ci} log(SRR_{ci})) / \Sigma m_{ci})$$
(5)

where the sums are over all specialty cohorts; note that if a hospital does not have index admissions in a given cohort ($m_{cj} = 0$) then that cohort contributes nothing to the overall score SRR_j . **This value, SRR_j, is the hospital-wide standardized risk ratio** for hospital *j*. To aid interpretation, this ratio is then

multiplied by the overall raw readmission rate for all index admissions in all cohorts for the 21 KPNC hospitals, to produce the risk-standardized hospital-wide readmission rate (RSRR_i).

$$RSRR_{i} = SRR_{i}^{*} \bar{Y}$$
 (6)

We completed hierarchical modeling and calculated measure results for the best-performing model containing the CCDE, which we will refer to as the HWR eMeasure, and the original HWR model. Assessment of the HWR eMeasure performance included model calibration (to assess over-fitting), discrimination in terms of predictive ability (wide range in the distribution of model results), and distribution of model residuals. These analyses were done in the development, validation, and testing (2012) sample. We also calculated the model estimates as well as the coefficients and 95% confidence intervals for risk-adjustment variables for the best-performing model in the development and validation samples.

To assess the internal consistency of the overall composite score and specialty cohort scores for the best-performing model, we will calculate the weighted correlations among specialty cohorts, the correlation between each specialty cohort SRR with the composite SRR, and the Cronbach's coefficient α to assess the overall internal consistency.

2.6 MEASURE TESTING

To determine the extent to which the assessments of a hospital using different but randomly selected subsets of patients produces similar measures of hospital performance, we calculated the RSRR from the HWR eMeasure using each half of the split-sample 2010-2011 data (the development and validation samples). Thus, we obtain two RSRRs for each hospital, using an entirely distinct set of patients from the same time period. To the extent that the calculated measures of these two subsets agree, we have evidence that the measure is assessing an attribute of the hospital, not of the patients. As a metric of agreement we calculated the intra-class correlation as defined by ICC (2,1) by Shrout and Fleiss (1979)^{9,10}.

We considered all measure testing as preliminary due to the small sample of hospitals in the KPNC database and the lack of diversity within the integrated network of KPNC hospitals. Establishing the validity and reliability of the measure requires data from a larger, more diverse set of hospitals and more than one EHR system. Currently there is no large national dataset that includes patient-level EHR data and captures admissions and readmissions to all hospitals from Medicare or non-Medicare claims data.

2.7 COMPARISON OF HWR EMEASURE AND ORIGINAL HWR MEASURE RESULTS

We compared the results of the original HWR measure with the results of the reengineered HWR eMeasure to describe differences in hospital performance assessed by the two measures. We calculated the correlations between the specialty cohort specific standardized risk ratios (SRRs) and the composite risk standardized readmission rates (RSRRs) from the two models. We also compared hospitals' ranking based on the composite RSRRs calculated using the two measures. These results should also be considered preliminary given the small number of hospitals used in these analyses.

3. RESULTS

3.1 COHORT

The exclusion criteria for the measure that were applied to the KPNC dataset are presented in <u>Section 2.2</u>. The percentage of patients meeting each exclusion criterion in the 2010-2012 dataset is presented in <u>Figure 3.1</u>. The number of index admissions for each specialty cohort in the KPNC dataset is listed in Table 3.1.

Initial Cohort
N=251,006

Discharged Against Medical Advice (0.27%)

Cancer Treatment (2.53%)

Psychiatric Treatment (0.24%)

Rehabilitation (0.35%)

Others Not in Specialty Cohorts (0.49%)

Final KPNC HWR Cohort
N=242,515 (96.62%)

Figure 3.1: Index HWR Cohort in 2010-2012 KPNC Dataset

Table 3.1: Index Admissions by Specialty Cohort

| Specialty Cohort | Number of Admissions |
|--------------------|----------------------|
| Surgery/gynecology | 72,162 |
| Cardiorespiratory | 27,695 |
| Cardiovascular | 24,483 |
| Neurology | 13,235 |
| Medicine | 104,940 |

3.2 OUTCOME

Assessment of the 30-Day Unplanned Readmission Outcome

The matching analysis performed to verify that KPNC captured all or nearly all readmissions to hospitals within and outside of their network showed that 98% of readmissions captured within the hospital inpatient claims database maintained by the California Office of Statewide Health Planning and Development were also captured in the KPNC database. This confirmed that the KPNC claims dataset is an accurate source of information to assess the readmission outcome.

The unplanned readmission rate for the patients in the development sample was 14.8%. Rates of unplanned readmission in the development sample varied across the five specialty cohorts from the lowest rate of 9.5% in the surgical cohort to 19.9% in the cardiorespiratory cohort. The rates were similar across the 3 samples with a slightly lower rate in the 2012 sample (Table 3.2).

Table 3.2: Unplanned Readmission Rates by Specialty Cohort and Data Sample

| Specialty Cohort | Developm | ent Sample | Validatio | on Sample | 2012 9 | Sample |
|------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| | Index Admissions | Readmission Rate | Index Admissions | Readmission Rate | Index Admissions | Readmission Rate |
| Surgery/ Gynecology | 23,201 | 9.5% | 23,490 | 10.1% | 25,471 | 8.5% |
| Cardiorespiratory | 9,261 | 19.9% | 9,364 | 20.0% | 9,070 | 19.1% |
| Cardiovascular | 8,108 | 10.2% | 8,037 | 10.6% | 8,338 | 9.3% |
| Neurology | 4,400 | 12.8% | 4,348 | 13.2% | 4,487 | 11.9% |
| Medicine | 34,619 | 18.4% | 34,574 | 18.2% | 35,747 | 16.7% |
| Overall | 79,589 | 14.8 | 79,813 | 15.0 | 83,113 | 13.4 |

3.3 RISK-ADJUSTMENT VARIABLES

Feasibility and Reliability of CCDE Risk Variables

Vital signs including blood pressure, heart rate, respiratory rate, temperature, and oxygen saturation (by pulse oximetry) were captured within 2 hours of arrival to the hospital in at least 90% of the hospital admissions in each specialty cohort. Laboratory test results (complete blood count and basic chemistry panel) were captured within 24 hours in more than 90% of admissions in each of the non-surgical specialty cohorts. Surgical patients typically have laboratory tests drawn in the days leading up to their surgery and may not be entered into the hospital's EHR system. Therefore, within this cohort the rate of capture for these data elements within 24 hours was 70.6% to 83.3% in the development sample. Rates of capture were consistent across the three samples (Table 3.3).

The median data values, 1st, and 99th percentile values for each of the retained CCDE variables (excluding age) were consistent across the development and validation samples (<u>Table 3.4</u>).

Table 3.3: Rates of Capture of CCDE in Specified Timeframes by Specialty Cohort and Data Sample

| | Development Sample | Validation Sample | 2012 Sample |
|--------------------|--------------------|-------------------|-------------|
| | Heart r | ate | |
| Surgery/Gynecology | 95.0 | 95.2 | 96.6 |
| Cardiorespiratory | 98.7 | 98.4 | 99.1 |
| Cardiovascular | 97.7 | 97.9 | 98.5 |
| Neurology | 97.7 | 98.1 | 98.6 |
| Medicine | 98.1 | 98.1 | 98.7 |
| | Systolic | ВР | |
| Surgery/Gynecology | 94.5 | 94.6 | 96.0 |
| Cardiorespiratory | 98.5 | 98.1 | 98.8 |
| Cardiovascular | 97.6 | 97.8 | 97.9 |
| Neurology | 97.7 | 98.1 | 98.5 |
| Medicine | 97.9 | 97.9 | 98.5 |

| | Development Sample | Validation Sample | 2012 Sample |
|--------------------|--------------------|-------------------|-------------|
| | | | |
| | Respirator | • | |
| Surgery/Gynecology | 94.4 | 94.4 | 96.1 |
| Cardiorespiratory | 97.8 | 97.7 | 98.1 |
| Cardiovascular | 96.8 | 97.3 | 97.3 |
| Neurology | 97.0 | 97.3 | 97.6 |
| Medicine | 97.1 | 97.2 | 97.6 |
| | Tempera | ture | |
| Surgery/Gynecology | 93.7 | 94.0 | 95.7 |
| Cardiorespiratory | 95.0 | 94.5 | 95.2 |
| Cardiovascular | 93.6 | 93.8 | 94.3 |
| Neurology | 93.1 | 94.0 | 94.5 |
| Medicine | 95.1 | 95.0 | 96.0 |
| | Weigh | t [*] | |
| Surgery/Gynecology | 94.1 | 94.1 | 95.7 |
| Cardiorespiratory | 93.7 | 93.6 | 94.9 |
| Cardiovascular | 94.3 | 94.7 | 95.2 |
| Neurology | 91.0 | 91.6 | 92.4 |
| Medicine | 91.1 | 91.2 | 92.3 |
| | Oxygen Sat | uration | |
| Surgery/Gynecology | 93.3 | 93.5 | 95.8 |
| Cardiorespiratory | 97.6 | 97.3 | 98.4 |
| Cardiovascular | 96.1 | 96.3 | 97.4 |
| Neurology | 96.2 | 96.6 | 97.4 |
| Medicine | 96.0 | 95.9 | 97.3 |
| | Hemato | crit | |
| Surgery/Gynecology | 83.3 | 83.8 | 82.0 |
| Cardiorespiratory | 98.5 | 98.5 | 99.0 |
| Cardiovascular | 95.4 | 95.5 | 94.9 |
| Neurology | 97.8 | 97.9 | 98.0 |
| Medicine | 97.6 | 97.6 | 98.0 |
| | Platele | ets | |
| Surgery/Gynecology | 79.3 | 80.0 | 78.5 |
| Cardiorespiratory | 98.4 | 98.2 | 98.8 |
| Cardiovascular | 95.2 | 95.2 | 94.7 |
| Neurology | 97.6 | 97.7 | 97.7 |
| Medicine | 97.2 | 97.3 | 97.6 |
| | WBC Co | unt | |
| Surgery/Gynecology | 79.4 | 80.1 | 78.6 |
| Cardiorespiratory | 98.5 | 98.4 | 98.9 |
| Cardiovascular | 95.3 | 95.3 | 94.9 |
| | | | |

^{*} Capture for weight is within the first 24 hours of admission because it is not likely to change substantially during that timeframe.

| | Development Sample | Validation Sample | 2012 Sample |
|--------------------|--------------------|-------------------|-------------|
| Neurology | 97.8 | 97.8 | 97.9 |
| Medicine | 97.4 | 97.4 | 97.8 |
| Wedicine | Potassi | - | 37.0 |
| Surgery/Gynecology | 70.6 | 71.1 | 70.0 |
| Cardiorespiratory | 96.8 | 96.5 | 97.1 |
| Cardiovascular | 93.6 | 93.6 | 93.5 |
| Neurology | 96.1 | 95.9 | 95.8 |
| Medicine | 95.6 | 95.6 | 95.8 |
| | Sodiu | m | |
| Surgery/Gynecology | 71.8 | 72.3 | 71.1 |
| Cardiorespiratory | 98.7 | 98.5 | 99.1 |
| Cardiovascular | 95.0 | 95.2 | 94.8 |
| Neurology | 98.0 | 98.0 | 98.3 |
| Medicine | 97.4 | 97.4 | 97.9 |
| | Bicarbor | nate | |
| Surgery/Gynecology | 71.3 | 71.7 | 70.8 |
| Cardiorespiratory | 98.8 | 98.5 | 99.1 |
| Cardiovascular | 95.0 | 95.3 | 94.8 |
| Neurology | 98.0 | 97.9 | 98.2 |
| Medicine | 97.4 | 97.4 | 97.8 |
| | Creatin | ine | |
| Surgery/Gynecology | 72.0 | 72.2 | 71.5 |
| Cardiorespiratory | 98.7 | 98.5 | 99.1 |
| Cardiovascular | 95.2 | 95.3 | 94.8 |
| Neurology | 98.1 | 98.0 | 98.3 |
| Medicine | 97.4 | 97.4 | 97.9 |
| | Glucos | se | |
| Surgery/Gynecology | 71.1 | 71.4 | 70.5 |
| Cardiorespiratory | 98.6 | 98.4 | 99.0 |
| Cardiovascular | 94.9 | 95.1 | 94.6 |
| Neurology | 98.0 | 97.9 | 98.2 |
| Medicine | 97.3 | 97.3 | 97.8 |

Table 3.4: CCDE Data Values by Specialty Cohort and Data Sample Median (1st percentile-99th percentile)

| manus (200 per obstatio 00 til. per obstatio) | | | | |
|---|--------------------|-------------------|-------------|--|
| | Development Sample | Validation Sample | 2012 Sample | |
| | Heart rate | (bpm) | | |
| Surgery/Gynecology | 72 (47-122) | 72 (47-122) | 72 (47-123) | |
| Cardiorespiratory | 87 (48-150) | 87 (46-150) | 87 (47-150) | |
| Cardiovascular | 75 (36-167) | 76 (35-166) | 76 (35-162) | |
| Neurology | 78 (47-138) | 78 (47-141) | 78 (48-137) | |
| Medicine | 84 (47-146) | 84 (47-145) | 85 (48-147) | |

| | Development Sample | Validation Sample | 2012 Sample |
|--------------------|----------------------|---------------------|-------------------|
| | Systolic Blood Pre | ssure (mmHg) | |
| Surgery/Gynecology | 139 (92-199) | 138 (92-198) | 139 (91-199) |
| Cardiorespiratory | 138 (83-215) | 138 (83-215) | 138 (83-211) |
| Cardiovascular | 141 (81-215) | 140 (81-212) | 140 (81-213) |
| Neurology | 148 (88-223) | 148 (87-224) | 149 (87-224) |
| Medicine | 136 (78-213) | 136 (78-213) | 135 (77-210) |
| | Respiratory Rate (br | eath per minute) | |
| Surgery/Gynecology | 18 (12-26) | 18 (12-25) | 18 (12-26) |
| Cardiorespiratory | 20 (14-40) | 20 (13-40) | 20 (13-40) |
| Cardiovascular | 18 (12-32) | 18 (12-33) | 18 (12-33) |
| Neurology | 18 (12-31) | 18 (12-32) | 18 (12-31) |
| Medicine | 18 (12-36) | 18 (12-36) | 18 (12-36) |
| | Temperatu | | |
| Surgery/Gynecology | 98.0 (96.3-100.5) | 98.0 (96.3-100.6) | 98.0 (96.4-100.6) |
| Cardiorespiratory | 98.1 (95.9-102.8) | 98.1 (95.6-102.7) | 98.1 (95.8-102.2) |
| Cardiovascular | 98.0 (95.9-101.3) | 98.0 (96.0-101.6) | 98.0 (96.0-100.7) |
| Neurology | 98.0 (95.8-101.7) | 98.1 (95.6-102.2) | 98.0 (95.8-101.3) |
| Medicine | 98.2 (95.5-103.1) | 98.2 (95.4-103.1) | 98.2 (95.6-103.2) |
| | Weight (po | ounds) [†] | |
| Surgery/Gynecology | 170 (94-293) | 169 (94-294) | 169 (94-293) |
| Cardiorespiratory | 162 (87-325) | 160 (85-316) | 164 (85-327) |
| Cardiovascular | 166 (92-295) | 166 (93-299) | 168 (95-302) |
| Neurology | 156 (87-275) | 158 (88-270) | 157 (86-286) |
| Medicine | 159 (85-304) | 159 (86-307) | 159 (86-307) |
| | Oxygen Satur | ration (%) | |
| Surgery/Gynecology | 98 (90-100) | 98 (90-100) | 98 (90-100) |
| Cardiorespiratory | 96 (73-100) | 96 (71-100) | 96 (70-100) |
| Cardiovascular | 98 (85-100) | 98 (85-100) | 98 (85-100) |
| Neurology | 98 (85-100) | 98 (85-100) | 98 (86-100) |
| Medicine | 97 (80-100) | 97 (81-100) | 97 (81-100) |
| | Hematocrit (% re | d blood cells) | |
| Surgery/Gynecology | 34.4 (22.0-47.8) | 34.4 (22.0-47.3) | 34.7 (22.0-47.6) |
| Cardiorespiratory | 36.4 (22.3-49.4) | 36.6 (22.5-49.7) | 36.3 (22.0-50.2) |
| Cardiovascular | 37.7 (23.0-49.0) | 37.8 (22.8-49.1) | 38.0 (23.5-49.1) |
| Neurology | 38.0 (22.6-49.6) | 37.9 (23.6-48.8) | 38.2 (24.2-49.8) |
| Medicine | 36.0 (18.7-49.2) | 36.1 (18.8-49.1) | 35.9 (18.3-49.1) |
| | Platelets (| count) | |
| Surgery/Gynecology | 196 (75-493) | 197 (74-479) | 197 (75-501) |
| Cardiorespiratory | 210 (64-550) | 210 (64-531) | 207 (67-525) |
| Cardiovascular | 202 (71-469) | 204 (78-477) | 203 (68-474) |
| Neurology | 210 (69-506) | 209 (51-520) | 210 (60-505) |
| | | • | |

 $^{^{\}dagger}$ Weight in the KPNC system was collected and exported in ounces and then converted to pounds.

| | Development Sample | Validation Sample | 2012 Sample | | | | |
|----------------------|--|-------------------|------------------|--|--|--|--|
| | | | | | | | |
| Medicine | 215 (47-564) | 214 (48-576) | 215 (43-578) | | | | |
| | White Blood Cell Count (cells/mL) | | | | | | |
| Surgery/Gynecology | | | | | | | |
| Cardiorespiratory | 9.0 (3.2-27.1) | 9.1 (3.2-29.0) | 8.8 (3.1-26.4) | | | | |
| Cardiovascular | 7.8 (3.4-22.5) 7.9 (3.4-22.0) 7.9 (3.4-2 | | | | | | |
| Neurology | 8.1 (3.4-23.3) | 8.1 (3.1-22.8) | 8.0 (3.2-22.5) | | | | |
| Medicine | 9.4 (2.0-30.2) | 9.3 (2.1-30.4) | 9.4 (1.8-31.2) | | | | |
| | Potassium (| mEq/L) | | | | | |
| Surgery/Gynecology | 4.2 (3.0-5.8) | 4.2 (3.0-5.8) | 4.2 (3.0-5.8) | | | | |
| Cardiorespiratory | 4.4 (3.0-6.3) | 4.4 (3.1-6.4) | 4.3 (3.1-6.3) | | | | |
| Cardiovascular | 4.3 (3.1-6.0) | 4.3 (3.1-6.1) | 4.3 (3.0-6.1) | | | | |
| Neurology | 4.3 (3.0-6.0) | 4.2 (3.1-5.9) | 4.2 (2.9-5.8) | | | | |
| Medicine | 4.3 (2.9-6.6) | 4.3 (2.9-6.5) | 4.3 (2.8-6.4) | | | | |
| | Sodium (n | nEq/L) | | | | | |
| Surgery/Gynecology | 137 (126-145) | 137 (126-145) | 138 (126-146) | | | | |
| Cardiorespiratory | 139 (121-147) | 138 (121-148) | 139 (122-148) | | | | |
| Cardiovascular | 139 (124-146) | 139 (124-146) | 139 (126-147) | | | | |
| Neurology | 139 (125-147) 139 (124-148) | | 140 (125-148) | | | | |
| Medicine | 138 (119-152) | 138 (119-151) | 138 (119-152) | | | | |
| Bicarbonate (mmol/L) | | | | | | | |
| Surgery/Gynecology | 27 (18-35) | 27 (18-35) | 26 (16-34) | | | | |
| Cardiorespiratory | 27 (17-44) | 27 (17-42) | 26 (16-40) | | | | |
| Cardiovascular | 27 (17-36) | 27 (17-36) | 25 (16-34) | | | | |
| Neurology | 27 (16-36) | 27 (17-36) | 26 (16-34) | | | | |
| Medicine | 27 (14-38) | 26 (14-38) | 25 (13-36) | | | | |
| | Creatinine (| mg/dL) | | | | | |
| Surgery/Gynecology | 0.88 (0.47-5.80) | 0.88 (0.47-6.23) | 0.86 (0.44-6.00) | | | | |
| Cardiorespiratory | 1.06 (0.46-6.31) | 1.06 (0.45-6.84) | 1.06 (0.45-6.10) | | | | |
| Cardiovascular | 1.02 (0.52-6.91) | 1.02 (0.52-6.70) | 1.00 (0.51-7.41) | | | | |
| Neurology | 0.96 (0.49-6.06) | 0.95 (0.50-6.45) | 0.93 (0.44-6.64) | | | | |
| Medicine | 1.05 (0.46-8.21) | 1.06 (0.47-8.39) | 1.04 (0.44-8.24) | | | | |
| | Glucose (n | ng/dL) | | | | | |
| Surgery/Gynecology | 122 (71-328) | 121 (71-319) | 120 (72-327) | | | | |
| Cardiorespiratory | 118 (63-382) | 118 (60-383) | 119 (62-379) | | | | |
| Cardiovascular | 114 (64-372) | 114 (66-376) | 114 (67-377) | | | | |
| Neurology | 112 (64-433) | 112 (65-407) | 112 (69-370) | | | | |
| Medicine | 118 (59-450) | 117 (57-458) | 118 (60-451) | | | | |
| | | | | | | | |

3.4 MODEL DEVELOPMENT AND VALIDATION

Selection of Best-Performing Model

To select the best-performing model containing the CCDE, we compared the results of logisitic regression models calculated using the four risk-adjustment approaches within each specialty cohort. In

the interest of reducing the amount of data included in this report, we omitted the full measure specifications for the models that were not selected as the best performer according to model discrimination in terms of the C-statistic. The full specifications for the best-performing model are provided in <u>Appendix B</u>. The C-statistics for each risk-adjustment approach by specialty cohort are shown in <u>Table 3.5</u>. The *CCDE with Original HWR* approach produced the model with the highest c-statistic for each of the 5 specialty cohorts, although the incremental gain in c-statistic over the *Original HWR* approach was modest.

Table 3.5: Logistic Regression C-Statistic Comparisons across Four Risk Model Approaches (Development Sample)

| Specialty Cohort | HWR | HWR + CCDE | CCDE+Principal Diagnosis | CCDE Only |
|--------------------|-------|------------|-----------------------------|-----------|
| Surgery/Gynecology | 0.800 | 0.802 | 0.770 | 0.617 |
| Cardiorespiratory | 0.653 | 0.668 | 0.645 | 0.611 |
| Cardiovascular | 0.713 | 0.731 | 0.692 | 0.686 |
| Neurology | 0.670 | 0.708 | 0.674 | 0.672 |
| Medicine | 0.646 | 0.651 | 0.611 | 0.585 |

Based on superior model discrimination the *CCDE* with *Original HWR* model was identified as the best-performing model of those evaluated and will be referred to as the HWR eMeasure. This model was carried forward for measure development and testing using hierarchical logistic regression. The other two approaches that included the *CCDE* were discarded.

Model Results

The final HWR eMeasure model variables for each specialty cohort can be found in <u>Appendix B</u> in <u>Table B.1</u>, <u>Table B.2</u>, <u>Table B.3</u>, <u>Table B.4</u>, and <u>Table B.5</u>. Those tables also list the parameter estimates, standard errors, odds ratios and 95% confidence intervals for the model risk factors for each specialty cohort in the development sample. The standardized risk ratios (SRRs) for each specialty cohort and the risk-standardized readmission rate (RSRRs) or full composite measure results for the HWR eMeasure are shown in <u>Table 3.6</u>.

Table 3.6: SRR & RSRR Distribution by Specialty Cohort for the HWR eMeasure (Development Sample)

| | Surgery/ Gynecology | Cardio- respiratory | Cardio- vascular | Neurology | Medicine | Overall |
|-----------------|------------------------|------------------------|---------------------|-----------|----------|---------|
| Mean SRR | 0.997 | 1.004 | 1.000 | 0.998 | 1.007 | 1.002 |
| Min SRR | 0.830 | 0.950 | 0.997 | 0.768 | 0.906 | 0.887 |
| Median SRR | 0.994 | 1.006 | 0.999 | 0.999 | 0.995 | 1.015 |
| Max SRR | 1.199 | 1.046 | 1.004 | 1.162 | 1.155 | 1.091 |
| Mean RSRR (%) | 9.48 | 20.02 | 10.20 | 12.77 | 18.49 | 14.84 |
| Min RSRR (%) | 7.88 | 18.94 | 10.17 | 9.83 | 16.63 | 13.15 |
| Median RSRR (%) | 9.44 | 20.06 | 10.19 | 12.79 | 18.27 | 15.04 |
| Max RSRR (%) | 11.39 | 20.87 | 10.24 | 14.87 | 21.21 | 16.16 |

Model Performance of the HWR eMeasure

Examination of the performance of the HWR eMeasure across the development, validation, and 2012

samples showed stable model characteristics in terms of model calibration (to assess over-fitting) and distribution of model residuals (to assess predictive ability) (<u>Table 3.7</u> and <u>Table 3.8</u>). We also found stability of model estimates and stability in the odds ratios and coefficients in the development and validation samples (<u>Appendix B</u>).

Table 3.7: Logistic Regression Model Statistics by Specialty Cohort and Data Sample

| | HWR eMeasure Development Sample | HWR eMeasure Validation Sample | HWR eMeasure 2012 Sample |
|--------------------|------------------------------------|-----------------------------------|-----------------------------|
| | Calibratio | n (γ0, γ1) | |
| Surgery/Gynecology | (0.000, 1.000) | (-0.049,0.948) | (-0.192,0.971) |
| Cardiorespiratory | (0.000, 1.000) | (-0.004,0.995) | (-0.111,0.931) |
| Cardiovascular | (0.000, 1.000) | (0.067,1.007) | (-0.333,0.854) |
| Neurology | (0.000, 1.000) | (-0.129,0.920) | (-0.464,0.781) |
| Medicine | (0.000, 1.000) | (-0.047,0.977) | (0.077,1.108) |
| | c-stat | istics | |
| Surgery/Gynecology | 0.802 | 0.799 | 0.800 |
| Cardiorespiratory | 0.668 | 0.673 | 0.666 |
| Cardiovascular | 0.731 | 0.717 | 0.726 |
| Neurology | 0.708 | 0.697 | 0.693 |
| Medicine | 0.651 | 0.656 | 0.665 |
| D | iscrimination-Predictive Ability (| lowest decile %, highest decile%) | |
| Surgery/Gynecology | 0-35 | 0-36 | 0-31 |
| Cardiorespiratory | 9-39 | 7-41 | 6-36 |
| Cardiovascular | 2-29 | 2-32 | 2-24 |
| Neurology | 4-33 | 5-37 | 5-34 |
| Medicine | 8-35 | 7-35 | 6-34 |

Table 3.8: Distribution of Model Residuals by Specialty Cohort and Data Sample

| Distribution of Model Residuals (%) | HWR eMeasure Development Sample | HWR eMeasure Validation Sample | HWR eMeasure 2012 Sample |
|--|------------------------------------|-----------------------------------|-----------------------------|
| | Surgery/0 | Gynecology | |
| <-2 | 0.0% | 0.0% | 0.0% |
| [-2,0 | 90.5% | 89.9% | 91.5% |
| [0,2] | 3.7% | 4.0% | 2.9% |
| [2+ | 5.8% | 6.1% | 5.6% |
| | Cardior | espiratory | |
| <-2 | 0.0% | 0.0% | 0.0% |
| [-2,0 | 80.1% | 80.0% | 80.9% |
| [0,2] | 12.2% | 12.3% | 11.2% |
| [2+ | 7.8% | 7.7% | 7.9% |
| | Cardio | vascular | |
| <-2 | 0.0% | 0.0% | 0.0% |
| [-2,0 | 89.8% | 89.4% | 90.7% |
| [0,2] | 3.1% | 3.3% | 2.1% |

| Distribution of Model Residuals (%) | HWR eMeasure Development Sample | HWR eMeasure Validation Sample | HWR eMeasure 2012 Sample |
|--|------------------------------------|-----------------------------------|-----------------------------|
| [2+ | 7.1% | 7.3% | 7.2% |
| | Neu | rology | |
| <-2 | 0.0% | 0.0% | 0.0% |
| [-2,0 | 87.2% | 86.8% | 88.1% |
| [0,2] | 4.4% | 4.9% | 4.0% |
| [2+ | 8.4 % | 8.3% | 7.9% |
| | Med | dicine | |
| <-2 | 0.0% | 0.0% | 0.0% |
| [-2,0 | 81.6% | 81.8% | 83.3% |
| [0,2] | 9.2% | 9.1% | 7.7% |
| [2+ | 9.2% | 9.1% | 9.0% |

3.5 MEASURE TESTING

Reliability of Measure Components and Results

When comparing the hospitals' RSRRs in the development and validation samples for the HWR eMeasure, hospital-level risk-standardized readmission rates were highly correlated (ICC=0.688), as shown in Figure 3.2.




Figure 3.2: Correlation of RSRRs in Development and Validation Samples

3.6 COMPARISON OF HWR AND HWR EMEASURE RESULTS

The original HWR measure was also calculated to compare with the HWR eMeasure results. The standardized risk ratios and risk standardized readmission rates were highly correlated between

the two models (<u>Table 3.9</u>). Ranking of hospitals based on the composite RSRRs differed only slightly by measure. Ranking tended to shift up or down by one or two positions on the list (<u>Table 3.10</u>).

Table 3.9: Correlation of Original HWR and HWR eMeasure RSRRs (Development Sample)

| | Surgery/ Gynecology | Cardio- respiratory | Cardiovascular | Neurology | Medicine | Overall |
|----------------------|------------------------|------------------------|----------------|-----------|----------|---------|
| Correlation of RSRRS | 0.9888 | 0.9829 | 0.9818 | 0.9707 | 0.9953 | 0.9902 |

Table 3.10: Hospital Rankings by Risk Model Approach (Development Sample)

| Hospital ID | Original HWR | | HWR eN | Measure |
|----------------|--------------|-------|--------|---------|
| | Rank | RSRR | Rank | RSRR |
| Α | 1 | 13.26 | 1 | 13.15 |
| В | 2 | 13.91 | 2 | 13.99 |
| С | 3 | 13.98 | 3 | 14.06 |
| D | 4 | 14.10 | 4 | 14.14 |
| E | 5 | 14.29 | 5 | 14.33 |
| F | 6 | 14.46 | 6 | 14.52 |
| G | 7 | 14.60 | 9 | 14.64 |
| Н | 8 | 14.62 | 7 | 14.56 |
| I | 9 | 14.74 | 8 | 14.59 |
| J | 10 | 14.83 | 11 | 15.04 |
| K | 11 | 14.89 | 10 | 14.86 |
| L | 12 | 15.04 | 14 | 15.12 |
| M | 13 | 15.05 | 13 | 15.12 |
| N | 14 | 15.14 | 12 | 15.10 |
| 0 | 15 | 15.16 | 16 | 15.16 |
| P | 16 | 15.19 | 17 | 15.19 |
| Q | 17 | 15.22 | 15 | 15.14 |
| R | 18 | 15.23 | 18 | 15.28 |
| S | 19 | 15.43 | 19 | 15.52 |
| T | 20 | 15.73 | 20 | 15.56 |
| U | 21 | 16.31 | 21 | 16.16 |

4. SUMMARY

This technical report describes the methodology used to reengineer the Hospital-Wide All-Cause Unplanned Readmission measure to include clinical data from patients' EHRs to adjust for the risk of readmission. We used a 3-year dataset to develop and evaluate a statistical model of all-cause unplanned readmission. The dataset consisted of all acute-care hospital admissions to the 21 hospitals in the KPNC network for patients who were 65-years and older. The results indicate that the CCDE combined with the Original HWR Approach to risk adjustment yielded the best predictive model of readmission. This approach uses a combination of claims data to capture patients' comorbidities and principal discharge diagnoses associated with each index admission, as well as clinical data from EHRs to capture patients' clinical status at the start of each encounter. Measure specifications were adopted from the original HWR measure methodology including the cohort definition, assessment of patients' principal discharge diagnoses, comorbidities, and the unplanned readmission outcome. Each hospital's risk-standardized readmission rate (RSRR) is the volume weighted average of the standardized risk ratios calculated from five hierarchical logistic regression models, each for one of the five specialty cohorts.

The HWR eMeasure represents and important innovation in hospital outcome measures in two areas.

- It responds to the preference of many providers and other stakeholders that physiological clinical data be used to adjust for patient-level factors in hospital outcome measures. By including the CCDE into the risk adjustment methodology, we have taken the first step toward outcome measures that rely, on physiological information captured in real time. This is the same data that clinicians use to assess how sick their patients are and to guide their treatment plans. This alignment tends to make sense to providers and gives face validity to the measures, and might eventually lead to measures that can be reported in real-time.
- It provides new efficiencies in measure development and implementation. The use of the CCDE across multiple measures can potentially simplify risk-adjustment strategies. The CCDE are a small manageable number of variables that can be applied across condition cohorts and outcomes (although some variables will be more and less important for specific models). If developers begin with these CCDE, even if there is a need to add a few additional data elements, we can greatly reduce the time and efforts involved in measure development and improve harmonization.
- It provides protection against purposeful gaming of data or non-purposeful temporal fluctuations in the use of specific ICD9/ICD10 codes. The use of data captured in real-time only to support patients' treatment are far less susceptible to gaming or coding drift because their definitions are standard and capture remains uniform and static over patients and over time. They are conceptually and temporally removed from the incentives that drive billing coding.

Thus, the use of the CCDE in the HWR eMeasure represents a first step toward developing more valid, efficient, and harmonized quality measurement system. The reengineered eMeasure also performed well. The model showed greater discrimination and yielded similar measure results compared with the original measure.

Measure testing and validation for this measure is preliminary at this stage due to the small, homogenous set of hospitals used for measure development. As yet there is no national test bed that includes both claims and EHR data from a broad and diverse set of hospitals for full measures testing.

The National Quality Forum (NQF) has created a process by which measure developers can obtain a temporary approval of new measures that rely on EHR data. This allows such measures to be implemented so that the necessary data can be collected from hospitals. Once these data are collected full scale measure testing can be completed.

Implementation of the HWR eMeasures will require a novel and somewhat complex implementation system including converting the CCDE into standard formats (value sets and measure logic, such as HQMF), communicating via implementation guides for providers and certification steps for vendors, determining the proper reporting period and frequency, putting into place the infrastructure to receive and audit data. Implementation also presents some additional challenges in that it requires reporting the CCDE on the broad cohort of all adult inpatient admissions uncoupled with an actual measure to ensure that the CCDE can be applied to an all-payer population, to multiple condition cohorts, and measure outcomes. It also requires that some claims data be submitted within CCDE data files to support linking with separate vital statistics claims data files for measure calculation.

It will be critical to consider and create strategies for these challenges in order to implement the CCDE and any measures that incorporate the CCDE in risk adjustment.

When added to claims data, the CCDE enhanced the discriminative ability of the 30-day unplanned readmission model. Therefore, we selected the *CCDE with Original HWR* approach as the best alternative choice for the new hybrid HWR eMeasures. Although our results indicate that the CCDE, by itself, is not as predictive of readmission as are claims data describing patients' comorbidities, under some circumstances there might be uses for more parsimonious models, such as, the *CCDE alone* and the *CCDE with principal discharge diagnosis* models. More parsimonious models are simpler to understand and calculate and, where they used with the CCDE, better harmonized with the physiological data clinicians are using. It is possible that additional clinical data captured in EHRs could be included in future versions of the CCDE to improve the performance of one of these more parsimonious models. However, any new clinical data elements would have to be feasible for extraction. Future version of the CCDE will ultimately have to improve discrimination, reliability, and validity over existing models.

5. GLOSSARY OF TERMS

- Administrative claims data: An electronic environment in which hospitals capture data to submit claims to insurance providers for payment. These databases allow providers to complete the Universal Bill required to submit Medicare claims and contain patient data, such as dates of birth, name, national and unique medical record identification numbers, dates of admission, dates of discharge, principal discharge diagnoses, and all hospital charges than might be included in a bill for care provided.
- Case Mix: The particular illness severity and age characteristics of patients with index admissions at a given hospital
- Clinical Classification Software (CCS) categories: Groupings of related ICD-9 diagnosis and procedure codes in clinically relevant categories. These categories are defined by the Agency for Healthcare Research & Quality (AHRQ) and can be found at http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.isp.
- *Cohort: The* index admissions used to calculate the measure after inclusion and exclusion criteria have been applied.
- Complications: Medical conditions that likely occurred as a consequence of care rendered during hospitalization.
- Comorbidities: Medical conditions that the patient had in addition to his/her primary reason for admission to the hospital
- Condition Categories (CCs): Groupings of ICD-9-CM diagnosis codes in clinically relevant categories, from the Hierarchical Condition Categories (HCCs) system. CMS uses the grouping but not the hierarchical logic of the system to create risk factor variables. Description of the CCs can be found at http://www.cms.hhs.gov/Reports/downloads/pope 2000 2.pdf
- Core Clinical Data Elements (CCDE): A standardized set of clinical data that are consistently
 obtained on adult hospital inpatients that could be feasibly extracted from electronic health
 records, to be used in risk-adjustment for hospital quality outcome measures.
- Data mapping: Data mapping is the process by which two distinct data models are created and a link between these models is defined. It is most readily used in software engineering to describe the best way to access or represent some form of information. In this report the two data models are the EHR's clinical interface where clinical, laboratory, and other staff capture relevant data and the thousands of linked data tables that make up the EHR's permanent data warehouse where those data are transmitted and stored.
- Electronic health records (EHR): A record in digital format that allows for systematic collection of
 electronic health information about individual patients or populations. It theoretically allows for
 sharing of information across different health care settings.
- Expected readmissions: The number of readmissions expected based on average hospital performance with a given hospital's case mix.
- Feasibility: Data elements that are consistently captured in current clinical practice, captured with a standard definition, and entered in structured fields across individuals as well as EHR and hospital systems.
- Hierarchical model: A widely accepted statistical method that enables fair evaluation of relative hospital performance by accounting for patient risk factors as well as the number of patients a hospital treats. This statistical model accounts for the structure of the data (patients clustered within hospitals) and calculates (1) how much variation in hospital readmission rates overall is accounted for by patients' individual risk factors (such as age and other medical conditions); and (2) how much variation is accounted for by hospital contribution to readmission risk.
- Hospital entry location: The department in which a patient first enters the hospital to receive care,

- such as the ED, the operating room, or the inpatient floor.
- Hospital-specific intercept: A measure of the hospital quality of care calculated based on the hospital's actual readmission rate relative to hospitals with similar patients, considering how many patients it served, its patients' risk factors, and how many died or were readmitted. The hospital-specific effect will be negative for a better-than-average hospital, positive for a worse-than-average hospital, and close to zero for an average hospital. The hospital-specific effect is used in the numerator to calculate "predicted" readmissions.
- *Index admission:* Any admission included in the measure calculation as the initial admission for an episode of care to which the outcome is attributed.
- Medicare fee-for-service (FFS): Original Medicare plan in which providers receive a fee or payment for each individual service provided directly from Medicare. All services rendered are unbundled and paid for separately. Only beneficiaries in Medicare FFS, not in managed care (Medicare Advantage), are included in the measure.
- *Outcome:* The result of a broad set of healthcare activities that affect patients' well-being. For this readmission measure, the outcome is readmission within 30 days of discharge.
- Patient management system: Electronic system or software environment that manages certain administrative activities including allocating physicians, applying policies, and assigning beds. These systems also capture and store patient information, such as name, gender, date of birth, date of encounter visit, national ID or hospital identification number. These systems capture data about patient care workflow, including the registration of patient information, bed tracking, and discharge. The system might or might not be integrated with the clinical EHR.
- Planned readmissions: A readmission within 30 days of discharge from an acute care hospital that is
 a scheduled part of the patient's plan of care. Planned readmissions are not counted as outcomes
 in this measure.
- *Predicted readmissions:* The number of readmissions within 30 days predicted based on the hospital's performance with its observed case mix.
- *Risk-adjustment:* Patient demographics and comorbidities used to standardize rates for differences in case mix across hospitals.
- Service Mix: The particular conditions and procedures of the patients with index admissions at a given hospital
- Specialty cohorts: A group of index admissions for patients with related conditions or procedures
 categories that are likely to be cared for by specific teams of clinicians; there are five defined
 cohorts in this report (medicine, neurology, cardiorespiratory, cardiovascular, surgery/gynecology).
- Structured data: Data captured in a format that is numerical, such as integers or fractions; pseudonumerical, such as dates; or list, such as "positive" or "negative".
- *Time of arrival*: The time stamp that is captured closest to the moment a patient first reaches the hospital for care.
- *Unplanned readmissions:* Acute clinical events a patient experiences that require urgent rehospitalization. Unplanned readmissions are counted as outcomes in the measure.

6. REFERENCES

- 2014 Measure Updates and Specifications: Hospital-Wide All-Cause Unplanned Readmission -Version 3.0. Prepared by Yale New Haven Health Services Corporation Center for Outcomes Research and Evaluation for the Centers for Medicare and Medicaid Services [PDF]. 2014; Available at:
 - https://www.qualitynet.org/dcs/BlobServer?blobkey=id&blobnocache=true&blobwhere=12288902 93099&blobheader=multipart%2Foctet-stream&blobheadername1=Content-Disposition&blobheadervalue1=attachment%3Bfilename%3DHosp-Wide Rdmsn Msr Updts 032114.pdf&blobcol=urldata&blobtable=MungoBlobs.
- 2. Technical Report: Core Clinical Data Elements. Prepared by Yale New Haven Health Services Corporation Center for Outcomes Research and Evaluation for the Centers for Medicare and Medicaid Services 2014; Available at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/CallforPublicComment.html.
- 3. Keenan PS, Normand SL, Lin Z, et al. An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. *Circulation. Cardiovascular quality and outcomes.* Sep 2008;1(1):29-37.
- 4. Krumholz HM, Lin Z, Drye EE, et al. An administrative claims measure suitable for profiling hospital performance based on 30-day all-cause readmission rates among patients with acute myocardial infarction. *Circulation. Cardiovascular quality and outcomes.* Mar 2011;4(2):243-252.
- 5. Rothman MJ, Rothman SI, Beals Jt. Development and validation of a continuous measure of patient condition using the Electronic Medical Record. *Journal of biomedical informatics*. Oct 2013;46(5):837-848.
- 6. Altenburg HP. Estimation of Radioimmunoassay Data Using Robust Nonlinear Regression Methods. In: Dodge Y, Whittaker J, eds. *Computational Statistics*: Physica-Verlag HD; 1992:367-372.
- 7. Dixon WJ, Yuen KK. Trimming and winsorization: A review. *Statistische Hefte*. 1974/06/01 1974;15(2-3):157-170.
- 8. Normand S-LT, Shahian DM. Statistical and Clinical Aspects of Hospital Outcomes Profiling. *Statistical Science*. 2007/05 2007:206-226.
- 9. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. *Psychological bulletin*. Mar 1979;86(2):420-428.
- 10. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics*. Mar 1977;33(1):159-174.

7. APPENDICES

APPENDIX A: ORIGINAL HWR MEASURE SPECIFICATIONS AND PLANNED READMISSION ALGORITHM

Cohort

Inclusion Criteria for HWR Measure

1. Enrolled in Medicare FFS

Rationale: Claims data are consistently available only for Medicare FFS.

2. Aged 65 or older

Rationale: Medicare patients younger than 65 usually qualify for the program due to severe disability. They are not included in the measure because Medicare patients younger than 65 are considered to be too clinically distinct from Medicare patients 65 and over.

3. Discharged from non-federal acute care hospitals

Rationale: Data from federal hospitals were not available during the development of this measure.

4. Without an in-hospital death

Rationale: Patients who are discharged alive are eligible for readmission.

5. Not transferred to another acute care facility

Rationale: Readmission is attributed to the hospital that discharged the patient to the non-acute care setting. Transferred patients are still included in the measure cohort, but the initial admitting hospital is not accountable for the outcome.

6. Enrolled in Part A for the 12 months prior to and including the date of the index admission Rationale: The 12-month prior enrollment ensures a full year of administrative data for risk adjustment.

Exclusion Criteria for HWR Measure

1. Admissions to Prospective Payment System (PPS)-exempt cancer hospitals

Rationale: These hospitals care for a unique population of patients that cannot reasonably be compared to patients admitted to other hospitals.

2. Without at least 30 days of post-discharge enrollment in FFS Medicare

Rationale: The 30-day readmission outcome cannot be assessed in this group since claims data are used to determine whether a patient was readmitted.

3. Discharged against medical advice (AMA)

Rationale: Providers did not have the opportunity to deliver full care and prepare the patient for discharge.

4. Admissions for primary psychiatric diagnoses

Rationale: Patients admitted for psychiatric treatment are typically cared for in separate psychiatric or rehabilitation centers that are not comparable to acute care hospitals.

5. Admissions for rehabilitation

Rationale: These admissions are not typically to an acute care hospital and are not for acute care.

6. Admissions for medical treatment of cancer

Rationale: These admissions have a different mortality and readmission profile than the rest of the Medicare population, and outcomes for these admissions do not correlate well with outcomes for other admissions. Patients with cancer admitted for other diagnoses or for surgical treatment of their cancer remain in the measure.

Figure A.1: HWR Flow Diagram of Inclusion and Exclusion Criteria and Specialty Cohort Assignment for the Index Admission




Table A.1: Psychiatric Discharge Diagnosis Categories Excluded from the Measure

| AHRQ Procedure CCS | Description |
|--------------------------|---|
| 657 | Mood disorders |
| 659 | Schizophrenia and other psychotic disorders |
| 651 | Anxiety disorders |
| 670 | Miscellaneous disorders |
| 654 | Developmental disorders |
| 650 | Adjustment disorders |
| 658 | Personality disorders |
| 652 | Attention-deficit, conduct, and disruptive behavior disorders |
| 656 | Impulse control disorders, NEC |
| 655 | Disorders usually diagnosed in infancy, childhood, or adolescence |
| 662 | Suicide and intentional self-inflicted injury |

Table A.2: Procedure Categories Defining the Surgery/Gynecology Cohort*

| AHRQ Procedure CCS | Description |
|--------------------------|--|
| 1 | Incision and excision of CNS |
| 2 | Insertion; replacement; or removal of extracranial ventricular shunt |
| 3 | Laminectomy; excision intervertebral disc |
| 9 | Other OR therapeutic nervous system procedures |
| 10 | Thyroidectomy; partial or complete |
| 12 | Other therapeutic endocrine procedures |
| 13 | Corneal transplant |
| 14 | Glaucoma procedures |
| 15 | Lens and cataract procedures |
| 16 | Repair of retinal tear; detachment |
| 17 | Destruction of lesion of retina and choroid |
| 20 | Other intraocular therapeutic procedures |
| 21 | Other extraocular muscle and orbit therapeutic procedures |
| 22 | Tympanoplasty |
| 23 | Myringotomy |
| 24 | Mastoidectomy |
| 26 | Other therapeutic ear procedures |
| 28 | Plastic procedures on nose |
| 30 | Tonsillectomy and/or adenoidectomy |
| 33 | Other OR therapeutic procedures on nose; mouth and pharynx |
| 36 | Lobectomy or pneumonectomy |
| 42 | Other OR Rx procedures on respiratory system and mediastinum |
| 43 | Heart valve procedures |
| 44 | Coronary artery bypass graft (CABG) |
| 49 | Other OR heart procedures |
| 51 | Endarterectomy; vessel of head and neck |

 $[\]ensuremath{^{\ast}}$ Not mutually exclusive; multiple procedures may be performed during a single admission

36

| AHRQ | |
|------------|---|
| Procedure | Description |
| ccs | |
| 52 | Aortic resection; replacement or anastomosis |
| 53 | 'Varicose vein stripping; lower limb |
| 55 | Peripheral vascular bypass |
| 56 | Other vascular bypass and shunt; not heart |
| 59 | Other OR procedures on vessels of head and neck |
| 60 | Embolectomy and endarterectomy of lower limbs |
| 66 | Procedures on spleen |
| 67 | Other therapeutic procedures; hemic and lymphatic system |
| 72 | Colostomy; temporary and permanent |
| 73 | lleostomy and other enterostomy |
| 74 | Gastrectomy; partial and total |
| 75 | Small bowel resection |
| 78 | Colorectal resection |
| 79 | Local excision of large intestine lesion (not endoscopic) |
| 80 | Appendectomy |
| 84 | Cholecystectomy and common duct exploration |
| 85 | Inguinal and femoral hernia repair |
| 86 | Other hernia repair |
| 89 | Exploratory laparotomy |
| 90 | Excision; lysis peritoneal adhesions |
| 94 | Other OR upper GI therapeutic procedures |
| 96 | Other OR lower GI therapeutic procedures |
| 99 | Other OR gastrointestinal therapeutic procedures |
| 101 | Transurethral excision; drainage; or removal urinary obstruction |
| 103 | Nephrotomy and nephrostomy |
| 104 | Nephrectomy; partial or complete |
| 105 | Kidney transplant |
| 106 112 | Genitourinary incontinence procedures |
| | Other OR therapeutic procedures of urinary tract Transurethral resection of prostate (TURP) |
| 113 114 | |
| 114 | Open prostatectomy Other OR therapeutic procedures; male genital |
| 119 | Oophorectomy; unilateral and bilateral |
| 120 | Other operations on ovary |
| 121 | Ligation or occlusion of fallopian tubes |
| 122 | Removal of ectopic pregnancy |
| 123 | Other operations on fallopian tubes |
| 124 | Hysterectomy; abdominal and vaginal |
| 125 | Other excision of cervix and uterus |
| 126 | Abortion (termination of pregnancy) |
| 127 | Dilatation and curettage (D&C); aspiration after delivery or abortion |
| 129 | Repair of cystocele and rectocele; obliteration of vaginal vault |
| 131 | Other non-OR therapeutic procedures; female organs |
| 132 | Other OR therapeutic procedures; female organs |
| 133 | Episiotomy |
| 134 | Cesarean section |
| 135 | Forceps; vacuum; and breech delivery |
| 136 | Artificial rupture of membranes to assist delivery |

| AHRQ Procedure CCS | Description |
|--------------------------|---|
| 137 | Other procedures to assist delivery |
| 139 | Fetal monitoring |
| 140 | Repair of current obstetric laceration |
| 141 | Other therapeutic obstetrical procedures |
| 142 | Partial excision bone |
| 143 | Bunionectomy or repair of toe deformities |
| 144 | Treatment; facial fracture or dislocation |
| 145 | Treatment; fracture or dislocation of radius and ulna |
| 146 | Treatment; fracture or dislocation of hip and femur |
| 147 | Treatment; fracture or dislocation of lower extremity (other than hip or femur) |
| 148 | Other fracture and dislocation procedure |
| 150 | Division of joint capsule; ligament or cartilage |
| 151 | Excision of semilunar cartilage of knee |
| 152 | Arthroplasty knee |
| 153 | Hip replacement; total and partial |
| 154 | Arthroplasty other than hip or knee |
| 157 | Amputation of lower extremity |
| 158 | Spinal fusion |
| 160 | Other therapeutic procedures on muscles and tendons |
| 161 | Other OR therapeutic procedures on bone |
| 162 | Other OR therapeutic procedures on joints |
| 164 | Other OR therapeutic procedures on musculoskeletal system |
| 166 | Lumpectomy; quadrantectomy of breast |
| 167 | Mastectomy |
| 172 | Skin graft |
| 175 | Other OR therapeutic procedures on skin and breast |
| 176 | Other organ transplantation |

Table A.3: Cancer Discharge Diagnosis Categories Excluded from the Measure

| AHRQ Diagnosis CCS | Description |
|--------------------------|---|
| 11 | Cancer of head and neck |
| 12 | Cancer of esophagus |
| 13 | Cancer of stomach |
| 14 | Cancer of colon |
| 15 | Cancer of rectum and anus |
| 16 | Cancer of liver and intrahepatic bile duct |
| 17 | Cancer of pancreas |
| 18 | Cancer of other GI organs; peritoneum |
| 19 | Cancer of bronchus; lung |
| 20 | Cancer; other respiratory and intrathoracic |
| 21 | Cancer of bone and connective tissue |
| 22 | Melanomas of skin |
| 23 | Other non-epithelial cancer of skin |
| 24 | Cancer of breast |

| AHRQ Diagnosis CCS | Description |
|--------------------------|---|
| 25 | Cancer of uterus |
| 26 | Cancer of cervix |
| 27 | Cancer of ovary |
| 28 | Cancer of other female genital organs |
| 29 | Cancer of prostate |
| 30 | Cancer of testis |
| 31 | Cancer of other male genital organs |
| 32 | Cancer of bladder |
| 33 | Cancer of kidney and renal pelvis |
| 34 | Cancer of other urinary organs |
| 35 | Cancer of brain and nervous system |
| 36 | Cancer of thyroid |
| 37 | Hodgkin`s disease |
| 38 | Non-Hodgkin`s lymphoma |
| 39 | Leukemias |
| 40 | Multiple myeloma |
| 41 | Cancer; other and unspecified primary |
| 42 | Secondary malignancies |
| 43 | Malignant neoplasm without specification of site |
| 44 | Neoplasms of unspecified nature or uncertain behavior |
| 45 | Maintenance chemotherapy; radiotherapy |

Table A.4: Diagnosis Categories Defining the Cardiorespiratory Cohort

| AHRQ Diagnosis CCS | Description |
|-----------------------|--|
| 56 | Cystic Fibrosis |
| 103 | Pulmonary heart disease |
| 108 | Congestive heart failure; nonhypertensive |
| 122 | Pneumonia (except that caused by tuberculosis or sexually transmitted disease) |
| 125 | Acute bronchitis |
| 127 | Chronic obstructive pulmonary disease and bronchiectasis |
| 128 | Asthma |
| 131 | Respiratory failure; insufficiency; arrest (adult) |

Table A.5: Diagnosis Categories Defining the Cardiovascular Cohort

| AHRQ Diagnosis CCS | Description |
|-----------------------|--|
| 96 | Heart valve disorders |
| 97 | Peri-; endo-; and myocarditis; cardiomyopathy (except that caused by tuberculosis or sexually transmitted) |
| 100 | Acute myocardial infarction |
| 101 | Coronary atherosclerosis and other heart disease |
| 102 | Nonspecific chest pain |
| 104 | Other and ill-defined heart disease |

| AHRQ Diagnosis CCS | Description |
|-----------------------|---|
| 105 | Conduction disorders |
| 106 | Cardiac dysrhythmias |
| 107 | Cardiac arrest and ventricular fibrillation |
| 114 | Peripheral and visceral atherosclerosis |
| 115 | Aortic; peripheral; and visceral artery aneurysms |
| 116 | Aortic and peripheral arterial embolism or thrombosis |
| 117 | Other circulatory disease |
| 213 | Cardiac and circulatory congenital anomalies |

Table A.6: Diagnosis Categories Defining the Neurology Cohort

| AHRQ Diagnosis CCS | Description |
|-----------------------|---|
| 78 | Other CNS infection and poliomyelitis |
| 79 | Parkinson`s disease |
| 80 | Multiple sclerosis |
| 81 | Other hereditary and degenerative nervous system conditions |
| 82 | Paralysis |
| 83 | Epilepsy; convulsions |
| 85 | Coma; stupor; and brain damage |
| 95 | Other nervous system disorders |
| 109 | Acute cerebrovascular disease |
| 110 | Occlusion or stenosis of precerebral arteries |
| 111 | Other and ill-defined cerebrovascular disease |
| 112 | Transient cerebral ischemia |
| 113 | Late effects of cerebrovascular disease |
| 216 | Nervous system congenital anomalies |
| 227 | Spinal cord injury |
| 233 | Intracranial injury |

Table A.7: Diagnosis Categories Defining the Medicine Cohort

| AHRQ Diagnosis CCS | Description |
|-----------------------|--|
| 1 | Tuberculosis |
| 2 | Septicemia (except in labor) |
| 3 | Bacterial infection; unspecified site |
| 4 | Mycoses |
| 5 | HIV infection |
| 6 | Hepatitis |
| 7 | Viral infection |
| 8 | Other infections; including parasitic |
| 9 | Sexually transmitted infections (not HIV or hepatitis) |
| 10 | Immunizations and screening for infectious disease |
| 46 | Benign neoplasm of uterus |
| 47 | Other and unspecified benign neoplasm |

| AHRQ Diagnosis CCS | Description |
|-----------------------|--|
| 48 | Thyroid disorders |
| 49 | Diabetes mellitus without complication |
| 50 | Diabetes mellitus with complications |
| 51 | Other endocrine disorders |
| 52 | Nutritional deficiencies |
| 53 | Disorders of lipid metabolism |
| 54 | Gout and other crystal arthropathies |
| 55 | Fluid and electrolyte disorders |
| 57 | Immunity disorders |
| 58 | Other nutritional; endocrine; and metabolic disorders |
| 59 | Deficiency and other anemia |
| 60 | Acute posthemorrhagic anemia |
| 61 | Sickle cell anemia |
| 62 | Coagulation and hemorrhagic disorders |
| 63 | Diseases of white blood cells |
| 64 | Other hematologic conditions |
| 76 | Meningitis (except that caused by tuberculosis or sexually transmitted disease) |
| 77 | Encephalitis (except that caused by tuberculosis or sexually transmitted disease) |
| 84 | Headache; including migraine |
| 86 | Cataract |
| 87 | Retinal detachments; defects; vascular occlusion; and retinopathy |
| 88 | Glaucoma |
| 89 | Blindness and vision defects |
| 90 | Inflammation; infection of eye (except that caused by tuberculosis or sexually transmitted |
| 90 | disease) |
| 91 | Other eye disorders |
| 92 | Otitis media and related conditions |
| 93 | Conditions associated with dizziness or vertigo |
| 94 | Other ear and sense organ disorders |
| 98 | Essential hypertension |
| 99 | Hypertension with complications and secondary hypertension |
| 118 | Phlebitis; thrombophlebitis and thromboembolism |
| 119 | Varicose veins of lower extremity |
| 120 | Hemorrhoids |
| 121 | Other diseases of veins and lymphatics |
| 123 | Influenza |
| 124 | Acute and chronic tonsillitis |
| 126 | Other upper respiratory infections |
| 129 | Aspiration pneumonitis; food/vomitus |
| 130 | Pleurisy; pneumothorax; pulmonary collapse |
| 132 | Lung disease due to external agents |
| 133 | Other lower respiratory disease |
| 134 | Other upper respiratory disease |
| 135 | Intestinal infection |
| 136 | Disorders of teeth and jaw |
| 137 | Diseases of mouth; excluding dental |

| AHRQ | Description |
|---------------|--|
| Diagnosis CCS | Description |
| 138 | Esophageal disorders |
| 139 | Gastroduodenal ulcer (except hemorrhage) |
| 140 | Gastritis and duodenitis |
| 141 | Other disorders of stomach and duodenum |
| 142 | Appendicitis and other appendiceal conditions |
| 143 | Abdominal hernia |
| 144 | Regional enteritis and ulcerative colitis |
| 145 | Intestinal obstruction without hernia |
| 146 | Diverticulosis and diverticulitis |
| 147 | Anal and rectal conditions |
| 148 | Peritonitis and intestinal abscess |
| 149 | Biliary tract disease |
| 151 | Other liver diseases |
| 152 | Pancreatic disorders (not diabetes) |
| 153 | Gastrointestinal hemorrhage |
| 154 | Noninfectious gastroenteritis |
| 155 | Other gastrointestinal disorders |
| 156 | Nephritis; nephrosis; renal sclerosis |
| 157 | Acute and unspecified renal failure |
| 158 | Chronic renal failure |
| 159 | Urinary tract infections |
| 160 | Calculus of urinary tract |
| 161 | Other diseases of kidney and ureters |
| 162 | Other diseases of bladder and urethra |
| 163 | Genitourinary symptoms and ill-defined conditions |
| 164 | Hyperplasia of prostate |
| 165 | Inflammatory conditions of male genital organs |
| 166 | Other male genital disorders |
| 167 | Nonmalignant breast conditions |
| 168 | Inflammatory diseases of female pelvic organs |
| 169 | Endometriosis |
| 170 | Prolapse of female genital organs |
| 171 | Menstrual disorders |
| 172 | Ovarian cyst |
| 173 | Menopausal disorders |
| 174 | Female infertility |
| 175 | Other female genital disorders |
| 197 | Skin and subcutaneous tissue infections |
| 198 | Other inflammatory condition of skin |
| 199 | Chronic ulcer of skin |
| 200 | Other skin disorders |
| 201 | Infective arthritis and osteomyelitis (except that caused by tuberculosis or sexually transmitted disease) |
| 202 | Rheumatoid arthritis and related disease |
| 203 | Osteoarthritis |
| 204 | Other non-traumatic joint disorders |
| | |

| AHRQ | Description |
|---------------|--|
| Diagnosis CCS | |
| 205 | Spondylosis; intervertebral disc disorders; other back problems |
| 206 | Osteoporosis Path algoritant fracture |
| 207 | Pathological fracture |
| 208 | Acquired foot deformities |
| 209 210 | Other acquired deformities Systemic lupus erythematosus and connective tissue disorders |
| 210 | Other connective tissue disease |
| 211 | Other bone disease and musculoskeletal deformities |
| 212 | Digestive congenital anomalies |
| 215 | Genitourinary congenital anomalies |
| 217 | Other congenital anomalies |
| 225 | Joint disorders and dislocations; trauma-related |
| 226 | Fracture of neck of femur (hip) |
| 228 | Skull and face fractures |
| 229 | Fracture of upper limb |
| 230 | Fracture of lower limb |
| 231 | Other fractures |
| 232 | Sprains and strains |
| 234 | Crushing injury or internal injury |
| 235 | Open wounds of head; neck; and trunk |
| 236 | Open wounds of extremities |
| 237 | Complication of device; implant or graft |
| 238 | Complications of surgical procedures or medical care |
| 239 | Superficial injury; contusion |
| 240 | Burns |
| 241 | Poisoning by psychotropic agents |
| 242 | Poisoning by other medications and drugs |
| 243 | Poisoning by nonmedicinal substances |
| 244 | Other injuries and conditions due to external causes |
| 245 | Syncope Syncope |
| 246 | Fever of unknown origin |
| 247 | Lymphadenitis |
| 248 | Gangrene |
| 249 | Shock |
| 250 | Nausea and vomiting |
| 251 | Abdominal pain |
| 252 | Malaise and fatigue |
| 253 | Allergic reactions |
| 255 | Administrative/social admission |
| 256 | Medical examination/evaluation |
| 257 | Other aftercare |
| 258 | Other screening for suspected conditions (not mental disorders or infectious disease) |
| 259 | Residual codes; unclassified |
| 653 | Delirium, dementia, and amnestic and other cognitive disorders |
| 660 | Alcohol-related disorders |
| 661 | Substance-related disorders |
| | |

| AHRQ Diagnosis CCS | Description |
|-----------------------|--|
| 663 | Screening and history of mental health and substance abuse codes |

Risk Adjustment

Table A.8: Principal Discharge Diagnosis Risk Variables Common to All HWR Specialty Cohorts

| Variable | Description |
|-------------------------------|---|
| n/a | Mean age, years |
| CC 7 | Metastatic cancer/acute leukemia |
| CC 8, 9 | Severe Cancer |
| CC 10-12 | Other cancers |
| CC 44 | Severe hematological disorders |
| CC 46 | Coagulation defects and other specified hematological disorders |
| CC 47 | Iron deficiency or other unspecified anemias and blood disease |
| CC 25, 26 | End-stage liver disease |
| CC 32 | Pancreatic disease |
| CC 130 | Dialysis status |
| CC 131 | Acute renal failure |
| CC 128, 174 | Transplants |
| CC 1, 3-5 | Severe Infection |
| CC 6, 111-113 | Other infectious diseases and pneumonias |
| CC 2 | Septicemia/Shock |
| CC 80 | CHF |
| CC 81-84, 89, 98, 99, 103-106 | Coronary atherosclerosis or angina, cerebrovascular disease |
| CC 92, 93 | Specified arrhythmias |
| CC 79 | Cardio-respiratory failure or cardio-respiratory shock |
| CC 108 | COPD |
| CC 109 | Fibrosis of lung or other chronic lung disorders |
| CC 21 | Protein-calorie malnutrition |
| CC 22, 23 | Disorders of fluid, electrolyte, acid-base |
| CC 38 | Rheumatoid arthritis and inflammatory connective tissue disease |
| CC 15-20, 119, 120 | Diabetes mellitus |
| CC 148, 149 | Decubitus ulcer or chronic skin ulcer |
| CC 67-69, 100-102, 177, 178 | Hemiplegia, paraplegia, paralysis, functional disability |
| CC 74 | Seizure disorders and convulsions |
| CC 77 | Respirator dependence/tracheostomy status |
| CC 51, 52 | Drug and Alcohol disorders |
| CC 54-56, 58, 60 | Psychiatric comorbidity |
| CC 158 | Hip fracture/dislocation |

Table A.9: Comorbidity Indicators for Medicine Specialty Cohort

| Variable | Description |
|----------|---------------------------------------|
| CCS 1 | Tuberculosis |
| CCS 2 | Septicemia (except in labor) |
| CCS 3 | Bacterial infection; unspecified site |
| CCS 4 | Mycoses |
| CCS 5 | HIV infection |

| Variable | Description |
|--------------------|--|
| CCS 6 | Hepatitis |
| CCS 7 | Viral infection |
| CCS 8 | Other infections; including parasitic |
| CCS 9 | Sexually transmitted infections (not HIV or hepatitis) |
| CCS 10 | Immunizations and screening for infectious disease |
| CCS 46 | Benign neoplasm of uterus |
| CCS 47 | Other and unspecified benign neoplasm |
| CCS 48 | Thyroid disorders |
| CCS 49 | Diabetes mellitus without complication |
| CCS 50 | Diabetes mellitus with complications |
| CCS 51 | Other endocrine disorders |
| CCS 52 | Nutritional deficiencies |
| CCS 53 | Disorders of lipid metabolism |
| CCS 54 | Gout and other crystal arthropathies |
| CCS 55 | Fluid and electrolyte disorders |
| CCS 57 | Immunity disorders |
| CCS 58 | Other nutritional; endocrine; and metabolic disorders |
| CCS 59 | Deficiency and other anemia |
| CCS 60 | Acute posthemorrhagic anemia |
| CCS 61 | Sickle cell anemia |
| CCS 62 | Coagulation and hemorrhagic disorders |
| CCS 63 | Diseases of white blood cells |
| CCS 64 | Other hematologic conditions |
| CCS 76 | Meningitis (except that caused by tuberculosis or sexually transmitted disease) |
| CCS 77 | Encephalitis (except that caused by tuberculosis or sexually transmitted disease) |
| CCS 84 | Headache; including migraine |
| CCS 86 | Cataract |
| CCS 87 | Retinal detachments; defects; vascular occlusion; and retinopathy |
| CCS 88 | Glaucoma |
| CCS 89 | Blindness and vision defects |
| CCS 90 | Inflammation; infection of eye (except that caused by tuberculosis or sexually transmitted |
| | disease) |
| CCS 91 | Other eye disorders |
| CCS 92 | Otitis media and related conditions |
| CCS 93 | Conditions associated with dizziness or vertigo |
| CCS 94 | Other ear and sense organ disorders |
| CCS 98 | Essential hypertension |
| CCS 99 CCS 118 | Hypertension with complications and secondary hypertension Phlebitis; thrombophlebitis and thromboembolism |
| CCS 118 | Varicose veins of lower extremity |
| CCS 119 | Hemorrhoids |
| CCS 120 CCS 121 | Other diseases of veins and lymphatics |
| CCS 121 | Influenza |
| CCS 123 | Acute and chronic tonsillitis |
| CCS 124 CCS 126 | |
| CCS 126 CCS 129 | Other upper respiratory infections Aspiration pneumonitis; food/vomitus |
| CCS 129 CCS 130 | Pleurisy; pneumothorax; pulmonary collapse |
| CCS 130 | Lung disease due to external agents |
| CC3 132 | Lung disease due to external agents |

| Variable | Description |
|----------|--|
| CCS 133 | Other lower respiratory disease |
| CCS 134 | Other upper respiratory disease |
| CCS 135 | Intestinal infection |
| CCS 136 | Disorders of teeth and jaw |
| CCS 137 | Diseases of mouth; excluding dental |
| CCS 138 | Esophageal disorders |
| CCS 139 | Gastroduodenal ulcer (except hemorrhage) |
| CCS 140 | Gastritis and duodenitis |
| CCS 141 | Other disorders of stomach and duodenum |
| CCS 142 | Appendicitis and other appendiceal conditions |
| CCS 143 | Abdominal hernia |
| CCS 144 | Regional enteritis and ulcerative colitis |
| CCS 145 | Intestinal obstruction without hernia |
| CCS 146 | Diverticulosis and diverticulitis |
| CCS 147 | Anal and rectal conditions |
| CCS 148 | Peritonitis and intestinal abscess |
| CCS 149 | Biliary tract disease |
| CCS 152 | Pancreatic disorders (not diabetes) |
| CCS 151 | Other liver diseases |
| CCS 153 | Gastrointestinal hemorrhage |
| CCS 154 | Noninfectious gastroenteritis |
| CCS 155 | Other gastrointestinal disorders |
| CCS 156 | Nephritis; nephrosis; renal sclerosis |
| CCS 157 | Acute and unspecified renal failure |
| CCS 158 | Chronic renal failure |
| CCS 159 | Urinary tract infections |
| CCS 160 | Calculus of urinary tract |
| CCS 161 | Other diseases of kidney and ureters |
| CCS 162 | Other diseases or bladder and urethra |
| CCS 163 | Genitourinary symptoms and ill-defined conditions |
| CCS 164 | Hyperplasia of prostate |
| CCS 165 | Inflammatory conditions of male genital organs |
| CCS 166 | Other male genital disorders |
| CCS 167 | Nonmalignant breast conditions |
| CCS 168 | Inflammatory diseases of female pelvic organs |
| CCS 169 | Endometriosis |
| CCS 170 | Prolapse of female genital organs |
| CCS 171 | Menstrual disorders |
| CCS 172 | Ovarian cyst |
| CCS 173 | Menopausal disorders |
| CCS 174 | Female infertility |
| CCS 175 | Other female genital disorders |
| CCS 197 | Skin and subcutaneous tissue infections |
| CCS 198 | Other inflammatory condition of skin |
| CCS 199 | Chronic ulcer of skin |
| CCS 200 | Other skin disorders |
| CCS 201 | Infective arthritis and osteomyelitis (except that caused by tuberculosis or sexually transmitted disease) |
| | · |

| Variable Description | |
|--|----------------|
| CCS 202 Rheumatoid arthritis and related disease | |
| CCS 203 Osteoarthritis | |
| CCS 204 Other non-traumatic joint disorders | |
| CCS 205 Spondylosis; intervertebral disc disorders; other back problems) | |
| CCS 206 Osteoporosis | |
| CCS 207 Pathological fracture | |
| CCS 208 Acquired foot deformities | |
| CCS 209 Other acquired deformities | |
| CCS 210 Systemic lupus erythematosus and connective tissue disorders | |
| CCS 211 Other connective tissue disease | |
| CCS 212 Other bone disease and musculoskeletal deformities | |
| CCS 214 Digestive congenital anomalies | |
| CCS 215 Genitourinary congenital anomalies | |
| CCS 217 Other congenital anomalies | |
| CCS 225 Joint disorders and dislocations; trauma-related | |
| CCS 226 Fracture of neck or femur (hip) | |
| CCS 228 Skull and face fractures | |
| CCS 229 Fracture of upper limb | |
| CCS 230 Fracture of lower limb | |
| CCS 231 Other fractures | |
| CCS 232 Sprains and strains | |
| CCS 234 Crushing injury or internal injury | |
| CCS 235 Open wounds of head; neck; and trunk | |
| CCS 236 Open wounds of extremities | |
| CCS 237 Complication of device; implant or graft | |
| CCS 238 Complications of surgical procedures or medical care | |
| CCS 239 Superficial injury; contusion | |
| CCS 240 Burns | |
| CCS 241 Poisoning by psychotropic agents | |
| CCS 242 Poisoning by other medications and drugs | |
| CCS 243 Poisoning by nonmedicinal substances | |
| CCS 244 Other injuries and conditions due to external causes | |
| CCS 245 Syncope | |
| CCS 246 Fever of unknown origin | |
| CCS 247 Lymphadenitis | |
| CCS 248 Gangrene | |
| CCS 249 Shock | |
| CCS 250 Nausea and vomiting | |
| CCS 251 Abdominal pain | |
| CCS 252 Malaise and fatigue | |
| CCS 253 Allergic reactions | |
| CCS 255 Administrative/social admission | |
| CCS 256 Medical examination/evaluation | |
| CCS 257 Other aftercare | |
| CCS 258 Other screening for suspected conditions (not mental disorders or infect | tious disease) |
| CCS 259 Residual codes; unclassified | · |
| CCS 653 Delirium, dementia, and amnestic and other cognitive disorders | |
| | |

| Variable | Description |
|----------|--|
| CCS 661 | Substance-related disorders |
| CCS 663 | Screening and history of mental health and substance abuse codes |

Table A.10: Comorbidity Indicators for Surgery/Gynecology Specialty Cohort

| Variable | Description |
|----------|--|
| CCS 1 | Tuberculosis |
| CCS 2 | Septicemia (except in labor) |
| CCS 3 | Bacterial infection; unspecified site |
| CCS 4 | Mycoses |
| CCS 5 | HIV infection |
| CCS 6 | Hepatitis |
| CCS 7 | Viral infection |
| CCS 8 | Other infections; including parasitic |
| CCS 9 | Sexually transmitted infections (not HIV or hepatitis) |
| CCS 10 | Immunizations and screening for infectious disease |
| CCS 11 | Cancer of head and neck |
| CCS 12 | Cancer of esophagus |
| CCS 13 | Cancer of stomach |
| CCS 14 | Cancer of colon |
| CCS 15 | Cancer of rectum and anus |
| CCS 16 | Cancer of liver and intrahepatic bile duct |
| CCS 17 | Cancer of pancreas |
| CCS 18 | Cancer of other GI organs; peritoneum |
| CCS 19 | Cancer of bronchus; lung |
| CCS 20 | Cancer; other respiratory and intrathoracic |
| CCS 21 | Cancer of bone and connective tissue |
| CCS 22 | Melanomas of skin |
| CCS 23 | Other non-epithelial cancer of skin |
| CCS 24 | Cancer of breast |
| CCS 25 | Cancer of uterus |
| CCS 26 | Cancer of cervix |
| CCS 27 | Cancer of ovary |
| CCS 28 | Cancer of other female genital organs |
| CCS 29 | Cancer of prostate |
| CCS 30 | Cancer of testis |
| CCS 31 | Cancer of other male genital organs |
| CCS 32 | Cancer of bladder |
| CCS 33 | Cancer of kidney and renal pelvis |
| CCS 34 | Cancer of other urinary organs |
| CCS 35 | Cancer of brain and nervous system |
| CCS 36 | Cancer of thyroid |
| CCS 37 | Hodgkin's disease |
| CCS 38 | Non-Hodgkin's lymphoma |
| CCS 39 | Leukemias |
| CCS 40 | Multiple myeloma |
| CCS 41 | Cancer; other and unspecified primary |
| CCS 42 | Secondary malignancies |

| Variable | Description |
|----------|--|
| CCS 43 | Malignant neoplasm without specification of site |
| CCS 44 | Neoplasms of unspecified nature or uncertain behavior |
| CCS 45 | Maintenance chemotherapy; radiotherapy |
| CCS 46 | Benign neoplasm of uterus |
| CCS 47 | Other and unspecified benign neoplasm |
| CCS 48 | Thyroid disorders |
| CCS 49 | Diabetes mellitus without complications |
| CCS 50 | Diabetes mellitus with complications |
| CCS 51 | Other endocrine disorders |
| CCS 52 | Nutritional deficiencies |
| CCS 53 | Disorders of lipid metabolism |
| CCS 54 | Gout and other crystal arthropathies |
| CCS 55 | Fluid and electrolyte disorders |
| CCS 57 | Immunity disorders |
| CCS 58 | Other nutritional; endocrine; and metabolic disorders |
| CCS 59 | Deficiency and other anemia |
| CCS 60 | Acute posthemorrhagic anemia |
| CCS 61 | Sickle cell anemia |
| CCS 62 | Coagulation and hemorrhagic disorders |
| CCS 63 | Diseases of white blood cells |
| CCS 64 | Other hematologic conditions |
| CCS 76 | Meningitis (except that caused by tuberculosis or sexually transmitted disease) |
| CCS 77 | Encephalitis (except that caused by tuberculosis or sexually transmitted disease) |
| CCS 78 | Other CNS infection and poliomyelitis |
| CCS 79 | Parkinson's disease |
| CCS 80 | Multiple sclerosis |
| CCS 81 | Other hereditary and degenerative nervous system conditions |
| CCS 82 | Paralysis |
| CCS 83 | Epilepsy; convulsions |
| CCS 84 | Headache; including migraine |
| CCS 85 | Coma; stupor; and brain damage |
| CCS 86 | Cataract |
| CCS 87 | Retinal detachments; defects; vascular occlusion; and retinopathy |
| CCS 88 | Glaucoma |
| CCS 89 | Blindness and vision defects |
| CCS 90 | Inflammation; infection of eye (except that caused by tuberculosis or sexually transmitted |
| | disease) |
| CCS 91 | Other eye disorders |
| CCS 92 | Otitis media and related conditions |
| CCS 93 | Conditions associated with dizziness or vertigo |
| CCS 94 | Other ear and sense organ disorders |
| CCS 95 | Other nervous system disorders |
| CCS 96 | Heart valve disorders |
| CCS 97 | Peri-; endo-; and myocarditis; cardiomyopathy (except that caused by tuberculosis or sexually transmitted disease) |
| CCS 98 | Essential hypertension |
| CCS 99 | Hypertension with complications and secondary hypertension |
| CCS 100 | Acute myocardial infarction |

| Variable | Description |
|----------|--|
| CCS 101 | Coronary atherosclerosis and other heart disease |
| CCS 102 | Nonspecific chest pain |
| CCS 103 | Pulmonary heart disease |
| CCS 104 | Other and ill-defined heart disease |
| CCS 105 | Conduction disorders |
| CCS 106 | Cardiac dysrhythmias |
| CCS 107 | Cardiac arrest and ventricular fibrillation |
| CCS 108 | Congestive heart failure; non-hypertensive |
| CCS 109 | Acute cerebrovascular disease |
| CCS 110 | Occlusion or stenosis of precerebral arteries |
| CCS 111 | Other and ill-defined cerebrovascular disease |
| CCS 112 | Transient cerebral ischemia |
| CCS 113 | Late effects of cerebrovascular disease |
| CCS 114 | Peripheral and visceral atherosclerosis |
| CCS 115 | Aortic; peripheral; and visceral artery aneurysms |
| CCS 116 | Aortic and peripheral arterial embolism or thrombosis |
| CCS 117 | Other circulatory disease |
| CCS 118 | Phlebitis; thrombophlebitis and thromboembolism |
| CCS 119 | Varicose veins of lower extremity |
| CCS 120 | Hemorrhoids |
| CCS 121 | Other diseases of veins and lymphatics |
| CCS 122 | Pneumonia (except that caused by tuberculosis or sexually transmitted disease) |
| CCS 123 | Influenza |
| CCS 124 | Acute and chronic tonsillitis |
| CCS 125 | Acute bronchitis |
| CCS 126 | Other upper respiratory infections |
| CCS 127 | Chronic obstructive pulmonary disease and bronchiectasis |
| CCS 128 | Asthma |
| CCS 129 | Aspiration pneumonitis; food/vomitus |
| CCS 130 | Pleurisy; pneumothorax; pulmonary collapse |
| CCS 131 | Respiratory failure; insufficiency; arrest (adult) |
| CCS 132 | Lung disease due to external agents |
| CCS 133 | Other lower respiratory disease |
| CCS 134 | Other upper respiratory disease |
| CCS 135 | Intestinal infection |
| CCS 136 | Disorders of teeth and jaw |
| CCS 137 | Diseases of mouth; excluding dental |
| CCS 138 | Esophageal disorders |
| CCS 139 | Gastroduodenal ulcer (except hemorrhage) |
| CCS 140 | Gastritis and duodenitis |
| CCS 141 | Other disorders of stomach and duodenum |
| CCS 142 | Appendicitis and other appendiceal conditions |
| CCS 143 | Abdominal hernia |
| CCS 144 | Regional enteritis and ulcerative colitis |
| CCS 145 | Intestinal obstruction without hernia |
| CCS 146 | Diverticulosis and diverticulitis |
| CCS 147 | Anal and rectal conditions |

| Variable | Description |
|----------|---|
| CCS 148 | Peritonitis and intestinal abscess |
| CCS 149 | Biliary tract disease |
| CCS 151 | Other liver diseases |
| CCS 152 | Pancreatic disorders (not diabetes) |
| CCS 153 | Gastrointestinal hemorrhage |
| CCS 154 | Noninfectious gastroenteritis |
| CCS 155 | Other gastrointestinal disorders |
| CCS 156 | Nephritis; nephrosis; renal sclerosis |
| CCS 157 | Acute and unspecified renal failure |
| CCS 158 | Chronis kidney disease |
| CCS 159 | Urinary tract infections |
| CCS 160 | Calculus of urinary tract |
| CCS 161 | Other diseases of kidney and ureters |
| CCS 162 | Other diseases or bladder and urethra |
| CCS 163 | Genitourinary symptoms and ill-defined conditions |
| CCS 164 | Hyperplasia of prostate |
| CCS 165 | Inflammatory conditions of male genital organs |
| CCS 166 | Other male genital disorders |
| CCS 167 | Nonmalignant breast conditions |
| CCS 168 | Inflammatory diseases of female pelvic organs |
| CCS 169 | Endometriosis |
| CCS 170 | Prolapse of female genital organs |
| CCS 171 | Menstrual disorders |
| CCS 172 | Ovarian cyst |
| CCS 173 | Menopausal disorders |
| CCS 175 | Other female genital disorders |
| CCS 197 | Skin and subcutaneous tissue infections |
| CCS 198 | Other inflammatory condition of skin |
| CCS 199 | Chronic ulcer of skin |
| CCS 200 | Other skin disorders |
| CCS 201 | Infective arthritis and osteomyelitis (except that caused by tuberculosis or sexually transmitted |
| CCS 201 | disease) |
| CCS 202 | Rheumatoid arthritis and related disease |
| CCS 203 | Osteoarthritis |
| CCS 204 | Other non-traumatic joint disorders |
| CCS 205 | Spondylosis; intervertebral disc disorders; other back problems |
| CCS 206 | Osteoporosis |
| CCS 207 | Pathological fracture |
| CCS 208 | Acquired foot deformities |
| CCS 209 | Other acquired deformities |
| CCS 210 | Systemic lupus erythematosus and connective tissue disorders |
| CCS 211 | Other connective tissue disease |
| CCS 212 | Other bone disease and musculoskeletal deformities |
| CCS 213 | Cardiac and circulatory congenital anomalies |
| CCS 214 | Digestive congenital anomalies |
| CCS 215 | Genitourinary congenital anomalies |
| CCS 216 | Nervous system congenital anomalies |
| CCS 217 | Other congenital anomalies |

| Variable | Description |
|----------|---|
| CCS 225 | Joint disorders and dislocations; trauma-related |
| CCS 226 | Fracture of neck or femur (hip) |
| CCS 227 | Spinal cord injury |
| CCS 228 | Skull and face fractures |
| CCS 229 | Fracture of upper limb |
| CCS 231 | Other fractures |
| CCS 234 | Crushing injury or internal injury |
| CCS 236 | Open wounds of extremities |
| CCS 237 | Complication of device; implant or graft |
| CCS 230 | Fracture of lower limb |
| CCS 232 | Sprains and strains |
| CCS 233 | Intracranial injury (CCS 233) |
| CCS 235 | Open wounds of head; neck; and trunk |
| CCS 238 | Complications of surgical procedures or medical care |
| CCS 239 | Superficial injury; contusion |
| CCS 240 | Burns |
| CCS 241 | Poisoning by psychotropic agents |
| CCS 242 | Poisoning by other medications and drugs |
| CCS 243 | Poisoning by nonmedical substances |
| CCS 244 | Other injuries and conditions due to external causes |
| CCS 248 | Gangrene |
| CCS 249 | Shock |
| CCS 250 | Nausea and vomiting |
| CCS 251 | Abdominal pain |
| CCS 252 | Malaise and fatigue |
| CCS 253 | Allergic reactions |
| CCS 256 | Medical examination/evaluation |
| CCS 257 | Other aftercare |
| CCS 258 | Other screening for suspected conditions (not mental disorders or infectious disease) |
| CCS 259 | Residual codes; unclassified |
| CCS 653 | Delirium, dementia, and amnestic and other cognitive disorders |
| CCS 660 | Alcohol-related disorders |
| CCS 661 | Substance-related disorders |
| CCS 663 | Screening and history of mental health and substance abuse codes |

Table A.11: Comorbidity Indicators for Cardiovascular Specialty Cohort

| Variable | Description |
|----------|--|
| CCS 96 | Heart valve disorders |
| CCS 97 | Peri-; endo-; and myocarditis; cardiomyopathy (except that caused by tuberculosis or sexually transmitted disease) |
| CCS 100 | Acute myocardial infarction |
| CCS 101 | Coronary atherosclerosis and other heart disease |
| CCS 102 | Nonspecific chest pain |
| CCS 104 | Other and ill-defined heart disease |
| CCS 105 | Conduction disorders |
| CCS 106 | Cardiac dysrhythmias |
| CCS 107 | Cardiac arrest and ventricular fibrillation |

| Variable | Description |
|----------|---|
| CCS 114 | Peripheral and visceral atherosclerosis |
| CCS 115 | Aortic; peripheral; and visceral artery aneurysms |
| CCS 116 | Aortic and peripheral arterial embolism or thrombosis |
| CCS 117 | Other circulatory disease |
| CCS 213 | Cardiac and circulatory congenital anomalies |

Table A.12: Comorbidity Indicators for Cardiorespiratory Specialty Cohort

| Variable | Description |
|----------|--|
| CCS 56 | Cystic fibrosis |
| CCS 103 | Pulmonary heart disease |
| CCS 108 | Congestive heart failure; non-hypertensive |
| CCS 122 | Pneumonia (except that caused by tuberculosis or sexually transmitted disease) |
| CCS 125 | Acute bronchitis |
| CCS 127 | Chronic obstructive pulmonary disease and bronchiectasis |
| CCS 128 | Asthma |
| CCS 131 | Respiratory failure; insufficiency; arrest (adult) |

Table A.13: Comorbidity Indicators for Neurology Specialty Cohort

| Variable | Description |
|----------|---|
| CCS 78 | Other CNS infection and poliomyelitis |
| CCS 79 | Parkinson's disease |
| CCS 80 | Multiple sclerosis |
| CCS 81 | Other hereditary and degenerative nervous system conditions |
| CCS 82 | Paralysis |
| CCS 83 | Epilepsy; convulsions |
| CCS 85 | Coma; stupor; and brain damage |
| CCS 95 | Other nervous system disorders |
| CCS 109 | Acute cerebrovascular disease |
| CCS 110 | Occlusion or stenosis of precerebral arteries |
| CCS 111 | Other and ill-defined cerebrovascular disease |
| CCS 112 | Transient cerebral ischemia |
| CCS 113 | Late effects of cerebrovascular disease |
| CCS 216 | Nervous system congenital anomalies |
| CCS 227 | Spinal cord injury |
| CCS 233 | Intracranial injury |

Table A.14: Complications of Care Variables Not Used in Risk Adjustment If Occurring Only During the Index Admission

| Variable | Description |
|----------|--|
| CC 2 | Septicemia/Shock |
| CC 6 | Other Infectious Diseases |
| CC 17 | Diabetes with Acute Complications |
| CC 23 | Disorders of Fluid/Electrolyte/Acid-Base |
| CC 28 | Acute Liver Failure/Disease |
| CC 31 | Intestinal Obstruction/Perforation |
| CC 34 | Peptic Ulcer, Hemorrhage, Other Specified Gastrointestinal Disorders |
| CC 46 | Coagulation Defects and Other Specified Hematological Disorders |

| Variable | Description |
|----------|--|
| CC 48 | Delirium and Encephalopathy |
| CC 75 | Coma, Brain Compression/Anoxic Damage |
| CC 77 | Respirator Dependence/Tracheostomy Status |
| CC 78 | Respiratory Arrest |
| CC 79 | Cardio-Respiratory Failure and Shock |
| CC 80 | Congestive Heart Failure |
| CC 81 | Acute Myocardial Infarction |
| CC 82 | Unstable Angina and Other Acute Ischemic Heart Disease |
| CC 92 | Specified Heart Arrhythmias |
| CC 93 | Other Heart Rhythm and Conduction Disorders |
| CC 95 | Cerebral Hemorrhage |
| CC 96 | Ischemic or Unspecified Stroke |
| CC 97 | Precerebral Arterial Occlusion and Transient Cerebral Ischemia |
| CC 100 | Hemiplegia/Hemiparesis |
| CC 101 | Diplegia (Upper), Monoplegia, and Other Paralytic Syndromes |
| CC 102 | Speech, Language, Cognitive, Perceptual |
| CC 104 | Vascular Disease with Complications |
| CC 105 | Vascular Disease |
| CC 106 | Other Circulatory Disease |
| CC 111 | Aspiration and Specified Bacterial Pneumonias |
| CC 112 | Pneumococcal Pneumonia, Emphysema, Lung Abscess |
| CC 114 | Pleural Effusion/Pneumothorax |
| CC 129 | End Stage Renal Disease |
| CC 130 | Dialysis Status |
| CC 131 | Renal Failure |
| CC 132 | Nephritis |
| CC 133 | Urinary Obstruction and Retention |
| CC 135 | Urinary Tract Infection |
| CC 148 | Decubitus Ulcer of Skin |
| CC 152 | Cellulitis, Local Skin Infection |
| CC 154 | Severe Head Injury |
| CC 155 | Major Head Injury |
| CC 156 | Concussion or Unspecified Head Injury |
| CC 158 | Hip Fracture/Dislocation |
| CC 159 | Major Fracture, Except of Skull, Vertebrae, or Hip |
| CC 163 | Poisonings and Allergic Reactions |
| CC 164 | Major Complications of Medical Care and Trauma |
| CC 165 | Other Complications of Medical Care |
| CC 174 | Major Organ Transplant Status |
| CC 175 | Other Organ Transplant/Replacement |
| CC 176 | Artificial Openings for Feeding or Elimination |
| CC 177 | Amputation Status, Lower Limb/Amputation |
| CC 178 | Amputation Status, Upper Limb |
| CC 179 | Post-Surgical States/Aftercare/Elective |

Outcome

Outcome Criteria for HWR Measure

1. 30-day time frame

Rationale: Outcomes occurring within 30 days of discharge can be influenced by hospital care and the early transition to the outpatient setting. The use of the 30-day time frame is a clinically meaningful period for hospitals to collaborate with their communities to reduce readmissions.

2. All-cause unplanned readmission

Rationale: From a patient perspective, an unplanned readmission from any cause is an adverse event.

3. Unplanned readmission

Rationale: Planned readmissions are generally not a signal of quality of care. Including planned readmissions in a readmission measure could create a disincentive to provide appropriate care to patients who are scheduled for elective or necessary procedures within 30 days of discharge.



Readmission Readmission is for bone marrow, Yes kidney, or other organ transplant* (Table PR1) No Readmission is for maintenance Yes chemotherapy or rehabilitation** (Table PR2) No Readmission includes a Yes potentially planned procedure (Table PR3) No Principal discharge diagnosis of readmission is acute or complication of care (Table PR4) Yes No **PLANNED UNPLANNED** *When the measure is used with all-payer data, readmissions for cesarean section or forceps, vacuum, or breech delivery are considered planned

**When the measure is used with all-payer data, readmissions for forceps or normal delivery are

considered planned

Figure PR.1 - Planned Readmission Algorithm Version 3.0 Flowchart

Planned Readmission Algorithm Version 3.0 Tables - HWR Measure

Table PR.1: Procedure Categories that are Always Planned (Version 3.0)

| Procedure CCS | Description |
|------------------|---|
| 64 | Bone marrow transplant |
| 105 | Kidney transplant |
| 134 | Cesarean section [‡] |
| 135 | Forceps; vacuum; and breech delivery [§] |
| 176 | Other organ transplantation |

Table PR.2: Diagnosis Categories that are Always Planned (Version 3.0)

| Diagnosis CCS | Description | |
|------------------|--------------------------------------|--|
| 45 | Maintenance chemotherapy | |
| 194 | Forceps delivery** | |
| 196 | Normal pregnancy and/or delivery *** | |
| 254 | Rehabilitation | |

Table PR.3: Potentially Planned Procedure Categories (Version 3.0)

| Procedure CCS | Description |
|------------------|--|
| 3 | Laminectomy; excision intervertebral disc |
| 5 | Insertion of catheter or spinal stimulator and injection into spinal |
| 9 | Other OR therapeutic nervous system procedures |
| 10 | Thyroidectomy; partial or complete |
| 12 | Other therapeutic endocrine procedures |
| 33 | Other OR therapeutic procedures on nose; mouth and pharynx |
| 36 | Lobectomy or pneumonectomy |
| 38 | Other diagnostic procedures on lung and bronchus |
| 40 | Other diagnostic procedures of respiratory tract and mediastinum |
| 43 | Heart valve procedures |
| 44 | Coronary artery bypass graft (CABG) |
| 45 | Percutaneous transluminal coronary angioplasty (PTCA) |
| 47 | Diagnostic cardiac catheterization; coronary arteriography |
| 48 | Insertion; revision; replacement; removal of cardiac pacemaker or cardioverter/defibrillator |
| 49 | Other OR heart procedures |

[‡] CCS to be included only in all-payer settings, not intended for inclusion in CMS' claims-based readmission measures for Medicare fee-for-service beneficiaries aged 65+ years.

[§] CCS to be included only in all-payer settings, not intended for inclusion in CMS' claims-based readmission measures for Medicare fee-for-service beneficiaries aged 65+ years.

^{**} CCS to be included only in all-payer settings, not intended for inclusion in CMS' claims-based readmission measures for Medicare fee-for-service beneficiaries aged 65+ years.

to CCS to be included only in all-payer settings, not intended for inclusion in CMS' claims-based readmission measures for Medicare fee-for-service beneficiaries aged 65+ years.

| Procedure | Description | |
|--------------|---|--|
| ccs | Description | |
| 51 | Endarterectomy; vessel of head and neck | |
| 52 | Aortic resection; replacement or anastomosis | |
| 53 | Varicose vein stripping; lower limb | |
| 55 | Peripheral vascular bypass | |
| 56 | Other vascular bypass and shunt; not heart | |
| 59 | Other OR procedures on vessels of head and neck | |
| 62 | Other diagnostic cardiovascular procedures | |
| 66 | Procedures on spleen | |
| 67 | Other therapeutic procedures; hemic and lymphatic system | |
| 74 | Gastrectomy; partial and total | |
| 78 | Colorectal resection | |
| 79 | Local excision of large intestine lesion (not endoscopic) | |
| 84 | Cholecystectomy and common duct exploration | |
| 85 | Inguinal and femoral hernia repair | |
| 86 | Other hernia repair | |
| 99 | Other OR gastrointestinal therapeutic procedures | |
| 104 | Nephrectomy; partial or complete | |
| 106 | Genitourinary incontinence procedures | |
| 107 | Extracorporeal lithotripsy; urinary | |
| 109 | Procedures on the urethra | |
| 112 | Other OR therapeutic procedures of urinary tract | |
| 113 | Transurethral resection of prostate (TURP) | |
| 114 | Open prostatectomy | |
| 119 | Oophorectomy; unilateral and bilateral | |
| 120 | Other operations on ovary | |
| 124 | Hysterectomy; abdominal and vaginal | |
| 129 | Repair of cystocele and rectocele; obliteration of vaginal vault | |
| 132 | Other OR therapeutic procedures; female organs | |
| 142 | Partial excision bone | |
| 152 | Arthroplasty knee | |
| 153 | Hip replacement; total and partial | |
| 154 | Arthroplasty other than hip or knee | |
| 157 | Amputation of lower extremity | |
| 158 | Spinal fusion | |
| 159 | Other diagnostic procedures on musculoskeletal system | |
| 166 | Lumpectomy; quadrantectomy of breast | |
| 167 | Mastectomy | |
| 169 | Debridement of wound; infection or burn | |
| 170 | Excision of skin lesion | |
| 172 | Skin graft | |
| ICD-9 Codes | Description | |
| 30.1, 30.29, | Laryngectomy, revision of tracheostomy, scarification of pleura (from Proc CCS 42- Other OR Rx | |
| 30.3, 30.4, | procedures on respiratory system and mediastinum) | |
| 31.74, 34.6 | | |
| 38.18 | Endarterectomy leg vessel (from Proc CCS 60- Embolectomy and endarterectomy of lower limbs) | |
| 55.03, 55.04 | Percutaneous nephrostomy with and without fragmentation (from Proc CCS 103- Nephrotomy and nephrostomy) | |
| 94.26, 94.27 | Electroshock therapy (from Proc CCS 218- Psychological and psychiatric evaluation and therapy) | |

Table PR.4: Acute Diagnosis Categories (Version 3.0)

| Diagnosis CCS | Description |
|---------------|---|
| 1 | Tuberculosis |
| 2 | Septicemia (except in labor) |
| 3 | Bacterial infection; unspecified site |
| 4 | Mycoses |
| 5 | HIV infection |
| 7 | Viral infection |
| 8 | Other infections; including parasitic |
| 9 | Sexually transmitted infections (not HIV or hepatitis) |
| 54 | Gout and other crystal arthropathies |
| 55 | Fluid and electrolyte disorders |
| 60 | Acute posthemorrhagic anemia |
| 61 | Sickle cell anemia |
| 63 | Diseases of white blood cells |
| 76 | Meningitis (except that caused by tuberculosis or sexually transmitted disease) |
| 77 | Encephalitis (except that caused by tuberculosis or sexually transmitted disease) |
| 78 | Other CNS infection and poliomyelitis |
| 82 | Paralysis |
| 83 | Epilepsy; convulsions |
| 84 | Headache; including migraine |
| 85 | Coma; stupor; and brain damage |
| 87 | Retinal detachments; defects; vascular occlusion; and retinopathy |
| 89 | Blindness and vision defects |
| 90 | Inflammation; infection of eye (except that caused by tuberculosis or sexually transmitted disease) |
| 91 | Other eye disorders |
| 92 | Otitis media and related conditions |
| 93 | Conditions associated with dizziness or vertigo |
| 99 | Hypertension with complications |
| 100 | Acute myocardial infarction (with the exception of ICD-9 codes 410.x2) |
| 102 | Nonspecific chest pain |
| 104 | Other and ill-defined heart disease |
| 107 | Cardiac arrest and ventricular fibrillation |
| 109 | Acute cerebrovascular disease |
| 112 | Transient cerebral ischemia |
| 116 | Aortic and peripheral arterial embolism or thrombosis |
| 118 | Phlebitis; thrombophlebitis and thromboembolism |
| 120 | Hemorrhoids |
| 122 | Pneumonia (except that caused by TB or sexually transmitted disease) |
| 123 | Influenza |
| 124 | Acute and chronic tonsillitis |
| 125 | Acute bronchitis |
| 126 | Other upper respiratory infections |
| 127 | Chronic obstructive pulmonary disease and bronchiectasis |
| 128 | Asthma |
| 129 | Aspiration pneumonitis; food/vomitus |
| 130 | Pleurisy; pneumothorax; pulmonary collapse |
| 131 | Respiratory failure; insufficiency; arrest (adult) |
| 135 | Intestinal infection |
| | |

| Diagnosis CCS | Description |
|---------------|--|
| 137 | Diseases of mouth; excluding dental |
| 139 | Gastroduodenal ulcer (except hemorrhage) |
| 140 | Gastritis and duodenitis |
| 142 | Appendicitis and other appendiceal conditions |
| 145 | Intestinal obstruction without hernia |
| 146 | Diverticulosis and diverticulitis |
| 148 | Peritonitis and intestinal abscess |
| 153 | Gastrointestinal hemorrhage |
| 154 | Noninfectious gastroenteritis |
| 157 | Acute and unspecified renal failure |
| 159 | Urinary tract infections |
| 165 | Inflammatory conditions of male genital organs |
| 168 | Inflammatory diseases of female pelvic organs |
| 172 | Ovarian cyst |
| 197 | Skin and subcutaneous tissue infections |
| 198 | Other inflammatory condition of skin |
| 225 | Joint disorders and dislocations; trauma-related |
| 226 | Fracture of neck of femur (hip) |
| 227 | Spinal cord injury |
| 228 | Skull and face fractures |
| 229 | Fracture of upper limb |
| 230 | Fracture of lower limb |
| 232 | Sprains and strains |
| 233 | Intracranial injury |
| 234 | Crushing injury or internal injury |
| 235 | Open wounds of head; neck; and trunk |
| 237 | Complication of device; implant or graft |
| 238 | Complications of surgical procedures or medical care |
| 239 | Superficial injury; contusion |
| 240 | Burns |
| 241 | Poisoning by psychotropic agents |
| 242 | Poisoning by other medications and drugs |
| 243 | Poisoning by nonmedicinal substances |
| 244 | Other injuries and conditions due to external causes |
| 245 | Syncope |
| 246 | Fever of unknown origin |
| 247 | Lymphadenitis |
| 249 | Shock |
| 250 | Nausea and vomiting |
| 251 | Abdominal pain |
| 252 | Malaise and fatigue |
| 253 | Allergic reactions Pacidual codes: unclassified |
| 259 650 | Residual codes; unclassified |
| 650 651 | Adjustment disorders |
| 651 652 | Anxiety disorders Attention deficit conduct and disruptive behavior disorders |
| 652 652 | Attention-deficit, conduct, and disruptive behavior disorders |
| 653 | Delirium, dementia, and amnestic and other cognitive disorders |
| 656 | Impulse control disorders, NEC |
| 658 | Personality disorders |

| Diagnosis CCS | Description |
|---------------------|--|
| 660 | Alcohol-related disorders |
| 661 | Substance-related disorders |
| 662 | Suicide and intentional self-inflicted injury |
| 663 | Screening and history of mental health and substance abuse codes |
| 670 | Miscellaneous disorders |
| ICD-9 codes | Description |
| Acute ICD-9 codes v | within Dx CCS 97: Peri-; endo-; and myocarditis; cardiomyopathy |
| 032.82 | Diphtheritic myocarditis |
| 036.40 | Meningococcal carditis nos |
| 036.41 | Meningococcal pericarditis |
| 036.42 | Meningococcal endocarditis |
| 036.43 | Meningococcal myocarditis |
| 074.20 | Coxsackie carditis nos |
| 074.21 | Coxsackie pericarditis |
| 074.22 | Coxsackie endocarditis |
| 074.23 | Coxsackie myocarditis |
| 112.81 | Candidal endocarditis |
| 115.03 | Histoplasma capsulatum pericarditis |
| 115.04 | Histoplasma capssulatum endocarditis |
| 115.13 | Histoplasma duboisii pericarditis |
| 115.14 | Histoplasma duboisii endocarditis |
| 115.93 | Histoplasmosis pericarditis |
| 115.94 | Histoplasmosis endocarditis |
| 130.3 | Toxoplasma myocarditis |
| 391.0 | Acute rheumatic pericarditis |
| 391.1 | Acute rheumatic endocarditis |
| 391.2 | Acute rheumatic myocarditis |
| 391.8 | Acute rheumatic heart disease nec |
| 391.9 | Acute rheumatic heart disease nos |
| 392.0 | Rheumatic chorea w heart involvement |
| 398.0 | Rheumatic myocarditis |
| 398.90 | Rheumatic heart disease nos |
| 398.99 | Rheumatic heart disease nec |
| 420.0 | Acute pericarditis in other disease |
| 420.90 | Acute pericarditis nos |
| 420.91 | Acute idiopath pericarditis |
| 420.99 | Acute pericarditis nec |
| 421.0 | Acute/subacute bacterial endocarditis |
| 421.1 | Acute endocarditis in other diseases |
| 421.9 | Acute/subacute endocarditis nos |
| 422.0 | Acute myocarditis in other diseases |
| 422.90 | Acute myocarditis nos |
| 422.91 | Idiopathic myocarditis |
| 422.92 | Septic myocarditis |
| 422.93 | Toxic myocarditis |
| 422.99 | Acute myocarditis nec |
| 423.0 | Hemopericardium |
| 423.1 | Adhesive pericarditis |
| 423.2 | Constrictive pericarditis |

| Diagnosis CCS | Description |
|---------------------|---|
| 423.3 | Cardiac tamponade |
| 429.0 | Myocarditis nos |
| Acute ICD-9 codes v | vithin Dx CCS 105: Conduction disorders |
| 426.0 | Atrioventricular |
| 426.10 | Atrioventricular block nos |
| 426.11 | Atrioventricular block-1st degree |
| 426.12 | Atrioventricular block-mobitz ii |
| 426.13 | Atrioventricular block-2nd degree nec |
| 426.2 | Left bundle branch hemiblock |
| 426.3 | Left bundle branch block nec |
| 426.4 | Right bundle branch block |
| 426.50 | Bundle branch block nos |
| 426.51 | Right bundle branch block/left posterior fascicular block |
| 426.52 | Right bundle branch block/left ant fascicular block |
| 426.53 | Bilateral bundle branch block nec |
| 426.54 | Trifascicular block |
| 426.6 | Other heart block |
| 426.7 | Anomalous atrioventricular excitation |
| 426.81 | Lown-ganong-levine syndrome |
| 426.82 | Long qt syndrome |
| 426.9 | Conduction disorder nos |
| | vithin Dx CCS 106: Dysrhythmia |
| 427.2 | Paroxysmal tachycardia nos |
| 785.0 | Tachycardia nos |
| 427.89 | Cardiac dysrhythmias nec |
| 427.9 | Cardiac dysrhythmia nos |
| 427.69 | Premature beats nec |
| | vithin Dx CCS 108: Congestive heart failure; nonhypertensive |
| 398.91 | Rheumatic heart failure |
| 428.0 | Congestive heart failure |
| 428.1 | Left heart failure |
| 428.20 | Unspecified systolic heart failure |
| 428.21 | Acute systolic heart failure |
| 428.23 | Acute on chronic systolic heart failure |
| 428.30 | Unspecified diastolic heart failure |
| 428.31 | Acute diastolic heart failure |
| 428.33 | Acute on chronic diastolic heart failure |
| 428.40 | Unspec combined syst & dias heart failure |
| 428.41 | Acute combined systolic & diastolic heart failure |
| 428.43 | Acute on chronic combined systolic & diastolic heart failure |
| 428.9 | Heart failure nos |
| | vithin Dx CCS 149: Biliary tract disease |
| 574.0 | Calculus of gallbladder with acute cholecystitis |
| 574.00 | Calculus of gallbladder with acute cholecystitis without mention of obstruction |
| 574.01 | Calculus of gallbladder with acute cholecystitis with obstruction |
| 574.3 | Calculus of bile duct with acute cholecystitis |
| 574.30 | Calculus of bile duct with acute cholecystitis without mention of obstruction |
| 574.31 | Calculus of bile duct with acute cholecystitis with obstruction |
| 574.6 | Calculus of gallbladder and bile duct with acute cholecystitis |

| Diagnosis CCS | Description |
|-------------------|---|
| 574.60 | Calculus of gallbladder and bile duct with acute cholecystitis without mention of obstruction |
| 574.61 | Calculus of gallbladder and bile duct with acute cholecystitis with obstruction |
| 574.8 | Calculus of gallbladder and bile duct with acute and chronic cholecystitis |
| 574.80 | Calculus of gallbladder and bile duct with acute and chronic cholecystitis without mention of obstruction |
| 574.81 | Calculus of gallbladder and bile duct with acute and chronic cholecystitis with obstruction |
| 575.0 | Acute cholecystitis |
| 575.12 | Acute and chronic cholecystitis |
| 576.1 | Cholangitis |
| Acute ICD-9 codes | with Dx CCS 152: Pancreatic disorders |
| 577.0 | Acute pancreatitis |



APPENDIX B: ADDITIONAL MODEL TESTING RESULTS

Table B.1: Surgery/Gynecology Specialty Cohort Hierarchical Logistic Regression Model Risk Factor Frequencies, Estimates, and Odds Ratios by Sample

| Surgery/Gynecology Readmission Rates | | | Development Samp 23,201) | le | | | Validation Sample 3,490) | | | |
|--|-----------|----------------|-----------------------------|-----------------------|-----------|----------------|-----------------------------|-----------------------|--|--|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | | |
| Intercept | -2.573 | 3.650 | | <i></i> | 0.168 | 3.333 | | | | |
| CCDE | | | | | | | | | | |
| Age | 0.029 | 0.004 | 1.03(1.02-1.04) | | 0.027 | 0.003 | 1.03(1.02-1.03) | | | |
| Systolic Blood Pressure | 0.000 | 0.001 | 1.00(1.00-1.00) | | 0.001 | 0.001 | 1.00(1.00-1.00) | | | |
| Heart Rate | 0.006 | 0.002 | 1.01(1.00-1.01) | | 0.006 | 0.002 | 1.01(1.00-1.01) | | | |
| Respiratory Rate | 0.033 | 0.010 | 1.03(1.01-1.05) | | 0.029 | 0.010 | 1.03(1.01-1.05) | | | |
| Temperature | -0.014 | 0.037 | 0.99(0.92-1.06) | | -0.041 | 0.034 | 0.96(0.90-1.03) | | | |
| Weight | 0.000 | 0.001 | 1.00(1.00-1.00) | | 0.000 | 0.001 | 1.00(1.00-1.00) | | | |
| Systolic Blood Pressure Square | 0.000 | 0.000 | 1.00(1.00-1.00) | | 0.000 | 0.000 | 1.00(1.00-1.00) | | | |
| Heart Rate Square | 0.000 | 0.000 | 1.00(1.00-1.00) | | 0.000 | 0.000 | 1.00(1.00-1.00) | | | |
| Temperature Square | -0.069 | 0.027 | 0.93(0.89-0.98) | | 0.013 | 0.023 | 1.01(0.97-1.06) | | | |
| Temperature Unknown | 0.083 | 0.100 | 1.09(0.89-1.32) | | -0.175 | 0.101 | 0.84(0.69-1.02) | | | |
| Weight Unknown | -0.025 | 0.100 | 0.98(0.80-1.19) | | 0.289 | 0.090 | 1.34(1.12-1.59) | | | |
| | | | Co | ndition | | | | | | |
| Low frequency conditions | -2.034 | 0.092 | 0.13(0.11-0.16) | 57.2% | -1.983 | 0.086 | 0.14(0.12-0.16) | 57.2% | | |
| Bunionectomy or repair of toe deformities (CCS 143) | -3.931 | 0.348 | 0.02(0.01-0.04) | 2.6% | -3.290 | 0.261 | 0.04(0.02-0.06) | 2.5% | | |
| Arthroscopy (CCS 149) | -2.698 | 0.201 | 0.07(0.05-0.10) | 2.7% | -2.886 | 0.206 | 0.06(0.04-0.08) | 2.8% | | |
| Insertion; replacement; or removal of extracranial ventricular shunt (CCS 2) | -0.968 | 0.113 | 0.38(0.30-0.47) | 4.4% | -0.989 | 0.109 | 0.37(0.30-0.46) | 4.2% | | |
| Electrographic cardiac monitoring (CCS 203) | -5.075 | 0.259 | 0.01(0.00-0.01) | 17.2% | -4.752 | 0.222 | 0.01(0.01-0.01) | 17.1% | | |
| Arterial blood gases (CCS 205) | -3.846 | 0.306 | 0.02(0.01-0.04) | 3.5% | -3.660 | 0.283 | 0.03(0.01-0.04) | 3.5% | | |
| Other diagnostic radiology and related techniques (CCS 226) | -4.092 | 0.220 | 0.02(0.01-0.03) | 5.7% | -4.235 | 0.229 | 0.01(0.01-0.02) | 5.6% | | |
| Complication of device; implant or graft (CCS 237) | -1.631 | 0.125 | 0.20 (0.15-0.25) | 4.3% | -1.458 | 0.118 | 0.23(0.18-0.29) | 4.4% | | |
| Complications of surgical procedures or medical care | Reference | Reference | Reference | 2.5% | Reference | Reference | Reference | 2.8% | | |

| Surgery/Gynecology Readmission Rates | HWR eMeasure Development Sample HWR eMeasure Validation Sample (N=23,201) (N=23,490) | | | | | | | | | | |
|--|--|----------------|------------------|-----------------------|----------|----------------|-----------------|-----------------------|--|--|--|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | | | |
| (CCS 238) | | | | | | | | | | | |
| | Comorbidity | | | | | | | | | | |
| Metastatic cancer/acute leukemia (CC 7) | 0.028 | 0.103 | 0.97 (0.79-1.18) | 5.5% | 0.100 | 0.095 | 1.11(0.92-1.33) | 5.7% | | | |
| Severe Cancer (CC 8, 9) | 0.164 | 0.088 | 1.26 (1.06-1.50) | 6.3% | 0.230 | 0.085 | 1.26(1.07-1.49) | 6.5% | | | |
| Other major cancers (CC 10- 12) | -0.139 | 0.064 | 0.94 (0.83-1.06) | 17.6% | -0.079 | 0.061 | 0.92(0.82-1.04) | 17.9% | | | |
| Other hematological disorders (CC 44) | -0.114 | 0.216 | 0.87 (0.56-1.35) | 0.8% | 0.370 | 0.196 | 1.45(0.99-2.13) | 0.7% | | | |
| Coagulation defects and other specified hematological disorders (CC 46) | 0.177 | 0.117 | 1.31 (1.04-1.65) | 2.8% | 0.100 | 0.121 | 1.11(0.87-1.40) | 2.5% | | | |
| Iron deficiency (CC 47) | 0.338 | 0.054 | 1.48 (1.33-1.64) | 40.5% | 0.380 | 0.051 | 1.46(1.32-1.62) | 41.1% | | | |
| End-stage liver disease (CC 25, 26) | 0.258 | 0.181 | 1.06 (0.72-1.55) | 1.2% | 0.414 | 0.176 | 1.51(1.07-2.14) | 1.1% | | | |
| Pancreatic disease (CC 32) | 0.142 | 0.119 | 1.09 (0.86-1.37) | 3.0% | 0.122 | 0.116 | 1.13(0.90-1.42) | 2.9% | | | |
| Dialysis status (CC 130) | 0.182 | 0.177 | 1.55 (1.11-2.17) | 1.0% | 0.617 | 0.165 | 1.85(1.34-2.56) | 1.0% | | | |
| Acute renal failure (CC 131) | -0.020 | 0.083 | 1.01 (0.85-1.19) | 9.5% | -0.035 | 0.080 | 0.97(0.82-1.13) | 9.7% | | | |
| Transplants (CC 128, 174) | 0.226 | 0.354 | 1.52 (0.81-2.87) | 0.3% | 0.813 | 0.334 | 2.25(1.17-4.34) | 0.2% | | | |
| Severe Infection (CC 1, 3-5) | 0.166 | 0.196 | 1.27 (0.88-1.82) | 1.0% | 0.143 | 0.180 | 1.15(0.81-1.64) | 1.1% | | | |
| Other infectious disease & pneumonias (CC 6, 111- | 0.066 | 0.074 | 1.07 (0.92-1.24) | 10.4% | 0.174 | 0.072 | 1.19(1.03-1.37) | 10.3% | | | |
| Septicemia/shock (CC 2) | -0.205 | 0.116 | 0.87 (0.69-1.10) | 3.2% | -0.099 | 0.112 | 0.91(0.73-1.13) | 3.3% | | | |
| CHF (CC 80) | 0.294 | 0.091 | 1.16 (0.97-1.39) | 6.4% | -0.055 | 0.092 | 0.95(0.79-1.13) | 6.3% | | | |
| Coronary atherosclerosis or angina, cerebrovascular disease (CC 81-84, 89, 98, 99, 103-106) | 0.314 | 0.055 | 1.29 (1.16-1.44) | 40.6% | 0.285 | 0.053 | 1.33(1.20-1.48) | 40.3% | | | |
| Specified arrhythmias (CC 92, 93) | 0.051 | 0.081 | 1.06 (0.90-1.24) | 8.9% | 0.120 | 0.079 | 1.13(0.97-1.32) | 8.9% | | | |
| Cardiorespiratory failure or cardiorespiratory shock (CC 79) | 0.082 | 0.117 | 1.14 (0.90-1.43) | 3.0% | 0.202 | 0.112 | 1.22(0.98-1.52) | 3.1% | | | |
| Coronary obstructive pulmonary disease (COPD) (CC 108) | 0.105 | 0.063 | 1.18 (1.05-1.34) | 14.1% | 0.228 | 0.060 | 1.26(1.12-1.41) | 14.3% | | | |

| Surgery/Gynecology Readmission Rates | | | Development Sample 23,201) | e | | | Validation Sample 3,490) | |
|--|----------|----------------|-------------------------------|-----------------------|----------|----------------|-----------------------------|-----------------------|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred |
| Fibrosis of lung or other chronic lung disorders (CC 109) | 0.179 | 0.143 | 1.04 (0.77-1.39) | 1.9% | 0.185 | 0.134 | 1.20(0.92-1.56) | 2.1% |
| Protein-calorie malnutrition (CC 21) | 0.276 | 0.088 | 1.08 (0.91-1.29) | 5.0% | 0.054 | 0.088 | 1.06(0.89-1.25) | 5.1% |
| Disorders of fluid, electrolyte, acid-base (CC 22, 23) | 0.141 | 0.072 | 1.15 (1.00-1.32) | 12.4% | 0.091 | 0.070 | 1.10(0.96-1.26) | 12.5% |
| Rheumatoid arthritis and inflammatory connective tissue disease (CC 38) | 0.154 | 0.101 | 1.13 (0.93-1.37) | 4.9% | 0.064 | 0.100 | 1.07(0.88-1.30) | 4.9% |
| Diabetes mellitus (CC 15-20, 119, 120) | 0.120 | 0.054 | 1.08 (0.97-1.20) | 27.8% | 0.154 | 0.053 | 1.17(1.05-1.30) | 26.6% |
| Ulcers (CC 148, 149) | 0.018 | 0.097 | 1.03 (0.85-1.25) | 4.2% | -0.139 | 0.097 | 0.87(0.72-1.05) | 4.5% |
| Hemiplegia, paraplegia, paralysis, functional disability (CC 67-69, 100-102, 177, 178) | -0.071 | 0.105 | 0.82 (0.67-1.02) | 3.9% | -0.059 | 0.104 | 0.94(0.77-1.16) | 3.9% |
| Seizure disorders and convulsions (CC 74) | 0.194 | 0.145 | 1.13 (0.85-1.51) | 1.9% | 0.364 | 0.136 | 1.44(1.10-1.88) | 1.9% |
| Respirator dependence/tracheostomy status (CC 77) | -0.219 | 0.463 | 3.60 (1.33-9.75) | 0.1% | 0.735 | 0.487 | 2.09(0.80-5.42) | 0.1% |
| Drug and alcohol disorders (CC 51, 52) | 0.218 | 0.106 | 1.28 (1.03-1.57) | 3.8% | 0.033 | 0.108 | 1.03(0.84-1.28) | 3.8% |
| Psychiatric comorbidity (CC 54- 56, 58, 60) | 0.129 | 0.057 | 1.14 (1.02-1.27) | 20.2% | 0.106 | 0.056 | 1.11(1.00-1.24) | 20.5% |
| Hip fracture/dislocation (CC 158) | 0.072 | 0.170 | 0.81 (0.57-1.15) | 1.3% | -0.459 | 0.168 | 0.63(0.45-0.88) | 1.5% |

Table B.2: Cardiorespiratory Specialty Cohort Hierarchical Logistic Regression Model Risk Factor Frequencies, Estimates, and Odds Ratios by Sample

| Cardiorespiratory Readmission Rates | ١ | | Development Sample =9,261) | : | | | e Validation Sample =9,364) | |
|--|----------|-------------------|-------------------------------|-----------------------|----------|-------------------|--------------------------------|-----------------------|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred |
| Intercept | 5.746 | 3.301 | | | 11.238 | 3.129 | | |
| | | | CC | DE | | | | |
| Age | 0.007 | 0.004 | 1.01 (1.00-1.01) | | 0.002 | 0.004 | 1.00(1.00-1.01) | |
| Bicarbonate | 0.010 | 0.006 | 1.01 (1.00-1.03) | | 0.017 | 0.006 | 1.02(1.01-1.03) | |
| Creatinine | 0.140 | 0.034 | 1.08 (1.01-1.15) | | 0.093 | 0.034 | 1.10(1.03-1.17) | |
| Glucose | 0.000 | 0.001 | 1.00 (1.00-1.00) | | 0.000 | 0.001 | 1.00(1.00-1.00) | |
| Hematocrit | -0.015 | 0.006 | 0.98 (0.97-1.00) | | -0.017 | 0.006 | 0.98(0.97-0.99) | |
| Sodium | -0.016 | 0.006 | 0.98 (0.97-0.99) | | -0.018 | 0.006 | 0.98(0.97-0.99) | |
| Systolic Blood Pressure | -0.005 | 0.001 | 1.00 (0.99-1.00) | | -0.005 | 0.001 | 0.99(0.99-1.00) | |
| Heart Rate | -0.001 | 0.001 | 1.00 (1.00-1.00) | | 0.003 | 0.001 | 1.00(1.00-1.01) | |
| Oxygen Saturation | 0.010 | 0.005 | 1.01 (1.00-1.02) | | 0.004 | 0.005 | 1.00(0.99-1.01) | |
| WBC Count | 0.032 | 0.009 | 1.03 (1.01-1.04) | | 0.009 | 0.009 | 1.01(0.99-1.03) | |
| Temperature | -0.061 | 0.032 | 0.92 (0.86-0.97) | | -0.108 | 0.030 | 0.90(0.85-0.95) | |
| Temperature Unknown | -0.040 | 0.125 | 1.03 (0.81-1.30) | | 0.102 | 0.115 | 1.11(0.88-1.39) | |
| Heart Rate Square | 0.000 | 0.000 | 1.00 (1.00-1.00) | | 0.000 | 0.000 | 1.00(1.00-1.00) | |
| WBC Count Square | -0.001 | 0.001 | 1.00 (1.00-1.00) | | 0.001 | 0.001 | 1.00(1.00-1.00) | |
| Temperature Square | 0.020 | 0.012 | 1.03 (1.01-1.06) | | 0.034 | 0.011 | 1.03(1.01-1.06) | |
| | | | Cond | dition | | | | |
| Low frequency conditions | -1.274 | 0.404 | 0.28(0.13-0.62) | 1.0% | -1.503 | 0.474 | 0.22(0.09-0.56) | 0.9% |
| Pulmonary heart disease (CCS 103) | -0.695 | 0.145 | 0.50(0.38-0.66) | 6.3% | -0.463 | 0.143 | 0.63(0.48-0.83) | 6.1% |
| Congestive heart failure; nonhypertensive (CCS 108) | -0.333 | 0.087 | 0.72(0.60-0.85) | 40.9% | -0.213 | 0.087 | 0.81(0.68-0.96) | 41.4% |
| Pneumonia (except that caused by tuberculosis or sexually transmitted disease) (CCS 122) | -0.910 | 0.100 | 0.40(0.33-0.49) | 21.8% | -0.679 | 0.099 | 0.51(0.42-0.62) | 21.9% |
| Chronic obstructive pulmonary disease and bronchiectasis (CCS 127) | -0.594 | 0.114 | 0.55(0.44-0.69) | 10.8% | -0.516 | 0.114 | 0.60(0.48-0.75) | 10.5% |
| Asthma (128) | -0.798 | 0.142 | 0.45(0.34-0.59) | 7.2% | -0.875 | 0.143 | 0.42(0.31-0.55) | 7.3% |

| Cardiorespiratory Readmission Rates | | | Development Sample =9,261) | e | | | e Validation Sample =9,364) | |
|--|-----------|-------------------|-------------------------------|-----------------------|-----------|-------------------|--------------------------------|-----------------------|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred |
| Respiratory failure; insufficiency; arrest (adult) (CCS 131) | Reference | Reference | Reference | 12.0% | Reference | Reference | Reference | 11.8% |
| | | | Como | orbidity | | | | |
| Metastatic cancer/acute leukemia (CC 7) | 0.212 | 0.151 | 1.24(0.92-1.66) | 3.7% | -0.144 | 0.157 | 0.87(0.64-1.18) | 3.7% |
| Severe Cancer (CC 8, 9) | 0.301 | 0.120 | 1.35(1.07-1.71) | 5.6% | 0.358 | 0.115 | 1.43(1.14-1.79) | 6.0% |
| Other major cancers (CC 10- 12) | -0.009 | 0.093 | 0.99(0.83-1.19) | 9.4% | 0.122 | 0.093 | 1.13(0.94-1.36) | 8.9% |
| Other hematological disorders (CC 44) | 0.223 | 0.171 | 1.25(0.89-1.75) | 2.2% | 0.143 | 0.166 | 1.15(0.83-1.60) | 2.3% |
| Coagulation defects and other specified hematological disorders (CC 46) | -0.018 | 0.100 | 0.98(0.81-1.20) | 7.6% | -0.022 | 0.099 | 0.98(0.81-1.19) | 7.4% |
| Iron deficiency (CC 47) | 0.001 | 0.066 | 1.00(0.88-1.14) | 50.4% | 0.141 | 0.066 | 1.15(1.01-1.31) | 50.1% |
| End-stage liver disease (CC 25, 26) | 0.127 | 0.215 | 1.14(0.75-1.73) | 1.4% | -0.247 | 0.229 | 0.78(0.50-1.22) | 1.4% |
| Pancreatic disease (CC 32) | 0.221 | 0.160 | 1.25(0.91-1.71) | 2.4% | -0.056 | 0.169 | 0.95(0.68-1.32) | 2.5% |
| Dialysis status (CC 130) | 0.116 | 0.191 | 1.12(0.77-1.63) | 2.1% | 0.099 | 0.191 | 1.10(0.76-1.61) | 2.3% |
| Acute renal failure (CC 131) | -0.057 | 0.078 | 0.94(0.81-1.10) | 28.4% | 0.184 | 0.078 | 1.20(1.03-1.40) | 27.8% |
| Transplants (CC 128, 174) | 0.364 | 0.381 | 1.44(0.68-3.04) | 0.4% | 0.376 | 0.384 | 1.46(0.69-3.09) | 0.4% |
| Severe Infection (CC 1, 3-5) | 0.338 | 0.192 | 1.40(0.96-2.04) | 1.7% | 0.101 | 0.215 | 1.11(0.73-1.69) | 1.5% |
| Other infectious disease & pneumonias (CC 6, 111- | -0.083 | 0.063 | 0.92(0.81-1.04) | 40.1% | 0.029 | 0.063 | 1.03(0.91-1.16) | 39.5% |
| Septicemia/shock (CC 2) | 0.139 | 0.090 | 1.15(0.96-1.37) | 10.3% | 0.072 | 0.091 | 1.07(0.90-1.29) | 9.8% |
| CHF (CC 80) | 0.108 | 0.082 | 1.11(0.95-1.31) | 33.4% | 0.072 | 0.083 | 1.08(0.91-1.27) | 33.8% |
| Coronary atherosclerosis or angina, cerebrovascular disease (CC 81-84, 89, 98, 99, 103-106) | 0.177 | 0.070 | 1.19(1.04-1.37) | 68.1% | 0.109 | 0.069 | 1.11(0.97-1.28) | 67.7% |
| Specified arrhythmias (CC 92, 93) | 0.191 | 0.075 | 1.21(1.05-1.40) | 30.6% | 0.058 | 0.074 | 1.06(0.92-1.22) | 31.4% |
| Cardiorespiratory failure or cardiorespiratory shock (CC 79) | 0.136 | 0.076 | 1.15(0.99-1.33) | 21.5% | 0.211 | 0.076 | 1.23(1.06-1.43) | 20.9% |

| Cardiorespiratory Readmission Rates | | | Development Sample =9,261) | | | | e Validation Sample =9,364) | |
|--|----------|-------------------|-------------------------------|-----------------------|----------|-------------------|--------------------------------|-----------------------|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred |
| Coronary obstructive pulmonary disease (COPD) (CC 108) | -0.038 | 0.064 | 0.96(0.85-1.09) | 48.0% | 0.089 | 0.063 | 1.09(0.97-1.24) | 47.6% |
| Fibrosis of lung or other chronic lung disorders (CC 109) | -0.012 | 0.101 | 0.99(0.81-1.20) | 7.8% | -0.026 | 0.096 | 0.97(0.81-1.18) | 8.4% |
| Protein-calorie malnutrition (CC 21) | 0.075 | 0.087 | 1.08(0.91-1.28) | 10.2% | 0.139 | 0.085 | 1.15(0.97-1.36) | 10.4% |
| Disorders of fluid, electrolyte, acid-base (CC 22, 23) | 0.123 | 0.069 | 1.13(0.99-1.29) | 29.3% | 0.023 | 0.069 | 1.02(0.89-1.17) | 28.4% |
| Rheumatoid arthritis and inflammatory connective tissue disease (CC 38) | 0.150 | 0.109 | 1.16(0.94-1.44) | 6.0% | 0.175 | 0.107 | 1.19(0.97-1.47) | 6.0% |
| Diabetes mellitus (CC 15-20, 119, 120) | 0.018 | 0.064 | 1.02(0.90-1.16) | 40.0% | 0.026 | 0.064 | 1.03(0.91-1.16) | 38.9% |
| Ulcers (CC 148, 149) | 0.330 | 0.095 | 1.39(1.15-1.68) | 7.1% | 0.234 | 0.093 | 1.26(1.05-1.52) | 7.8% |
| Hemiplegia, paraplegia, paralysis, functional disability (CC 67-69, 100-102, 177, 178) | 0.087 | 0.103 | 1.09(0.89-1.34) | 6.7% | 0.081 | 0.103 | 1.08(0.89-1.33) | 6.5% |
| Seizure disorders and convulsions (CC 74) | 0.089 | 0.148 | 1.09(0.82-1.46) | 3.3% | 0.159 | 0.139 | 1.17(0.89-1.54) | 3.6% |
| Respirator dependence/tracheostomy status (CC 77) | -0.045 | 0.313 | 0.96(0.52-1.77) | 0.6% | -0.020 | 0.316 | 0.98(0.53-1.82) | 0.5% |
| Drug and alcohol disorders (CC 51, 52) | 0.114 | 0.124 | 1.12(0.88-1.43) | 4.7% | 0.132 | 0.124 | 1.14(0.90-1.45) | 4.7% |
| Psychiatric comorbidity (CC 54-56, 58, 60) | 0.146 | 0.059 | 1.16(1.03-1.30) | 30.1% | 0.171 | 0.059 | 1.19(1.06-1.33) | 30.4% |
| Hip fracture/dislocation (CC 158) | -0.281 | 0.196 | 0.75(0.51-1.11) | 2.1% | -0.104 | 0.180 | 0.90(0.63-1.28) | 2.0% |

Table B.3: Cardiovascular Specialty Cohort Hierarchical Logistic Regression Model Risk Factor Frequencies, Estimates, and Odds Ratios by Sample

| Cardiovascular Readmission Rates | | | Development Sample =8,108) | | | | e Validation Sample =8,037) | |
|--|-----------|-------------------|-------------------------------|-----------------------|-----------|-------------------|--------------------------------|-----------------------|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred |
| Intercept | 0.309 | 2.001 | | | 4.939 | 1.915 | | |
| | | | CC | DE | | | | |
| Age | 0.014 | 0.005 | 1.01(1.00-1.03) | | 0.008 | 0.005 | 1.01(1.00-1.02) | |
| Bicarbonate | 0.022 | 0.011 | 1.02(1.00-1.04) | | 0.009 | 0.011 | 1.01(0.99-1.03) | |
| Creatinine | 0.186 | 0.043 | 1.20(1.11-1.31) | | 0.189 | 0.045 | 1.21(1.11-1.32) | |
| Hematocrit | -0.022 | 0.009 | 0.98(0.96-0.99) | | -0.017 | 0.009 | 0.98(0.97-1.00) | |
| Potassium | -0.017 | 0.074 | 0.98(0.85-1.14) | | -0.072 | 0.073 | 0.93(0.81-1.07) | |
| Sodium | -0.022 | 0.010 | 0.98(0.96-1.00) | | -0.036 | 0.009 | 0.96(0.95-0.98) | |
| WBC Count | 0.021 | 0.016 | 1.02(0.99-1.05) | | 0.022 | 0.016 | 1.02(0.99-1.05) | |
| Systolic Blood Pressure | 0.002 | 0.001 | 1.00(1.00-1.01) | | 0.001 | 0.001 | 1.00(1.00-1.00) | |
| Heart Rate | 0.009 | 0.002 | 1.01(1.00-1.01) | | 0.007 | 0.002 | 1.01(1.00-1.01) | |
| Oxygen Saturation | -0.024 | 0.013 | 0.98(0.95-1.00) | | -0.040 | 0.012 | 0.96(0.94-0.98) | |
| Respiratory Rate | 0.005 | 0.011 | 1.01(0.98-1.03) | <i>y</i> - | 0.018 | 0.011 | 1.02(1.00-1.04) | |
| Bicarbonate Square | 0.003 | 0.002 | 1.00(1.00-1.01) | | 0.003 | 0.002 | 1.00(1.00-1.01) | |
| Potassium Square | 0.178 | 0.078 | 1.20(1.03-1.39) | | 0.149 | 0.072 | 1.16(1.01-1.34) | |
| WBC Count Square | 0.000 | 0.002 | 1.00(1.00-1.00) | | 0.001 | 0.002 | 1.00(1.00-1.01) | |
| Systolic Blood Pressure Square | 0.000 | 0.000 | 1.00(1.00-1.00) | | 0.000 | 0.000 | 1.00(1.00-1.00) | |
| Heart Rate Square | 0.000 | 0.000 | 1.00(1.00-1.00) | | 0.000 | 0.000 | 1.00(1.00-1.00) | |
| | | | Cond | dition | | | | |
| Low frequency conditions | 0.052 | 0.113 | 1.05(0.84-1.31) | 22.7% | -0.145 | 0.113 | 0.86(0.69-1.08) | 21.1% |
| Acute myocardial infarction (CCS 100) | -0.046 | 0.123 | 0.95(0.75-1.21) | 18.1% | 0.024 | 0.113 | 1.02(0.82-1.28) | 20.6% |
| Coronary atherosclerosis and other heart disease (CCS 101) | -0.320 | 0.138 | 0.73(0.55-0.95) | 19.3% | -0.610 | 0.142 | 0.54(0.41-0.72) | 19.7% |
| Nonspecific chest pain (CCS 102) | -0.230 | 0.138 | 0.79(0.61-1.04) | 14.9% | -0.142 | 0.134 | 0.87(0.67-1.13) | 14.0% |
| Cardiac dysrhythmias (CCS106) | Reference | Reference | Reference | 24.9% | Reference | Reference | Reference | 24.6% |
| | | | Como | rbidity | | | | |
| Metastatic cancer/acute | 0.363 | 0.258 | 1.44(0.87-2.38) | 1.7% | 0.512 | 0.263 | 1.67(1.00-2.79) | 1.5% |

| Cardiovascular Readmission Rates | | | Development Sample =8,108) | | | | e Validation Sample =8,037) | |
|--|----------|-------------------|-------------------------------|-----------------------|----------|-------------------|--------------------------------|-----------------------|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred |
| leukemia (CC 7) | | | | | | | | |
| Severe Cancer (CC 8, 9) | 0.138 | 0.187 | 1.15(0.80-1.66) | 3.4% | 0.034 | 0.204 | 1.03(0.69-1.54) | 2.9% |
| Other major cancers (CC 10-12) | 0.022 | 0.135 | 1.02(0.78-1.33) | 7.8% | -0.094 | 0.144 | 0.91(0.69-1.21) | 7.0% |
| Other hematological disorders (CC 44) | 0.245 | 0.261 | 1.28(0.77-2.13) | 1.4% | 0.184 | 0.252 | 1.20(0.73-1.97) | 1.5% |
| Coagulation defects and other specified hematological disorders (CC 46) | 0.375 | 0.154 | 1.45(1.08-1.97) | 4.2% | -0.023 | 0.159 | 0.98(0.72-1.33) | 4.6% |
| Iron deficiency (CC 47) | 0.125 | 0.097 | 1.13(0.94-1.37) | 35.6% | 0.149 | 0.097 | 1.16(0.96-1.40) | 35.1% |
| End-stage liver disease (CC 25, 26) | 0.160 | 0.337 | 1.17(0.61-2.27) | 0.8% | 0.912 | 0.287 | 2.49(1.42-4.37) | 0.9% |
| Pancreatic disease (CC 32) | 0.665 | 0.210 | 1.94(1.29-2.93) | 1.9% | 0.293 | 0.213 | 1.34(0.88-2.04) | 2.1% |
| Dialysis status (CC 130) | -0.139 | 0.241 | 0.87(0.54-1.40) | 2.2% | -0.355 | 0.250 | 0.70(0.43-1.14) | 2.0% |
| Acute renal failure (CC 131) | 0.137 | 0.116 | 1.15(0.91-1.44) | 18.2% | 0.258 | 0.115 | 1.29(1.03-1.62) | 18.1% |
| Transplants (CC 128, 174) | -0.126 | 0.443 | 0.88(0.37-2.10) | 0.6% | 0.189 | 0.455 | 1.21(0.49-2.95) | 0.4% |
| Severe Infection (CC 1, 3-5) | 0.107 | 0.341 | 1.11(0.57-2.17) | 0.9% | 0.211 | 0.345 | 1.24(0.63-2.43) | 0.8% |
| Other infectious disease & pneumonias (CC 6, 111- | 0.332 | 0.101 | 1.39(1.14-1.70) | 17.2% | 0.232 | 0.101 | 1.26(1.03-1.54) | 17.1% |
| Septicemia/shock (CC 2) | -0.165 | 0.163 | 0.85(0.62-1.17) | 4.3% | 0.148 | 0.158 | 1.16(0.85-1.58) | 4.2% |
| CHF (CC 80) | 0.419 | 0.116 | 1.52(1.21-1.91) | 16.7% | 0.170 | 0.118 | 1.19(0.94-1.49) | 17.8% |
| Coronary atherosclerosis or angina, cerebrovascular disease (CC 81-84, 89, 98, 99, 103-106) | -0.151 | 0.101 | 0.86(0.71-1.05) | 74.2% | 0.023 | 0.101 | 1.02(0.84-1.25) | 74.7% |
| Specified arrhythmias (CC 92, 93) | 0.154 | 0.110 | 1.17(0.94-1.45) | 19.5% | 0.146 | 0.109 | 1.16(0.93-1.43) | 20.4% |
| Cardiorespiratory failure or cardiorespiratory shock (CC 79) | 0.131 | 0.136 | 1.14(0.87-1.49) | 6.6% | 0.040 | 0.142 | 1.04(0.79-1.37) | 6.1% |
| Coronary obstructive pulmonary disease (COPD) (CC 108) | 0.194 | 0.093 | 1.21(1.01-1.46) | 19.5% | 0.060 | 0.093 | 1.06(0.88-1.27) | 19.6% |
| Fibrosis of lung or other chronic lung disorders (CC | 0.418 | 0.158 | 1.52(1.12-2.07) | 3.8% | 0.151 | 0.169 | 1.16(0.83-1.62) | 3.7% |

| Cardiovascular Readmission Rates | | | Development Sample =8,108) | | HWR eMeasure Validation Sample (N=8,037) | | | | |
|--|----------|-------------------|-------------------------------|-----------------------|---|-------------------|-----------------|-----------------------|--|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | |
| 109) | | | | | | | | | |
| Protein-calorie malnutrition (CC 21) | 0.261 | 0.157 | 1.30(0.95-1.77) | 3.9% | 0.106 | 0.161 | 1.11(0.81-1.53) | 3.8% | |
| Disorders of fluid, electrolyte, acid-base (CC 22, 23) | -0.112 | 0.109 | 0.89(0.72-1.11) | 16.7% | 0.069 | 0.108 | 1.07(0.87-1.32) | 16.9% | |
| Rheumatoid arthritis and inflammatory connective tissue disease (CC 38) | 0.306 | 0.141 | 1.36(1.03-1.79) | 5.7% | 0.005 | 0.160 | 1.00(0.73-1.37) | 5.1% | |
| Diabetes mellitus (CC 15-20, 119, 120) | 0.228 | 0.084 | 1.26(1.07-1.48) | 37.7% | 0.039 | 0.083 | 1.04(0.88-1.22) | 37.7% | |
| Ulcers (CC 148, 149) | 0.169 | 0.168 | 1.18(0.85-1.65) | 3.4% | 0.290 | 0.164 | 1.34(0.97-1.84) | 3.6% | |
| Hemiplegia, paraplegia, paralysis, functional disability (CC 67-69, 100-102, 177, 178) | 0.238 | 0.154 | 1.27(0.94-1.71) | 4.6% | 0.082 | 0.159 | 1.09(0.80-1.48) | 4.2% | |
| Seizure disorders and convulsions (CC 74) | -0.170 | 0.253 | 0.84(0.51-1.38) | 2.3% | 0.073 | 0.229 | 1.08(0.69-1.69) | 2.3% | |
| Respirator dependence/tracheostomy status (CC 77) | -0.395 | 1.184 | 0.67(0.07-6.86) | 0.1% | -0.725 | 1.157 | 0.48(0.05-4.67) | 0.1% | |
| Drug and alcohol disorders (CC 51, 52) | -0.104 | 0.223 | 0.90(0.58-1.39) | 2.4% | 0.307 | 0.188 | 1.36(0.94-1.96) | 2.7% | |
| Psychiatric comorbidity (CC 54-56, 58, 60) | 0.144 | 0.089 | 1.15(0.97-1.37) | 22.3% | 0.152 | 0.087 | 1.16(0.98-1.38) | 23.1% | |
| Hip fracture/dislocation (CC 158) | 0.083 | 0.339 | 1.09(0.56-2.11) | 0.8% | -0.444 | 0.377 | 0.64(0.31-1.34) | 0.8% | |

Table B.4: Neurology Specialty Cohort Hierarchical Logistic Regression Model Risk Factor Frequencies, Estimates, and Odds Ratios by Sample

| Neurology Readmission Rates | | | Development Sample =4,400) | • | | HWR eMeasure Validation Sample (N=4,348) | | | |
|---|-----------|-------------------|-------------------------------|-----------------------|-----------|---|-----------------|-----------------------|--|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | |
| Intercept | 3.350 | 2.409 | | | 2.770 | 2.373 | | | |
| | | | CC | CDE | | | | | |
| Age | -0.004 | 0.006 | 1.00(0.98-1.01) | - | -0.008 | 0.006 | 0.99(0.98-1.00) | | |
| Creatinine | 0.134 | 0.057 | 1.14(1.02-1.28) | | 0.273 | 0.054 | 1.31(1.18-1.46) | | |
| Hematocrit | -0.027 | 0.010 | 0.97(0.95-0.99) | | -0.053 | 0.011 | 0.95(0.93-0.97) | | |
| Sodium | -0.037 | 0.011 | 0.96(0.94-0.98) | | 0.000 | 0.011 | 1.00(0.98-1.02) | | |
| WBC Count | -0.001 | 0.018 | 1.00(0.96-1.03) | | 0.024 | 0.018 | 1.02(0.99-1.06) | | |
| Systolic Blood Pressure | 0.000 | 0.002 | 1.00(1.00-1.00) | | -0.002 | 0.002 | 1.00(0.99-1.00) | | |
| Heart Rate | 0.010 | 0.003 | 1.01(1.00-1.02) | | 0.006 | 0.003 | 1.01(1.00-1.01) | | |
| Oxygen Saturation | -0.015 | 0.017 | 0.99(0.95-1.02) | | -0.035 | 0.016 | 0.97(0.94-1.00) | | |
| Respiratory Rate | 0.052 | 0.015 | 1.05(1.02-1.08) | | 0.005 | 0.015 | 1.00(0.98-1.03) | | |
| WBC Count Square | 0.003 | 0.002 | 1.00(1.00-1.01) | | 0.002 | 0.002 | 1.00(1.00-1.01) | | |
| Systolic Blood Pressure Square | 0.000 | 0.000 | 1.00(1.00-1.00) | | 0.000 | 0.000 | 1.00(1.00-1.00) | | |
| Temperature Square | -0.003 | 0.024 | 1.00(0.95-1.04) | | 0.012 | 0.019 | 1.01(0.98-1.05) | | |
| Temperature Unknown | -0.197 | 0.210 | 0.82(0.54-1.24) | | -0.007 | 0.206 | 0.99(0.66-1.49) | | |
| | | | Con | dition | | | | | |
| Low frequency conditions | 0.188 | 0.099 | 1.21(0.99-1.46) | 49.3% | 0.048 | 0.098 | 1.05(0.87-1.27) | 50.4% | |
| Acute cerebrovascular disease (CCS109) | Reference | Reference | Reference | 50.7% | Reference | Reference | Reference | 49.6% | |
| | | | Como | orbidity | | | | | |
| Metastatic cancer/acute leukemia (CC 7) | -0.354 | 0.255 | 0.70(0.43-1.16) | 3.7% | -0.105 | 0.241 | 0.90(0.56-1.45) | 4.2% | |
| Severe Cancer (CC 8, 9) | 0.258 | 0.206 | 1.29(0.86-1.94) | 4.7% | -0.002 | 0.219 | 1.00(0.65-1.53) | 4.3% | |
| Other major cancers (CC 10- 12) | 0.284 | 0.154 | 1.33(0.98-1.80) | 9.6% | 0.183 | 0.155 | 1.20(0.89-1.63) | 9.6% | |
| Other hematological disorders (CC 44) | 0.448 | 0.345 | 1.57(0.80-3.08) | 1.3% | 0.379 | 0.284 | 1.46(0.84-2.55) | 1.8% | |
| Coagulation defects and other specified hematological disorders (CC 46) | -0.444 | 0.231 | 0.64(0.41-1.01) | 4.1% | 0.446 | 0.185 | 1.56(1.09-2.25) | 5.2% | |

| Neurology Readmission Rates | HWR eMeasure Development Sample HWR eMeasure Validation Sample (N=4,400) (N=4,348) | | | | | | | |
|--|--|-------------------|-----------------|-----------------------|----------|-------------------|-----------------|-----------------------|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred |
| Iron deficiency (CC 47) | 0.096 | 0.119 | 1.10(0.87-1.39) | 34.1% | -0.019 | 0.119 | 0.98(0.78-1.24) | 34.9% |
| End-stage liver disease (CC 25, 26) | -0.107 | 0.407 | 0.90(0.40-2.00) | 1.2% | 0.811 | 0.306 | 2.25(1.24-4.10) | 1.5% |
| Pancreatic disease (CC 32) | 0.314 | 0.305 | 1.37(0.75-2.49) | 1.8% | 0.086 | 0.314 | 1.09(0.59-2.02) | 1.9% |
| Dialysis status (CC 130) | 0.787 | 0.325 | 2.20(1.16-4.15) | 1.5% | -0.496 | 0.320 | 0.61(0.33-1.14) | 2.0% |
| Acute renal failure (CC 131) | -0.111 | 0.154 | 0.90(0.66-1.21) | 15.6% | 0.213 | 0.145 | 1.24(0.93-1.64) | 16.6% |
| Transplants (CC 128, 174) | 0.391 | 0.656 | 1.48(0.41-5.35) | 0.3% | 0.455 | 0.597 | 1.58(0.49-5.08) | 0.4% |
| Severe Infection (CC 1, 3-5) | 0.398 | 0.331 | 1.49(0.78-2.85) | 1.4% | 0.374 | 0.334 | 1.45(0.75-2.80) | 1.4% |
| Other infectious disease & pneumonias (CC 6, 111- | 0.279 | 0.127 | 1.32(1.03-1.70) | 20.2% | 0.192 | 0.123 | 1.21(0.95-1.54) | 20.5% |
| Septicemia/shock (CC 2) | 0.303 | 0.190 | 1.35(0.93-1.97) | 5.5% | -0.116 | 0.203 | 0.89(0.60-1.32) | 5.4% |
| CHF (CC 80) | 0.168 | 0.155 | 1.18(0.87-1.60) | 13.5% | 0.269 | 0.155 | 1.31(0.97-1.77) | 13.4% |
| Coronary atherosclerosis or angina, cerebrovascular disease (CC 81-84, 89, 98, 99, 103-106) | 0.339 | 0.111 | 1.40(1.13-1.75) | 57.7% | 0.001 | 0.111 | 1.00(0.81-1.24) | 56.7% |
| Specified arrhythmias (CC 92, 93) | 0.304 | 0.140 | 1.35(1.03-1.78) | 17.6% | 0.182 | 0.139 | 1.20(0.91-1.58) | 18.1% |
| Cardiorespiratory failure or cardiorespiratory shock (CC 79) | 0.069 | 0.189 | 1.07(0.74-1.55) | 6.0% | -0.221 | 0.195 | 0.80(0.55-1.17) | 6.1% |
| Coronary obstructive pulmonary disease (COPD) (CC 108) | 0.100 | 0.123 | 1.10(0.87-1.40) | 16.7% | -0.121 | 0.131 | 0.89(0.69-1.15) | 16.2% |
| Fibrosis of lung or other chronic lung disorders (CC 109) | -0.296 | 0.281 | 0.74(0.43-1.29) | 2.7% | 0.028 | 0.259 | 1.03(0.62-1.71) | 2.9% |
| Protein-calorie malnutrition (CC 21) | 0.049 | 0.174 | 1.05(0.75-1.48) | 7.1% | 0.280 | 0.162 | 1.32(0.96-1.82) | 7.8% |
| Disorders of fluid, electrolyte, acid-base (CC 22, 23) | -0.110 | 0.135 | 0.90(0.69-1.17) | 18.9% | -0.002 | 0.129 | 1.00(0.77-1.28) | 20.5% |
| Rheumatoid arthritis and inflammatory connective tissue disease (CC 38) | 0.206 | 0.181 | 1.23(0.86-1.75) | 5.6% | -0.265 | 0.200 | 0.77(0.52-1.14) | 5.9% |

| Neurology Readmission Rates | | | Development Sample =4,400) | : | HWR eMeasure Validation Sample (N=4,348) | | | | |
|--|----------|-------------------|-------------------------------|-----------------------|---|-------------------|------------------|-----------------------|--|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | |
| Diabetes mellitus (CC 15-20, 119, 120) | 0.000 | 0.105 | 1.00(0.81-1.23) | 34.1% | -0.076 | 0.105 | 0.93(0.75-1.14) | 34.5% | |
| Ulcers (CC 148, 149) | 0.085 | 0.197 | 1.09(0.74-1.60) | 4.6% | -0.024 | 0.206 | 0.98(0.65-1.46) | 4.6% | |
| Hemiplegia, paraplegia, paralysis, functional disability (CC 67-69, 100-102, 177, 178) | 0.175 | 0.151 | 1.19(0.89-1.60) | 10.0% | 0.081 | 0.149 | 1.08(0.81-1.45) | 10.6% | |
| Seizure disorders and convulsions (CC 74) | -0.024 | 0.139 | 0.98(0.74-1.28) | 13.7% | 0.031 | 0.145 | 1.03(0.78-1.37) | 12.2% | |
| Respirator dependence/tracheostomy status (CC 77) | -0.117 | 0.869 | 0.89(0.16-4.88) | 0.2% | 1.622 | 0.691 | 5.06(1.31-19.63) | 0.3% | |
| Drug and alcohol disorders (CC 51, 52) | -0.026 | 0.233 | 0.97(0.62-1.54) | 4.3% | 0.182 | 0.221 | 1.20(0.78-1.85) | 3.9% | |
| Psychiatric comorbidity (CC 54-56, 58, 60) | -0.027 | 0.106 | 0.97(0.79-1.20) | 28.4% | 0.081 | 0.103 | 1.08(0.89-1.33) | 30.0% | |
| Hip fracture/dislocation (CC 158) | -0.004 | 0.320 | 1.00(0.53-1.86) | 1.6% | -0.083 | 0.315 | 0.92(0.50-1.71) | 1.8% | |

Table B.5: Medicine Specialty Cohort Hierarchical Logistic Regression Model Risk Factor Frequencies, Estimates, and Odds Ratios by Sample

| Medicine Readmission Rates | | | Development Sample =34,619) | • | | HWR eMeasure Validation Sample (N=34,574) | | | |
|---|----------|-------------------|--------------------------------|-----------------------|----------|--|-----------------|-----------------------|--|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | |
| Intercept | 4.474 | 1.570 | | | 5.603 | 1.549 | | | |
| | | | CC | CDE | | | | | |
| Age | -0.001 | 0.002 | 1.00(1.00-1.00) | | -0.003 | 0.002 | 1.00(0.99-1.00) | | |
| Bicarbonate | 0.012 | 0.004 | 1.01(1.01-1.02) | | 0.015 | 0.004 | 1.02(1.01-1.02) | | |
| Creatinine | 0.024 | 0.014 | 1.02(1.00-1.05) | | -0.011 | 0.014 | 0.99(0.96-1.02) | | |
| Glucose | 0.000 | 0.000 | 1.00(1.00-1.00) | | 0.000 | 0.000 | 1.00(1.00-1.00) | | |
| Hematocrit | -0.014 | 0.003 | 0.99(0.98-0.99) | | -0.015 | 0.003 | 0.98(0.98-0.99) | | |
| Potassium | 0.043 | 0.023 | 1.04(1.00-1.09) | | 0.039 | 0.024 | 1.04(0.99-1.09) | | |
| Sodium | -0.008 | 0.003 | 0.99(0.99-1.00) | | -0.005 | 0.003 | 0.99(0.99-1.00) | | |
| WBC Count | -0.004 | 0.004 | 1.00(0.99-1.00) | | -0.012 | 0.004 | 0.99(0.98-1.00) | | |
| Systolic Blood Pressure | 0.000 | 0.001 | 1.00(1.00-1.00) | | 0.000 | 0.001 | 1.00(1.00-1.00) | | |
| Heart Rate | 0.001 | 0.001 | 1.00(1.00-1.00) | | 0.001 | 0.001 | 1.00(1.00-1.00) | | |
| Respiratory Rate | 0.009 | 0.004 | 1.01(1.00-1.02) | | 0.014 | 0.004 | 1.01(1.01-1.02) | | |
| Temperature | -0.055 | 0.015 | 0.95(0.92-0.98) | | -0.070 | 0.015 | 0.93(0.91-0.96) | | |
| Potassium Unknown | -0.053 | 0.073 | 0.95(0.82-1.09) | | -0.045 | 0.074 | 0.96(0.83-1.10) | | |
| Temperature Unknown | 0.171 | 0.064 | 1.19(1.05-1.35) | | 0.012 | 0.066 | 1.01(0.89-1.15) | | |
| Bicarbonate Square | 0.000 | 0.000 | 1.00(1.00-1.00) | | 0.002 | 0.000 | 1.00(1.00-1.00) | | |
| WBC Count Square | 0.000 | 0.000 | 1.00(1.00-1.00) | | 0.000 | 0.000 | 1.00(1.00-1.00) | | |
| Systolic Blood Pressure Square | 0.000 | 0.000 | 1.00(1.00-1.00) | | 0.000 | 0.000 | 1.00(1.00-1.00) | | |
| Heart Rate Square | 0.000 | 0.000 | 1.00(1.00-1.00) | | 0.000 | 0.000 | 1.00(1.00-1.00) | | |
| Temperature Square | -0.004 | 0.005 | 1.00(0.99-1.01) | | 0.001 | 0.005 | 1.00(0.99-1.01) | | |
| | | | Cond | dition | | | | | |
| Low frequency conditions | -0.425 | 0.107 | 0.65(0.53-0.81) | 33.1% | -0.307 | 0.108 | 0.74(0.60-0.91) | 32.8% | |
| Aspiration pneumonitis; food/vomitus (CCS 129) | 0.326 | 0.139 | 1.39(1.06-1.82) | 1.8% | 0.257 | 0.143 | 1.29(0.98-1.71) | 1.7% | |
| Intestinal infection (CCS 135) | 0.053 | 0.140 | 1.05(0.80-1.39) | 1.9% | 0.384 | 0.137 | 1.47(1.12-1.92) | 2.0% | |
| Intestinal obstruction without hernia (CCS 145) | -0.066 | 0.136 | 0.94(0.72-1.22) | 2.6% | 0.033 | 0.135 | 1.03(0.79-1.35) | 2.8% | |
| Diverticulosis and diverticulitis (CCS 146) | -0.490 | 0.154 | 0.61(0.45-0.83) | 2.1% | -0.566 | 0.162 | 0.57(0.41-0.78) | 2.0% | |
| Biliary tract disease (CCS 149) | -0.178 | 0.159 | 0.84(0.61-1.14) | 1.5% | 0.001 | 0.158 | 1.00(0.73-1.37) | 1.5% | |
| | | | | | | | | | |

| Medicine Readmission Rates | HWR eMeasure Development Sample HWR eMeasure Validation Sample (N=34,619) (N=34,574) | | | | | | | |
|---|--|-------------------|-----------------|-----------------------|-----------|-------------------|-----------------|-----------------------|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred |
| Gastrointestinal hemorrhage (CCS 153) | -0.380 | 0.130 | 0.68(0.53-0.88) | 3.5% | -0.318 | 0.131 | 0.73(0.56-0.94) | 3.7% |
| Other gastrointestinal disorders (CCS 155) | -0.195 | 0.152 | 0.82(0.61-1.11) | 1.6% | -0.063 | 0.152 | 0.94(0.70-1.26) | 1.6% |
| Acute and unspecified renal failure (CCS 157) | -0.200 | 0.128 | 0.82(0.64-1.05) | 3.3% | 0.048 | 0.128 | 1.05(0.82-1.35) | 3.1% |
| Urinary tract infections (CCS 159) | -0.426 | 0.132 | 0.65(0.50-0.85) | 3.7% | -0.340 | 0.133 | 0.71(0.55-0.92) | 3.7% |
| Skin and subcutaneous tissue infections (CCS 197) | -0.628 | 0.155 | 0.53(0.39-0.72) | 2.1% | -0.531 | 0.154 | 0.59(0.43-0.80) | 2.2% |
| Septicemia (except in labor) (CCS 2) | 0.030 | 0.108 | 1.03(0.83-1.27) | 23.5% | 0.039 | 0.109 | 1.04(0.84-1.29) | 23.8% |
| Complication of device; implant or graft (CCS 237) | -0.111 | 0.119 | 0.89(0.71-1.13) | 4.8% | 0.016 | 0.121 | 1.02(0.80-1.29) | 4.6% |
| Complications of surgical procedures or medical care (CCS 238) | -0.062 | 0.132 | 0.94(0.72-1.22) | 2.7% | 0.038 | 0.136 | 1.04(0.80-1.36) | 2.5% |
| Syncope (CCS 245) | -0.622 | 0.151 | 0.54(0.40-0.72) | 2.4% | -0.681 | 0.155 | 0.51(0.37-0.69) | 2.5% |
| Diabetes mellitus with complications (CCS 50) | -0.340 | 0.135 | 0.71(0.55-0.93) | 2.6% | -0.265 | 0.136 | 0.77(0.59-1.00) | 2.6% |
| Fluid and electrolyte disorders (CCS 55) | -0.411 | 0.134 | 0.66(0.51-0.86) | 3.1% | -0.075 | 0.131 | 0.93(0.72-1.20) | 3.2% |
| Cataract (CCS 86) | -0.930 | 0.163 | 0.39(0.29-0.54) | 2.2% | -0.688 | 0.159 | 0.50(0.37-0.69) | 2.2% |
| Hypertension with complications and secondary hypertension (CCS 99) | Reference | Reference | Reference | 1.6% | Reference | Reference | Reference | 1.6% |
| | | | Como | rbidity | | | | |
| Metastatic cancer/acute leukemia (CC 7) | 0.032 | 0.069 | 1.03(0.90-1.18) | 5.0% | -0.063 | 0.071 | 0.94(0.82-1.08) | 4.9% |
| Severe Cancer (CC 8, 9) | 0.290 | 0.054 | 1.34(1.20-1.49) | 7.1% | 0.338 | 0.055 | 1.40(1.26-1.56) | 6.9% |
| Other major cancers (CC 10- 12) | 0.035 | 0.045 | 1.04(0.95-1.13) | 12.2% | 0.079 | 0.045 | 1.08(0.99-1.18) | 12.1% |
| Other hematological disorders (CC 44) | 0.327 | 0.077 | 1.39(1.19-1.61) | 3.0% | 0.126 | 0.080 | 1.13(0.97-1.33) | 2.9% |
| Coagulation defects and other | 0.178 | 0.052 | 1.19(1.08-1.32) | 7.5% | 0.166 | 0.052 | 1.18(1.07-1.31) | 7.5% |

| Medicine Readmission Rates | | | Development Sample 34,619) | | | HWR eMeasure Validation Sample (N=34,574) | | | |
|--|----------|-------------------|-------------------------------|-----------------------|----------|--|-----------------|-----------------------|--|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | |
| specified hematological disorders (CC 46) | | | | | | | | | |
| Iron deficiency (CC 47) | 0.056 | 0.036 | 1.06(0.99-1.13) | 52.9% | 0.047 | 0.036 | 1.05(0.98-1.12) | 53.0% | |
| End-stage liver disease (CC 25, 26) | 0.315 | 0.078 | 1.37(1.18-1.60) | 3.0% | 0.270 | 0.076 | 1.31(1.13-1.52) | 3.2% | |
| Pancreatic disease (CC 32) | 0.230 | 0.061 | 1.26(1.12-1.42) | 5.1% | 0.199 | 0.061 | 1.22(1.08-1.38) | 5.2% | |
| Dialysis status (CC 130) | 0.059 | 0.086 | 1.06(0.90-1.26) | 3.3% | 0.086 | 0.085 | 1.09(0.92-1.29) | 3.5% | |
| Acute renal failure (CC 131) | 0.080 | 0.041 | 1.08(1.00-1.17) | 24.3% | 0.075 | 0.041 | 1.08(0.99-1.17) | 24.2% | |
| Transplants (CC 128, 174) | 0.177 | 0.154 | 1.19(0.88-1.61) | 0.7% | 0.383 | 0.141 | 1.47(1.11-1.93) | 0.8% | |
| Severe Infection (CC 1, 3-5) | 0.084 | 0.099 | 1.09(0.90-1.32) | 1.9% | 0.096 | 0.100 | 1.10(0.91-1.34) | 1.8% | |
| Other infectious disease & pneumonias (CC 6, 111- | -0.003 | 0.035 | 1.00(0.93-1.07) | 34.4% | 0.112 | 0.035 | 1.12(1.04-1.20) | 34.5% | |
| Septicemia/shock (CC 2) | 0.005 | 0.047 | 1.00(0.92-1.10) | 11.4% | 0.074 | 0.046 | 1.08(0.98-1.18) | 11.3% | |
| CHF (CC 80) | 0.121 | 0.043 | 1.13(1.04-1.23) | 19.6% | 0.185 | 0.043 | 1.20(1.11-1.31) | 19.8% | |
| Coronary atherosclerosis or angina, cerebrovascular disease (CC 81-84, 89, 98, 99, 103-106) | 0.139 | 0.034 | 1.15(1.07-1.23) | 61.1% | 0.254 | 0.035 | 1.29(1.20-1.38) | 61.1% | |
| Specified arrhythmias (CC 92, 93) | 0.133 | 0.039 | 1.14(1.06-1.23) | 21.6% | 0.092 | 0.040 | 1.10(1.01-1.19) | 21.5% | |
| Cardiorespiratory failure or cardiorespiratory shock (CC 79) | 0.073 | 0.048 | 1.08(0.98-1.18) | 10.7% | 0.021 | 0.048 | 1.02(0.93-1.12) | 10.9% | |
| Coronary obstructive pulmonary disease (COPD) (CC 108) | 0.131 | 0.034 | 1.14(1.07-1.22) | 23.7% | 0.095 | 0.035 | 1.10(1.03-1.18) | 23.6% | |
| Fibrosis of lung or other chronic lung disorders (CC 109) | 0.127 | 0.064 | 1.14(1.00-1.29) | 4.6% | 0.054 | 0.064 | 1.06(0.93-1.20) | 4.7% | |
| Protein-calorie malnutrition (CC 21) | 0.137 | 0.042 | 1.15(1.06-1.24) | 13.5% | 0.140 | 0.041 | 1.15(1.06-1.25) | 13.9% | |
| Disorders of fluid, electrolyte, acid-base (CC 22, 23) | 0.186 | 0.037 | 1.20(1.12-1.30) | 28.8% | 0.141 | 0.037 | 1.15(1.07-1.24) | 29.3% | |
| Rheumatoid arthritis and inflammatory connective | 0.110 | 0.054 | 1.12(1.00-1.24) | 6.8% | 0.026 | 0.056 | 1.03(0.92-1.15) | 6.6% | |

| Medicine Readmission Rates | | HWR eMeasure Development Sample (N=34,619) | | | | HWR eMeasure Validation Sample (N=34,574) | | | | |
|--|----------|---|-----------------|-----------------------|----------|--|-----------------|-----------------------|--|--|
| Name | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | Estimate | Standard Error | OR (LOR-UOR) | Frequency Occurred | | |
| tissue disease (CC 38) | | | | | | | | | | |
| Diabetes mellitus (CC 15-20, 119, 120) | 0.113 | 0.034 | 1.12(1.05-1.20) | 38.9% | 0.072 | 0.034 | 1.07(1.01-1.15) | 39.2% | | |
| Ulcers (CC 148, 149) | 0.154 | 0.048 | 1.17(1.06-1.28) | 9.0% | 0.047 | 0.049 | 1.05(0.95-1.15) | 9.2% | | |
| Hemiplegia, paraplegia, paralysis, functional disability (CC 67-69, 100-102, 177, 178) | 0.028 | 0.050 | 1.03(0.93-1.13) | 8.6% | 0.064 | 0.050 | 1.07(0.97-1.18) | 8.2% | | |
| Seizure disorders and convulsions (CC 74) | 0.165 | 0.064 | 1.18(1.04-1.34) | 4.6% | 0.020 | 0.066 | 1.02(0.90-1.16) | 4.6% | | |
| Respirator dependence/tracheostomy status (CC 77) | 0.282 | 0.184 | 1.33(0.92-1.90) | 0.4% | 0.124 | 0.191 | 1.13(0.78-1.65) | 0.4% | | |
| Drug and alcohol disorders (CC 51, 52) | 0.089 | 0.060 | 1.09(0.97-1.23) | 5.7% | 0.121 | 0.059 | 1.13(1.00-1.27) | 5.9% | | |
| Psychiatric comorbidity (CC 54-56, 58, 60) | 0.075 | 0.031 | 1.08(1.01-1.15) | 30.0% | 0.116 | 0.031 | 1.12(1.06-1.19) | 30.1% | | |
| Hip fracture/dislocation (CC 158) | 0.140 | 0.083 | 1.15(0.98-1.35) | 2.4% | -0.244 | 0.090 | 0.78(0.66-0.94) | 2.5% | | |